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1 Zusammenfassung 
Herzerkrankungen sind weltweit die Hauptursache für einen vorzeitigen Tod. 
Sowohl Gentransfer als auch zelluläre Therapien werden derzeit als neue 
Behandlungsmöglichkeiten für diese Erkrankungen entwickelt. 
Im ersten Teil dieser Arbeit sollte der AAV-vermittelte Gentransfer von Transgenen 
ins Herzgewebe von Donororganen, die anschließend transplantiert wurden, 
etabliert werden. Als Tiermodelle für die heterotopen Herztransplantationen 
wurden Sprague Dawley Ratten und Deutsche Landrasseschweine gewählt. rAAV 
Serotype 2, welcher für diesen Zweck als geeignet beschrieben wurde, wurde 
intracoronar entweder in das normotherme (n=3) oder hypotherme (n=3) Herz 
appliziert, welches anschließend in eine Empfängerratte transplantiert wurde. Der 
Gentransfer erfolgte mit einer besseren Effizienz in normotherme Herzen 
verglichen mit hypothermen Herzen. Trotz des erfolgreichen Transfers und der 
Nachweisbarkeit von Vektor-DNA in Gewebeproben 28 Tage nach Transplantation 
konnte jedoch weder Transgen-spezifische mRNA noch Proteinexpression 
detektiert werden. Zur Bestimmung potentieller Barrieren, welche die rAAV2-
vermittelte Transgenexpression in unserem Rattenmodell beeinträchtigen, wurden 
in vitro Analysen in Rattenaortenendothelzellen (RAECs) durchgeführt. Wir 
konnten Zelleintritt und intrazelluläres trafficking der viralen Partikel ebenso als 
inhibierende Faktoren ausschließen wie die Expression vom gewählten CMV 
Promotor. Die Applikation des Proteasomeninhibitors MG132 erhöhte die 
Transgenexpression jedoch signifikant für die Serotypen 1 und 2 (6-fach und 7.3-
fach). Ersterer war in unseren in vitro Experimenten der effizienteste Serotyp der 
analysierten 5 Serotypen (rAAV1 bis rAAV5). Da MG132 die Funktion der 
Proteasomen inhibitiert, könnte eine blockierte Vektordegradation die 
beobachteten Ergebnisse erklären. Darüberhinaus sind auch indirekte Effekte wie 
eine erhöhte Ubiquitinierung des Vektorkapsids denkbar, von der man annimmt, 
dass sie das sogenannte vector uncoating oder die Translokation in den Nucleus 
erleichtert (Duan et al., 2000; Yan et al., 2002). Des Weiteren konnte eine 
geringfügig eingeschränkte Fähigkeit zur Zweitstrangsynthese beobachtet werden. 
Diese wird benötigt, um das einzelsträngige DNA-Genom herkömmlich 
verwendeter AAV-Vektoren in einen transkribierbaren Doppelstrang zu 
verwandeln. Zusammenfassend muss man feststellen, dass sich die analysierten 
rAAV Serotypen als ungeeignete Gentransfervektoren für Rattenendothelzellen 
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erwiesen haben. Im Gegensatz dazu wurde in primären Rattencardiomyocyten in 
vitro eine deutlich höhere Transduktionseffizienz erzielt. Dies veranlasste uns, die 
vasoaktive Substanz Histamin in unserem heterotopen porcinen Transplantations-
modell anzuwenden, um in vivo sowohl Endothelzellen als auch Cardiomyocyten 
zu transduzieren. Interessanterweise zeigten in vitro Analysen porciner 
Aortenendothelzellen – im Gegensatz zu unseren erfolglosen Versuchen in 
RAECs – Transduktionseffizienzen von ca. 90 % mit rAAV2. Daher wurde dieser 
Serotyp zusammen mit Histamin in normotherme Herzen appliziert unter 
Verwendung des neuentwickelten in situ Langendorff Reperfusionssystems, 
welches eine verlängerte Rezirkulation des Vektors im Herzen erlaubte. In beiden 
Tieren konnte der Nachweis eines erfolgreichen Gentransfers anhand deutlich 
messbarer Transgen-DNA-Mengen erbracht werden. In einem der beiden Tiere 
wurde zudem funktionales Protein nachgewiesen. Dieses Schwein hatte zehnmal 
höhere Vektormengen erhalten. Dieser Vektor kodierte zudem für das Transgen 
Luciferase und wies eine self-complementary (Pseudo-Doppelstrang) 
Vektorgenom-Konformation auf. Im Gegensatz dazu wurde das Schwein, das 
keine Expression zeigte, mit einem Vektor behandelt, der für beta-Galaktosidase 
in einer Einzelstrang-Vektorgenom-Konformation kodierte. Obwohl weitere 
Experimente zur Bestimmung des Einflusses der drei Parameter (Vektormenge, 
Vektorgenom-Konformation und Wahl des Transgens), einzeln oder in 
Kombination, benötigt werden, konnten wir zeigen, dass ein rAAV2-vermittelter 
Gentransfer in porcines Herzgewebe im Rahmen eines (Xeno-) 
Transplantationsansatzes im Prinzip möglich ist. 
Im zweiten Teil meiner Arbeit wurde ein Protokoll zur effizienten Transduktion 
humaner CD34+ Zellen aus Nabelschnurblut etabliert. Derartige Protokolle 
ermöglichen eine Kombination von Zell- und Gentherapie, welche für ein breites 
Spektrum an Anwendungen vorteilhaft ist. Vergleiche der Serotypen 2, 3 und 5 
ermittelten rAAV2 als den effizientesten Serotyp in Zelleintritt und 
Transgenexpression. Der Zelleintritt von rAAV2 in CD34+ Zellen war abhängig von 
Heparansulfatproteoglycan, wie mithilfe von Kompetitionsexperimenten bestimmt 
wurde, und von α5β1 Integrin, was wir mittels einer Mutante für die Bindung des 
Rezeptors ermittelten. Interessanterweise waren nur auf vorexpandierten Zellen 
α5β1 Integrine nachweisbar. Dies erlaubt den Schluss, dass zumindest einige der 
kontroversen Berichte zur rAAV-vermittelten Transduktion von CD34+ Zellen auf 
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die verwendeten Kulturbedingungen zurückzuführen sind. Darüberhinaus ist die 
Synthese des Zweitstrangs in CD34+ Zellen beeinträchtigt, da nur die Zugabe von 
Vektoren mit Genomen in der self-complementary Konformation in erfolgreichen 
Transduktionen resultierte. Die ohnehin schon sehr effiziente Transduktion (61 %), 
die mit rAAV2 Vektoren mit self-complementary Genomen in vorexpandierten 
Zellen erzielt wurde, konnte signifikant (auf 86 %) durch die Zugabe von all-trans 
Retinsäure und dem Histon-Deacetylase-Inhibitor Trichostatin A erhöht werden. 
Darüberhinaus weisen unsere Ergebnisse darauf hin, dass Transduktionen mit 
rAAV nicht mit der Fähigkeit der CD34+ Zellen zur endothelialen Differenzierung 
interferieren. Zusammenfassend kann festgestellt werden, dass unter Verwendung 
des hier etablierten Protokolls CD34+ Zellen effizient mit rAAV2 transduziert 
werden können und sich rAAV2 somit als ein geeignetes Vektorsystem zur 
transienten Modifikation dieser Zellen  anbietet.  
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2 Abstract 
Heart diseases are the main cause of premature death in the population world-
wide. Gene transfer as well as cell-based therapies are currently developed as 
new treatment options. 
In the first part of this thesis, AAV-mediated gene transfer to deliver transgenes 
into heart tissue before transplantation ought to be established. As model system, 
the Sprague Dawley heterotopic rat model and the German Landrace pig model 
were chosen. rAAV serotype 2, described to be suited for this purpose, was 
intracoronarily delivered either in the normothermic (n=3) or hypothermic (n=3) 
hearts which were subsequently transplanted into a recipient rat. Gene transfer 
into normothermic hearts occurred with a better efficiency compared to 
hypothermic hearts. However, despite successful delivery and detection of vector 
DNA in tissue samples 28 d post transplantation, neither transgene-specific mRNA 
nor protein expression could be detected. To identify potential barriers that impair 
rAAV2-mediated transgene expression in our rat model, in vitro analyses in rat 
aortic endothelial cells (RAECs) were performed. We could exclude cell entry, 
intracellular trafficking of viral particles as well as expression from the chosen 
CMV promoter as inhibiting factors. However, application of the proteasome 
inhibitor MG132 significantly enhanced rAAV1- and rAAV2-mediated transgene 
expression (6-fold and 7.3-fold, respectively). The latter was in our hand the most 
efficient serotype in RAEC transduction among the serotypes rAAV1 to rAAV5. 
Since MG132 is a proteasome inhibitor blocking of vector degradation could be an 
explanation for the observed effect. Moreover, also indirect effects can be 
imagined like enhanced ubiquitination of the vector capsid, which is believed to 
facilitate vector uncoating or nuclear translocation of vector genomes (Duan et al., 
2000; Yan et al., 2002). Furthermore, we observed a certain, albeit rather minor, 
limitation in second-strand synthesis. This step is necessary for the generation of a 
double-stranded DNA as template for transcription of the commonly used single-
stranded DNA genome. In summary, the analyzed rAAV serotypes have been 
revealed as inappropriate gene transfer vectors in targeting of rat endothelial cells. 
In contrast, in primary rat cardiomyocytes in vitro a higher transduction efficiency 
was observed. Therefore, we decided to administer the vasoactive substance 
histamine in our heterotopic pig heart transplantation model in order to target 
cardiomyocytes in addition to endothelial cells. Interestingly, in vitro analyses of 
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porcine aortic endothelial cells revealed – in contrast to the unsuccessful attempts 
on RAECs – transduction efficiencies of about 90 % using rAAV2. Thus, this 
serotype was applied together with histamine into normothermic hearts using the 
newly developed in situ Langendorff reperfusion system which permitted 
prolonged recirculation of the vector in the heart. Transgene DNA detected in the 
graft of two transplanted animals displayed successful gene transfer. In one of the 
two animals functional protein was detected. This pig had received tenfold higher 
amounts of the vector which displayed a self-complementary vector genome 
conformation and encoded for the transgene luciferase. In contrast, the animal 
showing no expression was treated with a vector coding for beta-galactosidase in 
the single-stranded vector genome conformation. Although further experiments are 
needed to determine the influence of the three parameters (vector amount, vector 
genome conformation and choice of transgene) alone or in combination we could 
show that rAAV2-mediated gene delivery into the porcine heart tissue in a (xeno-) 
transplantation setting is in principle possible. 
In the second part of my thesis, a protocol for efficient transduction of human cord 
blood-derived CD34+ cells was established. Such protocols enable a combination 
of cell and gene therapy which is advantageous for a wide range of applications. 
Among the serotypes 2, 3 and 5, rAAV2 was identified as the most efficient 
serotype in cell entry and in transgene expression. Cell entry of rAAV2 into CD34+ 
cells was dependent on heparin sulfate proteoglycan as determined by 
competition experiments, and on α5β1  integrin as assessed by a receptor binding 
mutant. Interestingly, only pre-expanded cells displayed α5β1 integrin allowing to 
conclude that at least some of the contradictory reports on rAAV-mediated 
transduction of CD34+ cells are due to the applied cultivation conditions. 
Furthermore, CD34+ cells are impaired in second-strand synthesis as only 
administration of vectors encoding the transgene in a self-complementary vector 
conformation resulted in successful transductions. The already high transduction 
level (61 %) achieved with rAAV2 using self-complementary vector genomes and 
pre-expanded cells could be significantly enhanced up to 86 % by addition of all-
trans retinoic acid and the histone deacetylase inhibitor Trichostatin A. 
Furthermore, our results provide strong evidence that transductions by rAAV2 
vectors do not interfere with endothelial differentiation potential of CD34+ cells. 
Thus, an efficient protocol for rAAV2-mediated transduction of CD34+ cells was 
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established revealing that rAAV2 is an appropriate vector system for transient 
modification of this cell type. 
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3 Introduction 
3.1 Adeno-associated virus 
3.1.1 Classification of adeno-associated virus 
Adeno-associated viruses are classed into the Parvoviridae family. The 
Parvoviridae belong to the smallest known viruses (lat. parvus = small) consisting 
of a non-enveloped icosahedral capsid with a 
diameter of 18 to 26 nm and a linear single-
stranded DNA genome (Figure 1). The 
Parvoviridae comprises two subfamilies: the 
vertebrate-infecting Parvovirinae and the 
Densovirinae which infect insects. The subfamily of 
Parvovirinae is further divided into the three 
genera Parvo-, Erythro- and Dependovirus. AAV 
belongs to the latter genus. Erythrovirinae infect 
erythroid precursor cells, whereas Parvovirus B19 
is the only human pathogenic parvovirus and 
causes fifth disease (Erythema infectiosum) and 
complications during pregnancy (anemia, hydrops fetalis, abortions). Viruses 
belonging to the genus of Parvovirus are pathogenic for animals, examples are 
feline, canine and porcine parvovirus as well as minute virus of mice or aleutian 
mink disease virus. While erythro- and parvoviruses are autonomous viruses, 
dependoviruses require the presence of a helper virus like adenovirus (Ad), 
herpes simplex virus (HSV), vaccinia virus, human cytomegalovirus (HCMV) or 
papilloma virus (HPV) to undergo a productive life cycle (Atchison, Casto, and 
Hammon, 1965; McPherson, Rosenthal, and Rose, 1985; Richardson and 
Westphal, 1981; Schlehofer, Ehrbar, and zur Hausen, 1986). On the other hand, 
AAV seems to inhibit replication of helper viruses and also to interfere with 
malignant transformation induced by adenovirus, human or bovine papilloma virus 
(Heilbronn et al., 1990; Hermonat, 1992; Timpe, Verrill, and Trempe, 2006; You et 
al., 2006). Moreover, it was described that replication might be induced upon 
cellular genotoxic stress (Schlehofer, Ehrbar, and zur Hausen, 1986; Yakobson et 
al., 1989; Yakobson, Koch, and Winocour, 1987; Yalkinoglu et al., 1988). 
Figure 1: Atomic structure of AAV 
serotype 2 determined by X-ray 
chrystallography.  (Xie et al., 
2003) 
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Until now, 12 serotypes have been described. In the 1960’s, AAV was discovered 
as contaminant of simian Adenovirus 15 preparations by several groups (Atchison, 
Casto, and Hammon, 1965; Mayor et al., 1965; Melnick et al., 1965). AAV 
serotype 2 has been isolated out of simian Adenovirus type 12 and AAV3 out of 
Adenovirus type 7 preparations (Hoggan, Blacklow, and Rowe, 1966). AAV4 has 
been found in African green monkeys infected with simian adenovirus 15 (Parks et 
al., 1967). In contrast, AAV5 was isolated out of a human clinical sample, a penile 
condylomatous lesion (Bantel-Schaal and zur Hausen, 1984). This virus is less 
related to the other serotypes considering sequence homology and serology 
(Chiorini et al., 1999). AAV6 has originally been identified as contaminant of an 
Adenovirus 5 stock. Its close relatedness to AAV1 with a variation of only 6 amino 
acids in the capsid sequence points either to a natural variant of serotype 1 or to a 
recombination between AAV1 and AAV2 as origin of AAV6 (Rutledge, Halbert, and 
Russell, 1998; Xiao et al., 1999). Wilson’s group discovered the serotypes AAV7 
and AAV8 by PCR scanning for AAV sequence homologies in rhesus monkey 
tissues (Gao et al., 2002). The same group screened human tissues from various 
sources to detect latent AAV genomes and identified thereby a serologically 
different serotype, called AAV9 (Gao et al., 2004). Mori and colleagues isolated 
two new AAV variants out of cynomolgus monkey tissue designated AAV10 and 
AAV11 (Mori et al., 2004). Despite their isolation out of non-human primate 
tissues, these serotypes are also suited for transduction of human tissues (Gao et 
al., 2004). Recently, AAV serotype 12 has been identified in simian Adenovirus 18 
contaminated vervet monkey cells from ATCC stocks (Schmidt et al., 2006). 
Considering seroepidemiologic analyses, the serotypes AAV2, 3 and 5 are 
suggested to be endemic in humans (Gao et al., 2002). So far, AAV9 has only 
been found in human tissue. In contrast, monkeys are suggested to be the natural 
host for the serotypes 1, 4, 7 and 8 (Chiorini et al., 1997; Grimm and Kay, 2003; 
Xiao et al., 1999). AAV serotypes differ in their tropism. For example, AAV1 is 
appropriate for transduction of skeletal muscle or retina, whereas AAV5 is better 
suited for applications in the central nervous system or the lung as determined in 
mouse models (Auricchio et al., 2001; Davidson et al., 2000; Xiao et al., 1999; 
Zabner et al., 2000).  
Moreover, AAV variants have also been isolated out of species other than 
primates including cow, bird, sheep, snake, lizard and goat (Bossis and Chiorini, 
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2003; Clarke et al., 1979; Farkas et al., 2004; Jacobson et al., 1996; Olson et al., 
2004; Schmidt et al., 2004). So far, the best investigated AAV is the human 
serotype 2. 
3.1.2 Genome organization 
Wild type AAV contains a single-stranded DNA genome within an icosahedric 
capsid of 25 nm diameter. AAV serotype 2, the first serotype available as vector,  
has a genome size of 4680 nt with two open reading frames (ORFs) (Srivastava, 
Lusby, and Berns, 1983). These ORFs, encoding for the structural (cap; capsid) 
and non-structural proteins (rep; replication), are flanked by the inverted terminal 
repeats (ITRs) (Carter and Samulski, 2000) (Figure 2). This organization is 
conserved in all serotypes. The AAV2 genome contains three promoters (p5, p19, 
p40, describing their map position), but all transcripts share a common 
polyadenylation signal. 
The 145 nt (for AAV2) long ITRs form the 3’- and 5’-end of the genome and 
hybridize to hairpin-like structures. Within the ITR region a Rep binding site (RBS) 
and a terminal resolution site (TRS) important for nicking of duplex DNA by the 
large Rep proteins are located (Im and Muzyczka, 1990; McCarty et al., 1994). In 
addition, this region is crucial for site-specific integration events, rescue of the 
provirus and serves as origin of replication (Berns, 1990; Feng et al., 2006; 
Hauswirth and Berns, 1977; Labow and Berns, 1988; McLaughlin et al., 1988). 
Moreover, the ITRs are required for packaging of the viral genomes into the 
preformed capsid. 
The 5’-ORF encodes for four multifunctional, non-structural proteins named 
Rep78, Rep68, Rep52 and Rep40, according to their size (Lusby and Berns, 
1982). While the p5 promoter controls the expression of the larger transcripts 
(Rep78 and Rep68) the expression of the smaller proteins Rep52 and Rep40 is 
under the control of the p19 promoter. Rep68 and Rep40 are splice variants of 
their larger counterparts (Figure 2). The Rep proteins have numerous functions. 
The two larger Rep proteins which possess a nuclear localization signal at their C-
terminus are essential for replication, transcription and site-specific integration 
(Cassell and Weitzman, 2004). The smaller Rep proteins mediate accumulation 
and packaging of the viral genome into the preformed capsid in a helicase-
dependent manner (Dubielzig et al., 1999; King et al., 2001). While the Rep 
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proteins can act as transactivator of transcription of the three viral promoters in 
presence of helper virus, they can also repress transcription of the p5 and p19 
promoters in absence of helper virus (Kyostio et al., 1994; Pereira, McCarty, and 
Muzyczka, 1997). Moreover, the large Rep proteins can regulate the processing of 
the cap transcripts (Qiu and Pintel, 2002). 
 
 
 
Figure 2: Genome organization of AAV2. The AAV2 genome, flanked by the ITRs, spans 4680 nt 
divided into units of 100 nt. Shown are the three promoters p5, p19 and p40 at map position 5, 19 
and 40 and the polyadenylation signal (polyA) at position 96. The open reading frames are 
indicated by rectangles, translated regions in red or blue, untranslated regions by thin solid lines 
while introns are marked as nicks. The p5 promoter controls expression of the large Rep proteins 
(Rep78, Rep68), while the p19 promoter is responsible for the expression of the small Rep proteins 
(Rep52, Rep40). Rep68 and Rep40 are spliced variants of Rep78 and Rep52, respectively. The 
gene encoding for the capsid proteins VP1, VP2 and VP3 is controlled by the p40 promoter. (Figure 
kindly provided by N. Huttner) 
 
The three structural proteins VP1, VP2 and VP3 are situated in the 3’-ORF cap 
controlled by the p40 promoter. These three proteins form the 60 subunits of the 
viral capsid at a ratio of 1:1:8 (Kronenberg, Kleinschmidt, and Bottcher, 2001; 
Rose et al., 1971). All capsid proteins share a common C-terminus, but differ in 
their N-terminus. The efficiency of translation for VP1 is regulated by alternative 
splicing while translation of VP2 is initiated from an unusual initiation codon (ACG) 
(Becerra et al., 1988; Becerra et al., 1985). This is the reason for the 10-fold lower 
translation efficiency of VP2 compared to VP3 which is regulated by an AUG 
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initiation codon (Becerra et al., 1985). The molecular weight of the three capsid 
proteins is 90 kDa (VP1), 72 kDa (VP2) and 60 kDa (VP3). Considering the 
functions of the capsid proteins, VP1 seems to be essential for infectivity whereas 
VP3 is sufficient for capsid formation (Warrington et al., 2004). VP2 is proposed to 
be neither necessary for capsid formation nor for production of infectious particles 
(Lux et al., 2005; Warrington et al., 2004).  
Regarding phylogenetic relations between AAV2 and the other serotypes, a 
homology of 80 to 90 % was 
observed for AAV1, 3, 6 to 8 
and 10 in the amino acid 
sequence of VP1 (Gao et al., 
2002; Mori et al., 2004) (Figure 
3). AAV4 and AAV11 showed a   
60 % and 65 % homology to 
AAV2 VP1, respectively (Gao 
et al., 2004; Mori et al., 2004). 
AAV12’s closest relatives within 
the AAV family are AAV11 (84 
%) and AAV4 (78 %) (Schmidt 
et al., 2007). AAV5 is the most divergent serotype with only 58 % similarity 
compared to AAV2 VP1 (Bantel-Schaal et al., 1999). Additionally to the divergence 
of the capsid protein to the other serotypes, AAV5 contains an extra 
polyadenylation signal located within the intron thus producing mainly the 
unspliced Rep proteins Rep78 and Rep52 (Qiu et al., 2002). In general, 
homologies in the VP1 proteins are comparable to the phylogenetic results 
obtained by the nucleotide sequence (Grimm and Kay, 2003). About the recently 
described serotypes AAV9 to 12 only little is known so far. 
3.1.3 Infection biology of AAV 
A successful infection of cells by AAV is a multistep process including attachment, 
uptake, intracellular trafficking, nuclear translocation and replication of the virus 
(Figure 4). Its understanding is crucial to identify potential barriers in AAV infection 
that have to be overcome for its use as gene therapy vector. The current 
knowledge of AAV2 infection is described in detail in the following chapters. 
Figure 3: Phylogenetic analysis of the amino acid 
sequences of the capsid protein VP1. Modified scheme 
(grey) (Mori et al., 2004). 
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Figure 4: Infection pathway of AAV2 in HeLa cells. AAV2 touches the host cell several times and 
attaches to its primary receptor heparan sulfate proteoglycan (HSPG) and to the coreceptors 
fibroblast growth factor receptor 1 (FGFR-1) and the integrin αvβ5. The virus is internalized by 
receptor-mediated endocytosis into clathrin-coated vesicles in a dynamin-dependent way. The 
GTP-binding protein Rac1 is believed to be activated by integrin-binding and rearranges the 
cytoskeleton thus facilitating endosomal trafficking. Acidification of the endosomes leads to an 
escape of the AAV particles, maybe due to conformational changes. Viral uncoating takes place 
before or during nuclear entry. Also the exact mechanism of viral DNA import into the nucleus is yet 
unknown.(aa, amino acid)(Buning et al., 2003a) 
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3.1.3.1 Virus-cell interaction 
As Single Virus Tracing studies revealed, AAV2 contacts the cell membrane 
several times before it enters the cell (Seisenberger et al., 2001). For AAV2, the 
widely expressed cell surface receptor heparan sulfate proteoglycan (HSPG) has 
been identified as primary receptor (Summerford and Samulski, 1998). This 
contact is mediated by surface structures on the AAV capsid, namely the residues 
R484, R487, K532, R585 and R588 in the common VP3 region (Kern et al., 2003; 
Wu et al., 2000). Attachment to HSPG seems to induce a reversible structural 
change thus facilitating coreceptor binding and cell entry (Asokan et al., 2006). 
Surprisingly, some cell lines have been shown to take up virions even in the 
absence of HSPG (Duan et al., 1998b; Duan et al., 2000). Also AAV3 is suggested 
to use HSPG as primary receptor whereas the serotypes 1, 4, 5 and 6 bind to 
sialic acid (Rabinowitz et al., 2002). In 2006, Wu identified α2,3 and α2,6 sialic 
acids present on N-linked glycoproteins as primary receptors for AAV1 and AAV6 
(Wu et al., 2006). AAV4 and AAV5 both bind to α2,3 sialic acid, but differ in their 
linkage specificity. While AAV4 requires O-linked, AAV5 prefers N-linked α2,3 
sialic acids (Kaludov et al., 2001; Walters et al., 2001). Recently, the 37/67 kDa 
laminin receptor was proposed as a receptor for AAV8 (Akache et al., 2006). 
Interestingly, overexpression of this receptor rendered cells also more susceptible 
for transduction with AAV2, 3 and 9 proposing a role for laminin receptor for cell 
infection of these serotypes. For AAV12, recently published data point towards a 
HSPG and sialic acid independent entry mechanism (Schmidt et al., 2007). The 
primary receptors for AAV7 and 9 to 12 have yet to be determined. 
For efficient internalization, the additional binding to coreceptors is required. For 
AAV2, five secondary receptors have been proposed so far. Human fibroblast 
growth factor receptor 1 (FGFR-1), hepatocyte growth factor receptor (HGFR or c-
met) and laminin receptor seem to support virus:cell interaction (Akache et al., 
2006; Kashiwakura et al., 2005; Qing et al., 1999). On the other hand, the integrins 
αvβ5 and α5β1 are proposed as further coreceptors (Asokan et al., 2006; Sanlioglu 
et al., 2000; Summerford, Bartlett, and Samulski, 1999).  
For AAV3, FGFR-1 has been described as potential coreceptor (Blackburn, 
Steadman, and Johnson, 2006). Concerning AAV5, the platelet-derived growth 
factor receptor (PDGFR) was identified as secondary receptor (Di Pasquale et al., 
2003). It is conceivable that PDGFR might act alone as AAV5 receptor as it is a 
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sialo-proteoglycan containing oligosaccharides chains with sialic acids (Daniel et 
al., 1987; Hosang, 1988). 
3.1.3.2 Receptor-mediated endocytosis 
Following receptor binding and structural rearrangement, the virion enters the cell 
predominantly by receptor-mediated endocytosis in a dynamin-dependent manner 
(Bartlett, Wilcher, and Samulski, 2000; Duan et al., 1999; Hinshaw and Schmid, 
1995). Single Virus Tracing studies revealed that the uptake of virions occurs 
within 100 ms (Seisenberger et al., 2001). Clustering of αvβ5 integrins seems to 
facilitate localization of the virion into clathrin-coated pits (Bartlett, Wilcher, and 
Samulski, 2000). Also for AAV5, localization in clathrin-coated pits has been 
claimed despite usage of alternate receptors (sialic acid and/or PDGFR) (Bantel-
Schaal, Hub, and Kartenbeck, 2002). In addition, integrins interact with 
intracellular signalling molecules, e.g. Rac1, which support the internalization 
processes (Sanlioglu et al., 2000). Moreover, the activation of this small GTP-
binding molecule leads to a subsequent activation of the phosphatidylinositol-3 
kinase (PI3K) pathway which is involved in vesicular trafficking and rearrangement 
of microtubules and microfilaments (Kapeller and Cantley, 1994; Sanlioglu et al., 
2000). Interestingly, Rac1 and PI3K pathways are also crucial for internalization of 
adenovirus, a helper virus of AAV which is also located in clathrin-coated vesicles 
shortly after cell entry (Li et al., 1998). 
3.1.3.3 Endosomal processing and escape 
Even though details about the endosomal pathway used by AAV remain to be 
elucidated, it seems to be assured that trafficking of the virion-containing 
endosomes along the microtubules and microfilaments towards the nuclear area is 
essential for successful transduction (Bartlett, Wilcher, and Samulski, 2000; Douar 
et al., 2001). As Sanlioglu and colleagues described, application of nocodazole to 
depolymerize microtubules reduces perinuclear accumulation of AAV2 (Sanlioglu 
et al., 2000). Moreover, investigations on certain non-transduceable cell types 
revealed inefficient endosomal processing and nuclear trafficking as critical steps 
(Duan et al., 2000; Hansen, Qing, and Srivastava, 2001a). However, publications 
about intracellular processes remain controversial. While some groups postulate 
an escape from the early endosome, others observe a trafficking into the late 
endosomal compartment (Bartlett, Wilcher, and Samulski, 2000; Douar et al., 
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2001; Hansen, Qing, and Srivastava, 2001a; Xiao et al., 2002). For AAV2 and 
AAV5, also an accumulation in the Golgi compartment was stated (Bantel-Schaal, 
Hub, and Kartenbeck, 2002; Pajusola et al., 2002). 
To escape from the endosomes for trafficking to the nucleus, AAV requires 
endosomal acidification. This assumption is based on the observation that 
inhibition of acidification by bafilomycin A or ammonium chloride blocks 
transduction (Bartlett, Wilcher, and Samulski, 2000). It has been postulated that 
the progressively decreasing pH inside the endosomes induces a conformational 
change in the capsid leading to the exposure of a phospholipase A2 (PLA2) 
homology domain within the N-terminus of VP1 (Kronenberg et al., 2005; Sonntag 
et al., 2006). This domain is conserved among parvoviruses and required for 
infectivity (Girod et al., 2002). It is discussed to be involved in nuclear entry or, 
most likely, in endosomal escape (Girod et al., 2002; Sonntag et al., 2006). The 
importance of endosomal acidification is also known for other viruses, e.g. for 
rhabdovirus which exposes domains to facilitate membrane fusion or for 
adenovirus to disrupt the endosome (Marsh and Helenius, 1989). 
When released from the endosomes, as shown for AAV2 and AAV5, the capsids 
are a target for ubiquitination which usually serves as a signal for proteasomal 
degradation (Yan et al., 2002). Ubiquitin, however, also mediates proteasome-
independent functions (Mukhopadhyay and Riezman, 2007). Interestingly, addition 
of proteasome inhibitors, e.g. MG132, resulted in an enhancement of transgene 
expression in some cell lines transduced by the serotypes 1 to 5 and by AAV2 in 
mouse lungs in vivo (Douar et al., 2001; Duan et al., 2000; Hacker et al., 2005; 
Jennings et al., 2005; Yan et al., 2004). Though the mechanisms remain unclear, it 
has been suggested that proteasome inhibitors block capsid degradation, facilitate 
vector uncoating, lead to an increased perinuclear accumulation or translocation 
into the nucleus (Duan et al., 2000; Yan et al., 2002). 
3.1.3.4 Nuclear translocation  
Viral particles start to accumulate in the perinuclear area between 15 and 30 min 
post infection (p.i.) (Bartlett, Wilcher, and Samulski, 2000; Seisenberger et al., 
2001). Moreover, viral capsids can be detected in nuclear invaginations (Lux et al., 
2005; Seisenberger et al., 2001). In comparison to entry and intracellular 
trafficking, translocation of the virus into the nucleus is a comparably slow and 
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inefficient step (Lux et al., 2005). However, reports on intact viral particles within 
the nucleus have been published (Sanlioglu et al., 2000). 
 If viral uncoating occurs before or after entering the nucleus is still a 
controversially discussed question. Lux and colleagues reported that uncoating 
occurs before or during entry into the nucleus independently of the helper virus 
since at viral-to-cell ratios at which viral genomes could be detected within the 
nucleus. Signals for intact viral capsid were exclusively detected outside the 
nucleus in the perinuclear area or in nuclear invaginations (Lux et al., 2005). In 
presence of helper virus, however, the rare event of intranuclear localization of 
intact virals capsids is increased (Xiao et al., 2002). 
Moreover, it is still discussed whether AAV and/or AAV genomes enter the nucleus 
through the nuclear pore complex (NPC) or in a NPC-independent way (Hansen, 
Qing, and Srivastava, 2001b). However, several agents have been shown to 
enhance nuclear accumulation and gene expression of AAV including adenovirus 
as well as hydroxyurea and the previously mentioned proteasome inhibitors 
(Hansen, Qing, and Srivastava, 2001a; Jennings et al., 2005; Xiao et al., 2002).  
3.1.3.5 Latent and lytic life cycle of AAV 
The presence or absence of helper virus determines if AAV enters a lytic or latent 
life cycle. Lacking the helper viral functions, the virus latently infects cells by 
integrating into the genome. Integration occurs in dividing and, to a lesser extent, 
in non-dividing cells (Podsakoff, Wong, and Chatterjee, 1994; Russell, Miller, and 
Alexander, 1994). First, second-strand synthesis of the single-stranded virus 
genome and a basal expression of the Rep proteins are activated (Brister and 
Muzyczka, 2000; Redemann, Mendelson, and Carter, 1989). In presence of the 
large Rep proteins (Rep68, Rep78) and intact ITRs, integration occurs, although 
not exclusively, at the so-called AAVS1 site on the human chromosome 19 
(19q13.3-qter) (Kotin, Linden, and Berns, 1992; Kotin et al., 1990). The AAVS1 
locus resides a Rep binding element (RBS) and a terminal resolution site (TRS) 
equivalent to the AAV genome (Linden et al., 1996; Linden, Winocour, and Berns, 
1996; Weitzman et al., 1994). Usually, proviral sequences are integrated as viral 
concatemers in a head-to-tail conformation (Linden et al., 1996). The ability to 
integrate site-specifically into the human genome is unique among eukaryotic 
viruses and explains the attractivity of AAV as vector for gene therapy. Helper viral 
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superinfection can rescue the integrated provirus initiating a lytic, productive life 
cycle (Berns and Giraud, 1996). 
During virus replication, the 3’-OH end of the hairpin-like ITR may serve as primer 
for second-strand synthesis (Berns, 1990). The large Rep proteins unwind the ITR 
by their helicase activity which leads to exposure of the TRS which is nicked by 
the Rep endonuclease and enables complete synthesis of the second-strand by 
switching templates (Brister and Muzyczka, 2000; Im and Muzyczka, 1990; Ni et 
al., 1994). The single-stranded DNA is then converted into a parental duplex 
replicative form and production of viral progeny can proceed. 
3.1.4 Adenovirus-free AAV production and recombinant AAV vectors 
(rAAV) 
For the production of recombinant AAV (rAAV), the only viral elements required in 
cis are the ITRs while the two ORFs rep and cap are sufficient when provided in 
trans (helper plasmid) (Collaco, Cao, and Trempe, 1999). The deleted rep/cap 
sequences of the parental virus can then be replaced by marker or therapeutic 
genes resulting in the production of vectors which are unable to replicate even in 
presence of helper virus (Collaco, Cao, and Trempe, 1999). The flanking ITRs are 
necessary for packaging into the newly formed capsids. In general, rAAV is 
produced in a helper virus-free manner to avoid helper virus contaminations of 
vector preparations. The essential adenoviral genes VA, E2A and E4 have been 
cloned into an adenoviral helper plasmid and are provided in trans (Collaco, Cao, 
and Trempe, 1999; Grimm and Kleinschmidt, 1999; Xiao, Li, and Samulski, 1998). 
HEK293 cells which are commonly used for the production of viral particles are 
transgenic for the adenoviral genes E1a and E1b.  
The helper, vector and adenoviral plasmids are brought in HEK293 cells by triple 
transfection (Figure 5). 48h later, viral progeny can be isolated out of the cell 
lysates and purified by either CsCl or Iodixanol gradient ultracentrifugation 
(Hermens et al., 1999; Zolotukhin et al., 1999). AAV2 is appropiate for purification 
directly from crude lysates or from gradient purified fractions by heparin affinity 
chromatography (Zolotukhin et al., 1999). 
All serotypes can be produced as recombinant vectors as described above. 
Therefore, only the cap sequence of AAV2 has to be replaced by the serotype-
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specific cap. The ITRs as well as the rep ORF are typically derived from AAV2. 
This method is called pseudotyping or cross-packaging (Rabinowitz et al., 2002). 
 
 
Figure 5: Packaging of recombinant AAV vectors. HEK293 cells are transfected by 3 plasmids: A 
helper plasmid encoding for the rep and cap ORFs, a vector plasmid carrying the desired transgene 
flanked by the packaging sequences (ITRs) and an adenoviral helper plasmid to provide helper 
virus functions. After vector assembly, the cells are lysed and rAAV is purified, e.g. by 
ultracentrifugation. (Figure was kindly provided by H. Büning) 
 
Transduction efficiency in numerous cell lines has been reported to be limited by 
insufficient second-strand synthesis of the single-stranded (ss) DNA genome 
(Ferrari et al., 1996; Fisher et al., 1996). This step is necessary to obtain a double-
stranded DNA template for initiation of gene expression. Hence, McCarty and 
colleagues developed a pseudo double-stranded, self-complementary (sc) 
genome in order to overcome this limitation (McCarty, Monahan, and Samulski, 
2001). Their construct contains an extra copy of the palindromic terminal repeat 
thus enabling the DNA to re-fold and form a duplex DNA (Figure 6). Thereby, the 
requirement for host cell-mediated second-strand DNA synthesis can be 
circumvented and high transduction efficiencies are obtained in vitro and in vivo 
(Hacker et al., 2005; McCarty et al., 2003; Wang et al., 2003). Due to the duplex 
structure of the self-complementary genome conformation, its packaging capacity 
is limited to half of the single-stranded construct that is about 2.3 kb compared to 
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4.6 kb including ITRs. Therefore, self-complementary vectors are not suitable for 
larger transgenes. 
 
Figure 6: Single-stranded and self-complementary vector genome conformation. On the left side, 
the natural, single-stranded conformation of AAV is shown. On the right side, the same transgene 
cassette consisting of a CMV promoter-driven eGFP gene is depicted as a self-complementary 
DNA. An additional terminal repeat allows folding into a duplex DNA. (McCarty, Monahan, and 
Samulski, 2001) 
3.1.5 AAV as vector in gene therapy 
Gene therapy bases on the idea of introducing genetic material into an organism in 
order to cure or improve the status of a disease. In general, two different systems 
are applied, the viral and non-viral vectors. Whereas the viral systems include 
adeno-, retro-, vaccinia-, pox-, herpes simplex- and adeno-associated-viral 
vectors, the non-viral vector strategy uses naked DNA and lipid- or 
polyethylenglycol- (PEG) covered DNA (Gould and Favorov, 2003; Minato et al., 
2003; Omori et al., 2003).  
Ideally, gene therapeutical vectors should combine efficiency and safety. Unique 
for AAV is that no disease could be related to this virus despite its broad tissue 
tropism (Berns and Linden, 1995). The transduceability of various cell types 
including dividing as well as post-mitotic or quiescent cells and differentiated 
tissues such as brain, muscle, lung and liver, qualifies AAV for a wide range of 
applications (Alexander et al., 1996; Fisher et al., 1997; Flotte et al., 1993; Kaplitt 
et al., 1994; Kaplitt et al., 1996; Manno et al., 2006; Podsakoff, Wong, and 
Chatterjee, 1994). Moreover, AAV has also been shown to mediate long-term 
expression, e.g. in a muscle-directed trial where transgene expression sustained 
for more than four years in a canine hemophilia B model (Fisher et al., 1997; 
Herzog et al., 1999). As another important aspect, AAV does not need to integrate 
into the host genome in contrast to lenti- or retroviral vectors. Actually, vector 
genomes seem more likely to exist as episomes (Duan et al., 1998a; Nakai et al., 
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2001). Moreover, in presence of the large Rep proteins, AAV is able to integrate 
site-specifically into the human chromosome 19 thus minimizing the risk of 
insertional mutagenesis (Huttner et al., 2003; Kotin et al., 1990). By the 
development of high titer-reaching helpervirus-free production methods as well as 
improvements in purification this vector system has become even more attractive. 
As recombinant AAV vectors are gutless vectors, they are unable to replicate even 
in presence of helper virus (Samulski, Chang, and Shenk, 1987).  
In general, immunologic reactions to AAV are low. The importance of that aspect 
becomes evident when AAV is compared to adenovirus which elicits high immune 
responses (Raper et al., 2003; Zaiss et al., 2002). Apparently, AAV has only a 
minimal inflammatory potential and seems not to engage pattern recognition 
receptors like toll-like receptors (TLRs) mediating innate immune responses 
(Hensley and Amalfitano, 2007; Zaiss et al., 2002). The prevalence of antibodies 
against AAV2 due to natural infections is as high as 50 to 96 % in the human 
population. The amount of neutralizing antibodies varies from 18 to 68 % 
depending on age and ethnic group (Chirmule et al., 1999; Erles, Sebokova, and 
Schlehofer, 1999; Moskalenko et al., 2000). Animal experiments have confirmed 
that neutralizing antibodies have strong negative implications on transduction 
efficiency if the same serotype is reapplied (Scallan et al., 2006). Although human 
data are limited, at least for one patient in a clinical hemophilia B trial, neutralizing 
antibodies seem to account for the absence of transgene expression (Manno et 
al., 2006). Additionally, an anti-capsid response was observed.  
Disadvantages of the AAV vector system are its small genome size limiting the 
coding capacity for transgenes including ITRs to a maximum of 4.1 to 4.9 kb  and 
its broad tissue tropism interfering with a cell-specific in in vivo gene transfer 
(Dong, Fan, and Frizzell, 1996). 
For overcoming pre-existing immune reactions and off-target gene expression, 
several options are available. The use of serotypes other than AAV2 which show 
different tropisms and immune responses can be considered and  technology, 
respectively, are likely to cope with these limitations (Buning et al., 2003b; Grimm 
and Kay, 2003; Limberis and Wilson, 2006; Wu, Asokan, and Samulski, 2006). 
Furthermore, several strategies have been developed to overcome the size 
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limitation (Duan et al., 2001). Overall, AAV is a promising vector for gene therapy 
as assessed in clinical trials.  
Since the first gene therapy clinical trial in 1989, 1308 more studies have been 
initiated worldwide (http://www.wiley.co.uk/genmed/clinical/). The main focus for 
gene therapeutical applications is the treatment of cancer with 66.5 % clinical trials 
followed by cardiovascular (9.1 %) and monogenic (8.3 %) diseases. In most 
cases, adeno- (24.7 %) or retroviral (22.8 %) vectors find application, while AAV 
vectors are used only in 3.5 % of the approaches. In complete, 32 clinical trials 
involving AAV vectors are still open, whereas 14 are already closed. Currently, 
evaluation of safety of AAV as a vector system is of main interest in clinical trials. 
First published data dealt with the monogenic diseases cystic fibrosis and 
hemophilia B in gene therapy trials. Administration of the cystic fibrosis 
transmembrane conductance regulator (CFTR) as transgene on the nasal sinus 
and bronchial epithelium resulted in an improvement of pulmonary function and 
partial correction of hyperinflammatory responses and electrophysiological defects 
(Moss et al., 2004; Wagner et al., 1999; Wagner et al., 1998). AAV was approved 
to be safe in these clinical settings as well as in the treatment of hemophilia B by 
intramuscular or intrahepatic vector administration (Kay et al., 2000; Manno et al., 
2003; Manno et al., 2006). Evidences for transduction were found in all patients of 
the muscle-directed study and long-term expression of the therapeutic gene, 
coagulation factor IX (FIX), could be detected albeit at low levels. Highest vector 
amount administered into the hepatic artery resulted in therapeutic, but transient 
(<8 weeks) transgene expression levels.  
3.1.5.1 Gene therapy of ischemic cardiovascular diseases 
As mentioned above, cardiovascular diseases are a main target for human gene 
therapy. Despite considerable advances in conventional treatment strategies, 
heart diseases remain the prevalent cause of disability and premature death in the 
human population (17 million deaths per year) world-wide (World Health 
Organization 2008). Since organ regeneration, pharmacotherapy and invasive 
interventions are limited, alternative therapies are urgently needed. Currently, 
xenotransplantation, gene- and cell-based therapies are the focus of intense 
investigations. Most efforts in the latter two fields are made on the development of 
strategies to induce angiogenesis (vessel formation from pre-existing ones) and 
vasculogenesis (de novo vessel formation) (Khan, Sellke, and Laham, 2003; Melo 
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et al., 2004). Such therapies could be administered either for protection of 
myocardium at risk or for rescue after infarction (Khan, Sellke, and Laham, 2003). 
Investigations on the molecular and cellular basis of cardiac diseases have 
identified potential therapeutic genes. The promising therapeutic potential of 
angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF) or hepatocyte growth factor (HGF) has already been 
successfully demonstrated in clinical trials (Baumgartner et al., 1998; Grines et al., 
2003; Losordo et al., 2002; Morishita et al., 2004). Overexpression of 
cytoprotective genes like antioxidant genes (e.g. heme oxygenase 1 (HO-1)), 
survival genes (e.g. Bcl-2, HGF), genes encoding for heat shock proteins and anti-
inflammatory cytokines (e.g. IL-4, IL-10, IL-13, TGF-β) as well as inhibition of 
proapoptotic genes (e.g. Bad) might be useful in myocardial protection as 
described in various publications and reviewed by Melo and colleagues (Melo et 
al., 2005).  
Generally, gene transfer vectors are administered into the heart tissue by either of 
the two routes, intracoronary or intramyocardial. Injection into the myocard 
resulted in local transgene expression in a patchy pattern (French et al., 1994). In 
order to reach homogenous vector distribution, vector can be applied 
intracoronary. However, this procedure is limited by the short exposure time of the 
vector to the endothelium and fast systemic distribution. If transduction of the 
myocardium is desired, the vector has to overcome the endothelial barrier. 
Therefore, novel techniques have been developed to increase endothelial 
permeability and to prolong exposure time. Capillary-modulating substances like 
histamine, serotonin or VEGF as well as high intravascular pressure or ultrasound 
have been described to permeabilize the endothelial barrier (Beeri et al., 2002; 
Bekeredjian et al., 2003; Donahue et al., 1998; Logeart et al., 2001). As 
demonstrated in a rat model, simultaneous clamping of the pulmonary artery and 
the aorta allowed the adenoviral vector to recirculate in the coronaries over a short 
period of time and resulted in successful transgene expression (Hajjar et al., 
1998). Prolongation can also be reached by hypothermia or cardiac arrest (Ding et 
al., 2004; Iwanaga et al., 2004).  
On the other hand, direct targeting of the endothelium might be favourable in 
endothelial dysfunction which plays a pivotal role in atherosclerosis, coronary 
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artery disease and hypercholesterolemia. Under physiological conditions, the 
endothelium retains numerous prominent roles in maintaining vessel wall 
homeostasis such as regulation of angiogenesis, thrombolysis, leukocyte 
adhesion, platelet adhesion and aggregation (Cooke, 2000). Therefore, anti-
thrombotic, anti-adhesion (e.g. inhibition of intercellular adhesion molecule 1 
(ICAM-1)) or anti-inflammatory genes are considered as therapeutic targets in 
endothelial dysfunction and should preferentially be expressed by endothelial cells 
(Vassalli et al., 2003). In diseases associated with high oxidative stress, the 
overexpression of enzymes that act as anti-oxidants could be beneficial as shown 
in a rat postmyocardial infarction model using rAAV to deliver heme oxygenase 1 
(HO-1) delivery (Liu et al., 2006).  
AAV2 was reported to transduce endothelial cells in vitro and in vivo with low 
efficiency (Nicklin et al., 2001a; Pajusola et al., 2002). Besides AAV, also adeno-, 
retro- and lentiviruses have been used as gene therapy vectors for cardiac 
diseases. Additionally to the disadvantages discussed above, the potential of 
retroviruses is limited as they require dividing cells for efficient transduction, 
whereas lentiviruses are appropriate vectors for endothelial transduction (Byun et 
al., 2000; Sakoda et al., 2007). Adenovirus might provoque myocarditis in 
response to immune reactions and shows only short-term transgene expression 
(Calabrese and Thiene, 2003; Guzman et al., 1993). In targeting of the 
myocardium, comparative analyses of the AAV serotypes in mouse and non-
human primate models revealed the recently discovered AAV9 as the most 
efficient serotype (Pacak et al., 2006; Palomeque et al., 2007). 
Recently, the identification of stem cells capable of contributing to tissue 
regeneration has ignited significant interest in the possibility that cell therapy might 
be used therapeutically for repair of damaged myocardium. Thereby, the 
combination of cell- and gene-based therapies could result in even higher 
beneficial effects. This interesting field is discussed separately in chapter 3.2.3. 
Transplantations as potential therapy are limited primarily by donor organ shortage 
and the need for optimal tissue matching to minimize the risk of organ rejection. 
Nevertheless, organ recipients require life-long immunosuppression. Currently, 
researchers are determining the potential and limiting factors of porcine grafts 
which are functionally and physically closely related to human hearts. In 
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xenotransplantation and transplantation, gene therapy could allow the production 
of immunomodulatory proteins locally within the donor graft or the induction of 
donor-specific tolerance and other mechanisms preventing graft rejection (Chen, 
Sung, and Bromberg, 2002). Moreover, the identification of beneficial effectors 
could account for the generation of transgenic animals for xenotransplantation. 
Both, innate and adaptive immune reactions are responsible for organ rejection. 
The hyperacute rejection occurring within minutes is due to complement-
dependent reactions of pre-existing alloantibodies to blood group or major 
histocompatibility complex (MHC) antigens. As complement-regulatory molecules 
are working less efficient across species-barriers and recognize directly certain 
porcine oligosaccharides (e.g. αGal), this step is very problematic for xenografts. 
Nevertheless, the main mediators for acute organ rejection are T-cells. They can 
be either activated directly by donor antigen-presenting cells (APC) or indirectly by 
the recipient’s APCs which present phagozytosed non-self molecules to T-cells. 
Additionally, T-cells play an important role in chronic rejection processes caused 
by inflammatory vascular injury. Briefly, alloreactive T-cells infiltrate the graft and 
recruit inflammatory cells by cytokine release and stimulation of endothelial 
adhesion molecules. Gene therapeutical approaches encompass the inhibition of 
anti-graft responses and induction of graft protective mechanisms (Chen, Sung, 
and Bromberg, 2002). As already discussed above, delivery of genes encoding for 
anti-adhesive, anti-apoptotic, anti-inflammatory and antioxidant proteins might be 
useful in this regard as well. Moreover, blockage of specific functions of the 
adaptive immune system showed promising effects. For example, inhibition of the 
costimulatory signal (CD28-CD80/86) between APC and T-cell by expression of 
CTLA-4Ig prolongs cardiac graft survival using AAV as vector system (Chen et al., 
2003). Expression of immunomodulatory cytokines such as IL-4, IL-10, IL-13 and 
TGF-β resulted in prolonged allograft survival in various models (Chan et al., 2000; 
David et al., 2000; Ke et al., 2000; Ke et al., 2002). Another example is viral IL-10 
(vIL-10) which is encoded by the Epstein-Barr virus. It has the same properties like 
IL-10, but lacks T-cell immunostimulatory functions and has been shown to 
prolong heart survival time in an adenovirus-mediated vIL-10 rat transplantation 
model (Zuo et al., 2001).    
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3.2 Stem cells 
By definition, stem cells (SC) are undifferentiated cells able to generate new stem 
cells of identical differentiation potency or to produce cells that differentiate along a 
lineage pathway. The first of these two activities of stem cells is described as 
symmetric, the second as asymmetric division. Both types of cell divisions 
contribute to the homeostasis of the stem cell population within the stem cell 
niche, whereas asymmetric divisions are responsible for renewal of the respective, 
differentiated tissue. In the adult tissue, quiescent stem or progenitor cells are 
normally mobilized upon stimuli for physiological and pathological tissue 
regeneration. 
Stem cells can be divided into three different types depending on their 
developmental potential. Embryonic totipotent stem cells are able to differentiate 
into all embryonic and extra-embryonic cell types (e.g. placenta, umbilical cord) 
while pluripotent – the so-called embryonic stem cells – possess the ability to 
generate all tissues of an adult organism. Pluripotent cells give rise to the three 
types of germ layer stem cells for ecto-, endo- and mesoderm (Figure 7). As 
development proceeds the differentiation properties get more restricted. The 
multipotent stem cell gives rise to only a limited number of cell types of fully 
developed organs maintaining a steady-state homeostasis in the tissue. If only one 
terminally differentiated cell type can be generated, the cell is referred to as 
unipotent.  
Multipotent and unipotent cells are designated as somatic or adult stem cells and 
are present in tissues where terminally differentiated cells do not divide or have 
only a short life span. Indeed, long time it was believed that organs responding 
poorly to regenerative pressure (e.g. heart, brain) would not reside any stem cells. 
Then it turned out that even organs considered as post-mitotic were able to 
regenerate although at lower levels. Anyway, multipotent stem cells are more 
abundant in tissues with a high cell turnover rate such as epithelia, vasculature or 
blood and to a lesser extent in organs or tissues undergoing little self-renewal like 
the central nervous system or the myocard (Beltrami et al., 2003; Lemoli, 2005; 
Lois and Alvarez-Buylla, 1993; Oh et al., 2003). The best characterized multipotent 
cells are hematopoietic stem cells (HSC) which give rise to the entire blood 
lineages.  
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Figure 7: Postnatal stem and progenitor cells. SC, stem cell.  (Asahara and Kawamoto, 2004) 
3.2.1 Hematopoietic stem cells and endothelial progenitor cells 
Since blood cells have only a limited life span and essential functions like gas 
transport, immunity and other vital functions have to be maintained, a continuous 
production of new cells is needed. The hematopoietic stem cell (HSC) provides all 
the blood lineage cells and is well described. In the 1960’s first evidence for the 
existence of clonogenic cells able to generate myeloerythroid cells after bone 
marrow transplantation in lethally irradiated mice was given (Becker, Mc, and Till, 
1963; Wu et al., 1968).  
Regarding embryonic development hematopoietic and endothelial progenitor cells 
share a common mesodermal precursor called hemangioblast. These cells can be 
found in the extra embryonic yolk sac where they are accumulating in the so-called 
blood islands. In the inner part of these aggregates cells possess hematopoietic 
properties whereas the outer cells begin to form endothelial cells (EC) (Asahara 
and Kawamoto, 2004). These first developing vessels are marking the onset of 
vasculogenesis. Long time it was believed that this process only takes place 
during embryogenesis in contrast to angiogenesis, meaning the sprouting of new 
vessels out of pre-existing ones. Then, in 1997, Asahara and colleagues published 
the intriguing observation that CD34+
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adults were able to differentiate ex vivo into the endothelial lineage (Asahara et al., 
1997). They were expressing a number of endothelial markers like Flk-1, Tie-2 and 
CD34 and were shown to incorporate into neovessels at ischemic sites. This 
subgroup of hematopoietic progenitor cells was named “endothelial progenitor 
cells” (EPC). In the following year, Rafii’s group showed that CD34+ cells cultured 
in presence of basic fibroblast growth factor, insulin-like growth factor-1 and 
vascular endothelial growth factor (VEGF) differentiated into endothelial cells as 
staining for von Willebrand Factor (vWF) and the incorporation of acetylated low-
density lipoprotein (Ac-LDL) proved (Shi et al., 1998). Even more interesting was 
the fact that after bone marrow transplantation in a canine animal model, donor 
“circulating bone marrow-derived endothelial cells” colonized a Dacron graft. This 
indicates that a CD34+ subpopulation can be mobilized to the circulation and 
populates prostheses.  
EPCs were described as positive for CD34 and for the endothelial marker vascular 
endothelial growth factor receptor 2 (VEGFR2) (Peichev et al., 2000). HSCs and 
postnatal EPCs share certain epitopes including Flk-1, Tie-2, CD133, Sca-1, c-Kit 
and CD34 which can also be found on mature endothelial cells (Hatzopoulos et al., 
1998). Further analysis revealed CD133 (also called AC133 or prominin), an 
orphan receptor, as a marker for more immature hematopoietic stem cells, 
because of its absence on mature endothelial cells and monocytic cells (Figure 8) 
(Peichev et al., 2000). Therefore it can be expected that CD133+VEGFR2+ cells 
may represent more likely the population of immature progenitor cells. 
Nevertheless, the ability to differentiate into the endothelial lineage and not 
preliminary the surface marker profile is defining the population of EPCs. Thus, the 
group of “EPCs” might range from stages of hemangioblast to fully differentiated 
ECs and also its putative precursors and stages of lineage differentiation remain to 
be investigated (Figure 8).  
Moreover, there are consolidating evidences also for myeloid cells as origin of 
EPCs. Hebbel and colleagues observed first that morphologically and functionally 
distinct endothelial cell subpopulations can be generated out of peripheral blood 
(Lin et al., 2000). CD14+/CD34- myeloid cells showed coexpression of endothelial 
markers and the ability to form tube-like structures in cell culture (Schmeisser et 
al., 2001). Even stronger evidence demonstrated in vivo experiments where ex 
vivo expanded CD14+ mononuclear cells were able to incorporate as endothelial 
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cells into newly formed vessels in a mouse hind limb model (Urbich et al., 2003). 
Thus, it can be concluded from these data that myeloid cells can differentiate (or 
transdifferentiate) into the endothelial lineage (Figure 8).  
 
 
 
Figure 8: Origin and differentiation of endothelial progenitor cells. Scheme depicts the potential 
origin and differentiation of EPCs from HSCs and nonhematopoietic cells. (Urbich and Dimmeler, 
2004) 
 
To further complicate that topic, several studies showed that stem cell populations 
beside the HSCs can generate endothelial cells (Figure 8). For example, Reyes 
and colleagues identified nonhematopoietic multipotent adult progenitor cells 
(MAPC) which copurified with the mesenchymal stem cells isolated out of the 
postnatal bone marrow. When the MAPCs (CD34-, CD133+, vascular endothelial 
cadherin– (VE-cadherin)) were cultured in presence of VEGF, expression of 
endothelial markers like CD34 and VE-cadherin were detected and the respective 
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MACs could be found in sites of neoangiogenesis in tumors (Reyes et al., 2002). 
Another cell type – the tissue-resident stem cell isolated out of the heart – has also 
been shown to give rise to endothelial cells (Beltrami et al., 2003). 
Different isolation methods and sources of CD34+ EPCs have been described so 
far (Asahara et al., 1997; Fan et al., 2003; Gehling et al., 2000; Hur et al., 2004; 
Lin et al., 2000; Reyes et al., 2002; Shi et al., 1998; Wijelath et al., 2004). CD34+ 
cells can be isolated either out of the bone marrow (BM), peripheral blood (PB) or 
umbilical cord blood (CB). The amount of HSCs in the PB is lower (around 0.1 %) 
compared to the CB and BM where about 1 % of the total mononuclear fraction is 
CD34+ (Hao et al., 1995; Kinniburgh and Russell, 1993; Sutherland et al., 1994). 
The fraction of circulating HSCs in the PB increases upon ischemia or under 
treatment with cytokines which are known to mobilize bone marrow-derived 
progenitors (Gill et al., 2001; Takahashi et al., 1999). Compared to the highly 
primitive populations of CD34+CD38- cells isolated out of BM, the cord blood-
derived cells show a much higher cloning efficiency, proliferate more rapidly upon 
cytokine stimulation and generate a higher number of progeny cells (Cardoso et 
al., 1993; Hao et al., 1995; Lu et al., 1993). For these reasons, CB is an ideal 
source for isolation of HSCs.  
3.2.2 Bone marrow stem cell niche, mobilization and homing 
Quiescence and activity of HSCs in their bone marrow niche are tightly regulated 
by the microenvironment. This is a necessity to maintain tissue homeostasis and 
to prevent exhaustion of the stem cell pool or tumor formation. Important 
components of the bone marrow stem cell niche are osteoblasts and stromal cells 
(Moore and Lemischka, 2006; Visnjic et al., 2001). The membrane-bound stem 
cell factor (SCF, c-Kit ligand, steel factor S1F) on stromal cells immobilizes HSCs 
by its SCF-receptor c-Kit. In general, adhesion between these two cell types is 
regulated by cytokines. Secretion of proteolytic enzymes like elastase, cathepsin 
G or matrix metalloproteinase (MMP) is playing a major role in this process. One 
important mechanism for the mobilization of stem cells is the cleavage of 
membrane-bound SCF by MMP9 which is induced by stromal cell-derived factor-1 
(SDF-1) thus diminishing chemoattraction to the bone marrow (Heissig et al., 
2002). Also other factors like vascular endothelial growth factor (VEGF) and 
granulocyte macrophage colony-stimulating factor (GM-CSF) have been shown to 
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augment EPC levels in the blood and promote neovascularization (Asahara et al., 
1999; Takahashi et al., 1999). Moreover, a number of proangiogenic factors 
including angiopoietin-1, placental growth factor and erythropoietin had similar 
effects (Dimmeler et al., 2001; Hattori et al., 2001; Hattori et al., 2002; Heeschen 
et al., 2003). Systemic treatment with HMG CoA reductase inhibitors (statins), 
estrogens, certain cytotoxic drugs (cyclophosphamide, hydroxyurea, 5-fluorouracil) 
and cytokines (e.g. G-CSF, GM-CSF, IL-11, IL-3, IL-8, SCF, Flt3L) as well as 
physical exercise enhanced HSC mobilization (Dimmeler et al., 2001; Iwakura et 
al., 2003; Laufs et al., 2004; Papayannopoulou et al., 2003). Incorporation of EPCs 
into newly formed vessels assumes not only EPC mobilization, but also a complex 
process composed of chemoattraction, adhesion, transmigration and finally 
differentiation into mature endothelial cells (Figure 9). The term “homing” which is 
often used in the context of stem cells comprises thereby the steps of adhesion, 
transmigration through the activated endothelium and migration to the target site. 
Besides homing to the ischemic or injured tissue also homing to the bone marrow 
occurs. This process which is far better understood than the homing to ischemic or 
injured tissue (Papayannopoulou, 2003). 
Physiologically, ischemia seems to be an important egress signal for EPCs from 
the bone marrow. As possible mechanisms, upregulation of VEGF and SDF-1 
have been proposed which could lead to induction of MMP9-mediated mobilization 
of EPCs (Aicher et al., 2003; Gill et al., 2001; Heissig et al., 2002; Takahashi et al., 
1999; Wysoczynski et al., 2005). It has also been shown that SDF-1 levels are 
enhanced during the first days after myocardial infarction (Askari et al., 2003). 
Moreover, the circulating EPCs are attracted by a SDF-1 and VEGF gradient to 
sites of ischemia or tissue injury (Shintani et al., 2001; Yamaguchi et al., 2003). 
Together with directly induced hypoxia-responsive genes, immune competent cells 
which are accumulating in the ischemic tissue may enhance the level of 
chemokines such as MCP-1 or interleukins to further recruit circulating EPCs 
(Fujiyama et al., 2003). Another probable homing signal could be given by 
necrosis through release of high mobility group box protein 1 (HMGB1). This 
chromatin-binding protein is mediating extracellular danger signals thus promoting 
homing of EPCs (Scaffidi, Misteli, and Bianchi, 2002). 
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Figure 9: Mechanisms of EPC homing and differentiation. Recruitment and incorporation of EPCs 
into ischemic tissues requires a coordinated multistep process including mobilization, 
chemoattraction, adhesion, transmigration, migration, tissue invasion and in situ differentiation. 
Factors that are proposed to regulate the distinct steps are indicated. (Urbich and Dimmeler, 2004) 
 
Adhesion and migration processes of diverse cell types including HSCs and 
leukocytes are controlled by integrins (Carlos and Harlan, 1994; Springer, 1994). 
This is, for example, a mechanism by which SDF-1 acts (De Falco et al., 2004). 
First step is the adhesion of HSCs to the activated endothelium. Integrins have 
been identified as potential mediators for homing as they are able to form cell-cell 
interactions (Chavakis et al., 2005; Soligo et al., 1990). In fact, there are evidences 
for the importance of different integrins depending on the target tissue (Scott, 
Priestley, and Papayannopoulou, 2003). Final attachment of embryonic progenitor 
cells to tumor endothelium was proposed to be mediated by P- and E-selectin and 
P-selectin glycoprotein ligand-1 (Vajkoczy et al., 2003). 
In contrast to homing into sites of ischemia, incorporation of EPCs into denuded 
arteries seems to be less dependent on cell-cell interaction and transmigration. 
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Instead, adhesion to the extracellular matrix via vitronectin receptors (αvβ3- and 
αvβ5-integrins) is a more important mechanism. This has also been shown in vivo 
by inhibiting vitronectin receptors using cyclic RGD peptides which blocked 
reendothelialization of injured carotid arteries (Walter et al., 2002). Furthermore, 
other sorts of integrins like the β1-subtype might play a role in adhesion to 
extracellular matrix proteins of denuded arteries (Fujiyama et al., 2003).  
Concerning migration and invasion through the endothelial monolayer to the site of 
ischemia little is known so far, but different proteases like cathepsins or 
metalloproteinases may take part in these processes. 
Mechanisms influencing differentiation of EPCs into endothelial cells also remain 
largely unknown. However, VEGF and its receptors have been shown to mediate 
endothelial differentiation in embryonic development (Ferrara et al., 1996; Fong et 
al., 1995; Shalaby et al., 1995). Also for various adult progenitor cells, this crucial 
role for VEGF in ex vivo endothelial differentiation could be approved (Dimmeler et 
al., 2001; Kalka et al., 2000).  
3.2.3 Therapeutic potentials of EPC transplantation and gene therapy 
CD34+ cells gained attention as a population of endothelial progenitor cells having 
the ability to self-renew, proliferate and differentiate into endothelial cells. 
Moreover, as hematopoietic stem cells they give rise to all blood cells thus being 
interesting for therapy of hematopoietic and autoimmune diseases. Especially, 
induction of neovascularization in sites of ischemia and reendothelialization after 
endothelial injury brought these cells into focus for the treatment of chronic heart 
disease and acute myocardial infarction. Increased mobilization of stem cells from 
the bone marrow stem cell niche and proliferation of these cells is an effective 
means to support self-regenerative processes (Figure 10). 
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Figure 10: Therapeutic application of EPCs for neovascularization. (Asahara and Kawamoto, 2004) 
 
In vivo expansion can be induced by application of growth factors, cytokines and 
pharmaceuticals like statins. Therapeutical success has been stated in several 
studies also in patients by treatment with VEGF (Kalka et al., 2000). Another 
possibility is the ex vivo expansion of CD34+ cells followed by transplantation. 
Asahara’s group published that transplantation of ex vivo expanded human CD34+ 
cells in a hind limb model of immunodeficient mice augmented blood flow and led 
to a 50 % reduction in autoamputation and limb necrosis (Asahara et al., 1999). In 
nude rat myocardial ischemia the positive effects of transplanted human CD34+ 
cells comprised their incorporation into neovessels and differentiation into 
endothelial cells, enhancement of neovascularization and prevention of fibrosis 
and ventricular dysfunction (Kawamoto et al., 2001). Most convincingly are 
currently ongoing clinical trials where ex vivo expanded progenitor cells are 
transplanted successfully into patients suffering from acute myocardial infarction 
(TOPCARE-AMI study) or chronic heart disease (TOPCARE-CHD study) 
improving different parameters pointing to heart regeneration (Assmus et al., 2007; 
Assmus et al., 2006a; Assmus et al., 2002; Assmus et al., 2006b; Britten et al., 
2003; Kissel et al., 2007; Schachinger et al., 2004; Schachinger et al., 2006a; 
Schachinger et al., 2006b; Schachinger et al., 2006c). The subsequently described 
strategy – together with ex vivo expansion – might be meaningful in patients where 
progenitor cell function is dysregulated like in hypercholesterolemia, type II 
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diabetes or in aged persons (Chauhan et al., 1996; Chen et al., 2004; Cosentino 
and Luscher, 1998; Heiss et al., 2005; Thum et al., 2007). Combination of cell- and 
gene-based strategies, e.g for the expression of angiogenic growth factors or 
genes favoring the differentiation along a certain lineage could improve the 
success of endothelial progenitor cell transplantation.  
Their easy accessibility and ex vivo expansion capability makes CD34+ cells an 
auspicious aim for gene therapy. Different approaches have already been made 
using adenovirus- (Ad), lentivirus-, retrovirus- or AAV-based vector systems as 
described (Evans et al., 1999; Iwaguro et al., 2002; Santat et al., 2005; Schmidt et 
al., 2002). First experiments report increased neovascularization and a 63.7 % 
reduction in limb necrosis and autoamputations after application of Ad-VEGF in a 
mouse hind limb model (Iwaguro et al., 2002). For curing different hematological 
disorders like X-linked severe combined immunodeficiency or adenosine 
deaminase deficiency, several clinical trials using retroviral vector systems to 
transduce CD34+ cells have been successful (Aiuti et al., 2002; Cavazzana-Calvo 
et al., 2000; Gaspar et al., 2006; Hacein-Bey-Abina et al., 2002). Also in two 
primate models, different clones of retrovirus-transduced CD34+ cells were still 
detectable in peripheral blood leukocytes after 33 months (Schmidt et al., 2002). 
Despite these promising results, retroviral vectors imply the risk of insertional 
mutagenesis (Hacein-Bey-Abina et al., 2003). In the case of AAV, a rarely 
integrating vector, transgene expression declines over time being ideal for 
purposes where only transient gene expression is required as for example in 
myocardial diseases (Nathwani et al., 2000). This makes the AAV2-based vector 
system an attractive alternative. However, published in vitro data concerning 
transduction of CD34+ cells by rAAV2 are conflicting. Transduction efficiencies are 
reported to vary from 0 % (Alexander, Russell, and Miller, 1997) to higher 
expression levels using high (multiplicity of infection (MOI) >106) or relatively low 
(MOI >100) vector to cell ratios (Chatterjee et al., 1999; Hargrove et al., 1997; 
Malik et al., 1997; Nathwani et al., 2000; Ponnazhagan et al., 1997; Zhou et al., 
1994). Different protocols for isolation and culturing of EPCs as well as differing 
vector production techniques, titration methods and applied vector amounts impair 
a direct comparison of results. So, prestimulation of EPCs with cytokines 
enhances AAV-mediated transgene expression while freshly isolated cells are 
resistant to transduction (Nathwani et al., 2000). Transduction efficiencies could be 
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enhanced from 10 to 51 % by using higher cytokine concentrations and addition of 
TNFα (MOI 106) (Nathwani et al., 2000). Early investigations reported 
transduceability of HSCs by rAAV, but using crude vector lysates (Fisher-Adams 
et al., 1996; Goodman et al., 1994; Zhou et al., 1994). These low purified 
preparations contain adenoviral contaminations which might persist in the vector 
preparation using Ad as helpervirus (Alexander, Russell, and Miller, 1997). 
Moreover, donor-depending differences in transgene expression have been 
reported varying from 0 to 80 % 48 h p.i. or 5 to 100 % in long-term culture-
initiating cells after 5 weeks (Chatterjee et al., 1999; Ponnazhagan et al., 1997). 
Nevertheless, transplantation of rAAV2-transduced CD34+ cells into immune-
deficient mice showed the potential to engraft. A certain amount of bone marrow 
cells was transgenic and remained stable as well as several blood cell lineages 
(Santat et al., 2005). Also in a rhesus monkey model a high amount of vector 
modified blood cells could be detected 15 months after transplantation 
demonstrating that transduction of CD34+ cells by rAAV leads to long-term 
expression of the transgene (Schimmenti et al., 1998). 
3.2.4 Aim of the study 
Despite considerable therapeutic advances heart diseases remain the main cause 
of premature death in the human population world-wide. Heart transplantation 
often represents the only possibility to rescue the patient, but this is limited by 
organ shortage and the risk of graft rejection. Due to recent improvements in 
vector technology and in identification of potential therapeutic genes for the 
treatment of heart diseases, gene therapeutical strategies have become an option. 
Another approach is presented by the use of stem and progenitor cells which has 
gained increasing attention. Endothelial progenitor cells, for example, have already 
been demonstrated to be promising tools to achieve revascularization in ischemic 
regions as they possess the ability to differentiate into endothelial cells and home 
to sites of ischemia. The combination of cell- and gene-based strategies offers 
clear advantages for certain applications as revascularization of ischemic sites, 
and is thus a topic of many pre- and clinical studies.  
Both parts of this thesis focus on heart diseases. The first part aimed to establish 
the rAAV-based gene transfer system for modification of heart tissue before 
transplantation. This included the identification of potential limitations for efficient 
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use of this system, and – if possible – the development of strategies for their 
solution. As heterotopic heart transplantation models served the Sprague Dawley 
rats as small and the German landrace piglets as large animal model. While the 
rodent model ought to be established to later allow a fast screening for transgenes 
which might prolong graft survival, the studies in pigs should be used as preclinical 
model. Firstly, conditions enabling vector entry without harming the graft had to be 
assessed. In this regard, efficiency of intracoronary vector delivery under 
normothermic and hypothermic conditions should be compared in the rat model 
and findings shall then be translated into the pig model.   
In the second part, a protocol for efficient rAAV-mediated transduction of CD34+ 
cells ought to be established. The great potential of these cells for the treatment of 
heart diseases is widely accepted. Furthermore, they are ideal targets for genetic 
modification as they can be isolated, cultivated ex vivo and reapplied into the 
patient where they home to ischemic regions. Since currently used vector systems 
bear – despite their efficiency – certain risks like insertional mutagenesis, rAAV is 
discussed as valid alternative. Thus, comparative analyses of different serotypes 
as well as single-stranded and self-complementary genome conformation ought to 
be performed. Furthermore, it should be determined which cellular receptors are 
engaged for vector entry. Since genetically modified CD34+ cells have to maintain 
their ability to differentiate into endothelial cells to be of use in the patient, a 
potential inhibitory effect of the rAAV-mediated gene transfer had to be excluded. 
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4 Results 
4.1 rAAV transfer into heart 
Numerous strategies for gene transfer into the heart have been developed. In 
most cases, investigators aimed to transduce the myocard either by direct 
intramyocardial injection or intracoronary delivery of the gene transfer vector (see 
also chapter 3.1.5.1). In the latter case, additional attempts are necessary to 
overcome the endothelial barrier. Successful examples are elevated vascular 
pressure or administration of capillary-modulating substances (e.g. histamine) to 
increase vascular permeability (Beeri et al., 2002; Donahue et al., 1998; Logeart et 
al., 2001). 
However, also the endothelium itself is a therapeutic target since it is an important 
determinant in endothelial dysfunction-associated disorders such as 
cardiovascular diseases (Cooke, 2000; Melo et al., 2004). Moreover, being the first 
donor-derived tissue encountered by the recipient’s circulating immune cells, the 
endothelium has major impact on successful organ transplantation and could thus 
serve as target for gene therapy to reduce graft rejection, e.g. graft arteriopathy 
(Vassalli et al., 2003) (for more details please refer to chapter 3.1.5.1).   
4.1.1 rAAV transfer into rodent heart 
4.1.1.1 Heterogenic rat heart transplantation 
Heart transplantation experiments with piglets are very time-consuming and 
complicated and large vector amounts are needed. Thus, a Sprague-Dawley rat 
heart transplantation model was established by our colleagues of the Department 
of Heart Surgery at the Ludwig-Maximillians University Munich aiming to use this 
model for a fast screening of potentially useful therapeutic genes transferred into 
the donor organ by rAAV-mediated gene transfer. Based on published results at 
the start of our project, which described successful applications of AAV2 vectors in 
rodent heart models we decided to use this serotype (Asfour et al., 2002; 
Hoshijima et al., 2002; Iwanaga et al., 2004; Li et al., 2003; Svensson et al., 1999). 
Firstly, we aimed to identify a transplantation technique allowing to transplant the 
heart as unharmed as possible providing at the same time the most feasible 
conditions for AAV-mediated gene transfer. Therefore, we compared the following 
techniques summarized in chapter 7.5.1: A) heart transplantations performed with 
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a non-beating, hypothermic heart after cardiac arrest by ice-cold cardioplegic 
solution and B) a beating heart at normothermia. Whereas hypothermia should 
preserve better from ischemic injury the low temperature may impair receptor-
mediated endocytosis of cell surface-bound AAV vectors. In contrast, 
normothermia might allow direct vector entry, but may harm the heart tissue. As 
depicted in Table 1, each group consisted of 3 animals. 
 
Operation technique Vector application Animal Vector amount 
normothermia intracoronary A1 5.2 x 1011 
   A2 3.4 x 1011 
   A3 8.5 x 1011 
      
hypothermia intracoronary B1 5.2 x 1011 
   B2 5.0 x 1010 
   B3 3.1 x 1011 
      
w/o transplantation systemic C1 5.2 x 1011 
   C2 3.0 x 1011 
        
  intramuscular M1 3.4 x 109 
    M2 5.6 x 109 
 
Table 1: Experimental scheme of heteropic rat heart transplantions. 2 groups consisting of 3 
animals were transplanted and rAAV2ssLacZ was applied intracoronary either into a normothermic, 
beating heart (A1-A3) or into a non-beating, hypothermic heart (B1-B3). In addition, two animals 
(C1 and C2) received rAAV2ssLacZ systemically via tail vein injection to determine the ability of 
rAAV2 vectors to target the heart. Moreover, the animals B2 and B3 received additionally a vector 
injection into skeletal muscle (M2 and M1, respectively) in order to control vector function. 
(rAAV2ssLacZ = AAV serotype 2 based vector encoding beta-galactosidase in the single-stranded 
vector genome conformation) 
 
For gene transfer, rAAV2 encoding for the transgene β-galactosidase (LacZ) in the 
commonly used single-stranded (ss) vector genome conformation was produced 
as described in 7.3.6.1, purified by iodixanal gradient centrifugation (7.3.6.2) and 
further by heparin affinity chromatography (7.3.6.3) to minimize inflammatory 
responses to vector preparation impurities. Before use, genomic titers of vector 
preparations were determined by qPCR (7.3.6.4). Subsequently, between 5 x 1010 
and 8.5 x 1011 DNA containing particles were applied into the coronaries of the 
grafts either in the normo- or hypothermia transplantation model (Table 1). In 
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addition, skeletal hind limb muscle injections and systemic application were 
performed to control vector function and to determine vector tropism for the heart 
tissue, respectively. 
To minimize organ rejection, all animals received Tacrolimus (0.3 mg/kg body 
weight) daily for immunosuppression. All rats recovered well from transplantation 
and showed palpable contractions of the graft. With exception of animal A2, all 
animals were healthy, behaved and ate normally until the time point of 
explantation. The rat A2 had to be explanted at day 22 while all other animals 
were sacrificed 28 d post transplantation. Transplanted heart, native heart and 
liver were harvested for histological analyses and extraction of DNA and mRNA. 
Only the transplanted heart was analyzed in the animal A2. From the systemically 
injected rats, also spleen and lung were analyzed. From the two animals (B3 and 
B2) receiving an additional injection of rAAV2 into the the left and right hind limb 
muscle, total DNA and mRNA were isolated from the sample M1 (animal B3), 
while sample M2 (animal B2) was analyzed histologically.  
4.1.1.1.1 Delivery of vector genomes into transplanted hearts 
Heart transplantations and vector applications were performed as described in the 
previous chapter. To determine the applicability of the AAV vector technology for 
genetic modification of heart transplants we first assessed the presence of vector 
genomes using the therefor established quantitative real-time PCR protocols 
(qPCR) as described in 7.2.8. Briefly, DNA was extracted from shock-frozen 
organs of rAAV- and non-treated animals. The Quantitect SYBR Green PCR Kit 
(Qiagen) was then used to analyze 100 ng DNA of each sample by qPCR. 
Additionally, negative controls only containing the elution buffer (Tris, 10 mM, pH 
8.0) (N1) or the PCR mix (N2) were included. The plasmid pZNL, the vector 
plasmid during rAAV packaging, served as positive control. For normalization, the 
housekeeping gene GAPDH was included to ensure that equal levels of DNA were 
used. PCR products were assayed by melting curve analyses and by agarose gel 
electrophoreses. Melting curve analyses showed no unspecific signals in the 
samples. The intensities of all GAPDH bands detected after electrophoretical 
separation and visualization were similar as expected from the values obtained by 
qPCR (qPCR data not shown) (Figure 11 A and B). Only in Figure 11 C, the 
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skeletal muscle probe M1 showed a stronger intensity of the band than the non-
transduced muscle sample.  
Quantification of vector-specific PCR products was not possible due to the low 
transgene DNA amounts in our samples. An increase in cycle numbers above 40 
resulted in measurable PCR products, but also in the untreated animals. Based on 
melting curve analysis and agarose gel electrophoresis specific transgene DNA 
was detected in the non-treated controls. Therefore, only presence or absence of 
transgene DNA could be determined in samples undergoing 40 PCR cycles by 
agarose gel electrophoresis. 
Amplification of LacZ genomes was clearly detectable in transplanted hearts 
(HTX) of the animals A1 and A2 (Figure 11 A). A3 only showed a faint band for 
LacZ (Figure 11 A). With exception of B2 (received the lowest vector amount), in 
all transplanted rat heart samples of group B LacZ amplification could be 
visualized (Figure 11 A).  In contrast, native heart samples (H) of transplanted rats 
were devoid of transgene DNA (Figure 11 A). However, vector DNA was 
detectable in the liver of A1, A3 and B1 and of both animals receiving systemic 
vector administration. While the latter result was expected from previous reports, 
the former reveals that rAAV was transported from the transplanted heart into 
other parts of the body. Following systemic vector administration (without heart 
transplantation; Figure 11 B), LacZ DNA could clearly be detected in the liver as 
already outlined, but also in the spleen of C1 and C2. Moreover, a faint band was 
visible in both lung samples. Neither of the two heart samples showed LacZ DNA 
in the heart after systemic vector delivery. Transgene DNA was detectable in 
skeletal muscle after vector injection (Figure 11 C).  
Vector genomes were neither detectable in untreated animals nor in PCR buffers 
while specific amplification products were obtained with pZNL which served as 
positive control.  
Thus, rAAV-mediated gene transfer into the transplanted heart was observed with 
both operation techniques revealing that vector entry in cells of the heart tissue is 
not impaired. However, the transplanted heart samples in the normothermia group 
showed better results in the amount of vector DNA (3/3 animals were positive) 
compared to the group of rats receiving vector upon hypothermia. In the latter 
group transgene DNA could be detected as faint bands in transplanted hearts (3/2 
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animals were positive). In contrast, no transgene DNA was measured in any of the 
systemically injected rats, revealing that rAAV2 does not possess a native tropism 
for this tissue. The liver tropism observed after systemic application is also obvious 
in the transplanted animals where vector genomes were detected in 50 % of the 
liver samples. 
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Figure 11: DNA analyses of rat organs. Total DNA was analyzed by qPCR for transgene (LacZ) 
and housekeeping gene (GAPDH) followed by agarose gel electrophoresis. Shown are 
representative pictures of 2 independent tissue extractions and 3 PCR runs. In (A), gel pictures of 
the 2 different groups receiving vectors in a transplantation model are depicted whereas results of 
animals with systemic vector application without transplantation are shown in (B). Intramuscularly 
injected samples are indicated in (C). Animal groups: N, negative animal; A, normothermia; B, 
hypothermia; C, systemic vector administration; M1, skeletal muscle after vector application; 
samples: H, native heart; HTX, transplanted heart; L, liver; K, kidney; S, spleen; Lu, lung; M, 
skeletal muscle; N1, negative control for DNA extraction; N2, non-template control for PCR; +, LacZ 
plasmid as positive control. 
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4.1.1.1.2 Transgene mRNA expression cannot be detected in 
transplanted hearts 
Next, we determined the amount of transgene mRNA as assumption of a 
successful transport of the vector genomes into the nucleus and transgene 
transcription. The same animals described in the previous chapter were analyzed 
by qPCR.  
First, RNA was isolated by phenol / chloroform extraction (7.2.6). Potential DNA 
contaminations were removed by DNase I digest and cDNA was synthesized 
using oligo-dT primer and the Transcriptor First Strand cDNA Synthesis Kit 
(Roche) as explained in 7.2.7. Around 140 ng cDNA were analyzed by qPCR to 
determine if transgene expression has occurred. For normalization, expression of 
the housekeeping gene GAPDH was used. 
The level of specific cDNA was lower than the amount of transgene DNA. Thus, 
quantification of LacZ mRNA expression was impossible and conclusions could 
only be drawn after visualization of PCR products by agarose gel electrophoreses 
according to the previous chapter. Based on results obtained for the transgene 
DNA (4.1.1.1.1) which revealed the absence of transgene in native heart of all 
transplanted animals, only transplanted heart and liver were analyzed for mRNA. 
In the case of A2, only the transplanted heart was available as described before. 
B3 only showed detectable transgene DNA in the transplanted heart, thus liver 
was not analyzed. 
Synthesis of cDNA from isolated mRNA was successful as GAPDH products were 
detectable in all samples. However, as the basal levels for GAPDH activity differ 
between the analyzed organs, band intensities are only comparable between the 
respective tissue samples. Nevertheless, amplified cDNA for LacZ could not be 
detected in transplanted hearts or livers in group A and B. Regarding the 2 rats 
having received systemic vector injection, only the second animal (C2) showed a 
faint band indicating LacZ expression in the liver. In contrast, injection into skeletal 
muscle resulted in well detectable signals for transgene-specific cDNA revealing 
that our vector preparation is functional and rAAV2 genomes can in principle be 
expressed in rats.  
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Figure 12: Agarose gel electrophoreses of amplified cDNA. RNA was extracted by phenol / 
chloroform extraction and digested with DNase I. Reverse Transcription was performed by 
Transcriptor First Strand cDNA Synthesis Kit (Roche). Then, qPCR analyses were performed and 
products were analyzed by agarose gel electrophoreses. Representative pictures are depicted 
here. Animal groups: N, negative animal; A, normothermia; B, hypothermia; C, systemic vector 
administration; M1, skeletal muscle after vector application; samples: H, native heart; HTX, 
transplanted heart; L, liver; K, kidney; S, spleen; Lu, lung; M, skeletal muscle; N, non-template 
control for PCR; +, LacZ plasmid as positive control. 
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4.1.1.1.3 Beta-Galactosidase activity is not detectable in tissue 
sections of transplanted hearts 
After evaluation of transgene DNA in the animal groups introduced above, we 
determined if transgene expression has occurred in native heart, liver and in 
transplanted heart (HTX) of groups A and B, despite undetectable LacZ cDNA 
levels. Therefore, tissue sections were stained for X-Gal activity as described in 
7.4.1. As already mentioned in 4.1.1.1, only the transplanted heart was analyzed 
in the case of A2 as this animal was explanted after 22 d instead of 28 d. 
Additionally, as  positive control, we stained sections of a liver transduced with 
adenovirus coding for LacZ which was kindly provided by M. Odenthal (Institute of 
Pathology, Cologne). 
 
Figure 13: X-Gal and eosin stained tissue sections of rats receiving vector into the transplanted 
heart at normothermia. Organs were shock-frozen in isopentan and liquid nitrogen. The samples 
were prepared by cryotom tissue dissection and stained with X-Gal solution (2 d) and 0.5 % eosin 
solution (8 min). Shown are representative images of native heart, transplanted heart (HTX) and 
liver sections. Of animal A2, only HTX was available. In none of the samples, X-Gal activity was 
detected by microscope analyses (200x magnification; Olympus Vanox-S AH-2 microscope). 
A1 
A3 
A2 
native heart                    HTX            liver 
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Following explantation, the organs were put into isopentan to preserve tissue 
structure and were immediately shock-frozen in liquid nitrogen. Cryotom tissue 
dissection was perfomed in the Institute of Pathology (Cologne). Thereby, several 
sections of 3 different planes were collected, air-dried over night and stored at -80 
°C. Without thawing, the sections were fixed in 1.5 % glutaraldehyde and stained 
for 2 d in X-Gal solution. Tissue sections were counterstained with 0.5 % eosin 
solution (no counterstaining in B3 and skeletal muscle sections) before 
dehydration. Object slides were covered and X-Gal staining was determined by 
microscopy (Olympus Vanox-S AH-2 microscope) (7.4.1). 
 
 
Figure 14: X-Gal and eosin stained tissue sections of transplanted animals after vector application 
into the hypothermic heart. Explanted organs were directly frozen in isopentan and liquid nitrogen 
before preparing by cryotom tissue dissection. Sections were stained for X-Gal activity (2 d) and 
counterstained with eosin (0.5 %, 8 min) (excluding B3) and analyzed by microscopy (200x 
magnification; Olympus Vanox-S AH-2 microscope). Representative images are shown here. 
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Microscope images of organs including vessels were analyzed for transgene 
expression in the endothelium. Neither the animals of the normothermic nor the 
hypothermic heart transplantation group showed X-Gal positive signals in any 
organ (Figure 13, Figure 14). A damaged morphological structure was visible in 
the transplanted heart of A2. Regarding the group that received a systemic vector 
administration into the tail vein, no positive staining for X-Gal could be detected in 
heart and liver despite detection of cDNA in the liver of C2 as depicted in 4.1.1.1.2  
(Figure 15). In contrast, intramuscular injection of rAAV2ssLacZ resulted in 
transgene expression and protein production (verifying cDNA analyses) since this 
tissue showed detectable β-Gal activity (blue color) as depicted in Figure 16. Also 
in our positive control, the adenovirus-transduced liver, positively stained cells 
were found while our non-treated controls were negative for X-Gal staining. 
 
 
Figure 15: X-Gal and eosin stained tissue sections of animals receiving vector via the tail vein 
(systemic application). Isopentan frozen liver and heart of 2 rats were analyzed for X-Gal activity 
and counterstained with eosin after organs were cryotom dissected. Shown are representative 
microscope images (200x magnification; Olympus Vanox-S AH-2 microscope). X-Gal could not be 
detected in any of the sections. 
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Figure 16: X-Gal stained tissue sections of control animals. X-Gal activity was determined in 
skeletal muscle of a rat having received rAAV2 intramuscular injection and a non-transduced 
control animal (skeletal muscle, heart and liver). The positive control of an adenovirus-transduced 
liver was kindly provided by M. Odenthal. After shock-freezing and cryotom tissue dissection, the 
tissue sections were stained for X-Gal (2 d) and eosin (8 min; no counterstaining in muscle) and 
microscope images were taken (200x magnification; Olympus Vanox-S AH-2 microscope). X-Gal 
activity (blue signals) could be detected in vector injected muscle and the positive control of 
adenovirus-transduced liver. LacZ in the positive control did not retain a nuclear localization signal 
in contrast to our transgene construct, thus displaying a positive X-Gal staining within the 
cytoplasm.  
 
4.1.1.2 In vitro analyses of rAAV-mediated rat cell transduction 
Since rAAV2 vector administration in both heterotopic rat heart transplantation 
models did not result in measureable transgene expression although vector DNA 
could be detected, we aimed to identify limiting factors by in vitro analyses. As in 
vitro model for rAAV-mediated rat endothelial cell transduction, primary rat aortic 
endothelial cells (RAECs) were used. Cells were kindly provided by M. Seifert 
(Charité, Berlin).  
To reconfirm the endothelial character of the obtained RAECs the acetylated low-
density lipoprotein (AcLDL) uptake assay was performed. Briefly, the acetylated 
form of the LDL complex is unable to bind its receptor. Instead it is taken up by 
negative heart           negative liver    positive control (liver) 
 negative muscle         positive muscle 
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macrophages and endothelial cells by “scavenger” receptors specific for AcLDL. 
This method is routinely performed to identify endothelial cells. Representative 
images of fluorescence and light microscopy of AcLDL-treated RAECs are shown 
in Figure 17 demonstrating an efficient uptake of red fluorescence-labeled AcLDL 
in all cells, thereby confirming the endothelial character of the RAECs. 
 
Figure 17: Dil-AcLDL uptake of RAEC. RAECs were incubated in Dil-AcLDL containing medium for 
4 h. After washing and fixation, fluorescence (A) and light microscope (B) images were taken (200x; 
Zeiss Axiovert S100). 
 
4.1.1.2.1 AAV2 capsids are detectable in the cytoplasm and 
perinuclear area of RAECs 
Considering the presence of transgene DNA, but the absence of β-Gal activity in 
transplanted rat hearts, we first investigated if entry and intracellular transport of 
the vector might represent a limitation for endothelial cell transduction.  
According to results published by us and others rAAV2 particles accumulate in the 
perinuclear area (Bartlett, Wilcher, and Samulski, 2000; Lux et al., 2005). First 
particles are detectable 15 min p.i. and remain visible for at least 24 hours (Lux et 
al., 2005; Seisenberger et al., 2001). RAECs were transduced with a GOI of 5 x 
104 rAAV2ssGFP and fixed 4 h p.i.. They were stained with antibodies against 
intact AAV2 capsids (A20 antibody and a secondary RRX-labeled antibody) and 
the nuclear membrane (anti-Lamin B and a Cy5-labeled secondary antibody) and 
were analyzed by confocal laser scanning microscopy (LSM 510 Meta, Zeiss). As 
depicted in Figure 18 A, signals for intact AAV2 particles were detected within the 
cell. Although fluorescent signals may suggest the presence of AAV particles 
A B 
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within the nucleus, vertical sectioning revealed that vector particles were 
detectable in the perinuclear region, but not in the nucleus (Figure 18 A and B). 
The latter result is in line with our observation on HeLa cells, where entry of viral 
genomes, but not of intact capsids into the nucleus could be detected. Thus, it can 
be assumed that rAAV2 vectors entered RAECs which is consistent with our in 
vivo results, and are trafficked to the perinuclear area. 
 
Figure 18: Visualization of RAEC transduced with rAAV2. RAECs were transduced with a GOI of 5 
x 104 rAAV2ssGFP and fixed 4 h p.i.. Nuclear membrane was stained by anti-lamin B (blue: Cy5-
labeled secondary antibody), while intact capsids were detected by A20 antibody (red: RRX-
conjugated secondary antibody). Analyses were performed by confocal microscopy (LSM 510 
Meta, Zeiss). Shown are representative confocal microscope images, one superimposed (A) and 
one image plane out of a z-stack stain of a horizontal section (0.2 µm). 
 
4.1.1.2.2 CMV promoter induces transgene expression after 
transfection 
Next, we investigated if lack of transgene expression in transplanted hearts might 
be due to inefficiency of the chosen strong viral CMV promoter. Therefore, two 
different plasmids both containing LacZ as transgene, but differing in the promoter 
were transfected into RAECs. We compared the endothelial cell-specific fms-like 
tyrosine kinase (FLT1) promoter described to mediate transgene expression in 
endothelial cells with “our” CMV promoter (Morishita, Johnson, and Williams, 
1995; Nicklin et al., 2001b). RAECs cultured in medium without penicillin and 
streptomycin were transfected with Lipofectamin 2000 and 0.8 µg plasmid DNA 
according to the manufacturer’s instructions. One day thereafter, the cells were 
A B 
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fixed and stained for 4 h with X-Gal solution, the substrate for β-galactosidase 
activity (LacZ). Light microscope pictures were taken with an Olympus Vanox-S 
AH-2 microscope. Representative images are shown in Figure 19. In both cases 
only marginal LacZ activity was detectable pointing towards a low transfectability 
of these cells at least with the chosen method. However, β-galactosidase activity 
was visualized with both constructs revealing that the CMV promoter is in principle 
able to express transgenes in RAECs. Moreover, repeated experiments showed 
no clear difference between CMV- (A) and FLT1-(B) driven transgene expression 
with regard to efficiency. 
  
 
Figure 19: Transfection of RAECs with pZNL or pMV10-FLT1. RAECs were transfected with 
plasmids (0.8 µg) coding for LacZ under the control of either a CMV promter (pZNL) (A) or a FLT1 
promoter (pMV10-FLT1) (B). The following day, cells were fixed and stained for LacZ activity for 4 
h. Pictures were taken with an Olympus Vanox-S AH-2 microscope. Figure C shows control cells 
transfected without DNA in the transfection mix. 
 
4.1.1.2.3 RAECs are poorly transduceable with AAV serotypes 1 to 
5, but show enhanced expression by administration of 
MG132 
As shown by experiments in the previous chapters, rAAV2 is able to enter RAECs 
and is transported to the perinuclear area. In addition, CMV promoter seems to be 
suited to control transgene expression in RAECs. Thus, we aimed to determine 
the efficiency of rAAV2-mediated transduction in RAECs. In order to identify a 
potentially more efficient serotype for transduction of these cells we included other 
serotypes, namely rAAV1 and rAAV3 to 5.  
Moreover, we were interested to investigate if second-strand synthesis may limit 
transduction efficiency as we and others have shown for cell lines as well as for 
primary cells (Hacker et al., 2005; McCarty et al., 2003; McCarty, Monahan, and 
Samulski, 2001; Wang et al., 2003). Therefore, we compared the five different 
A C B 
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serotypes for their efficiencies encoding the transgene cassette in the self-
complementary (sc) or the natural single-stranded genome conformation (ss). 
Furthermore, we assessed the effect of the proteasome inhibitor MG132 (also 
Carbobenzoxyl-L-leucyl-L-leucyl-Leucinal; Z-LLL) on AAV-mediated transduction 
of primary RAECs. Although the mechanism of action remains to be elucidated, 
the enhancement in transduction efficiency in vitro and in vivo has been reported 
in various cell types (Hacker et al., 2005; Nicklin et al., 2001a; Pajusola et al., 
2002; Yan et al., 2004). 
Briefly, cells were transduced with 5 x 104 genomic particles per cell (GOI) of 
rAAV1 to 5 encoding for ssGFP or scGFP vector genomes, respectively. The 
proteasome inhibitor MG132 (40 µM diluted in medium) or the solvent (DMSO) 
were applied at the time of transduction. Cells were washed intensely 3 times with 
PBS after 4 h. Flow cytometric analyses were performed 3 d p.i. (Figure 20). 
Comparisons between the serotypes identified rAAV1 as the most efficient 
serotype followed by rAAV2, whereas rAAV3, rAAV4 and rAAV5 showed only 
marginal GFP expression with a maximum of 1.5 ± 0.7 % (mean ± standard error 
of the mean (SEM)) for rAAV5scGFP. The ranking of the serotypes was consistent 
between the group of rAAV encoding for scGFP and for ssGFP as depicted in 
Figure 20 A and B. Nonetheless, the absolute values for transduction with rAAV1 
(16.6 ± 7.5 %) and rAAV2 (4.2 ± 0.7 %) scGFP vectors exceeded the efficiencies 
for rAAV1 (3.8 ± 2.0 %) and rAAV2 (2.3 ± 1.1 %) ssGFP vectors, respectively.  
Interestingly, administration of the proteasome inhibitor MG132 resulted in a 
significant enhancement of transgene expression for serotype 1 as well as for 
serotype 2. An increase of 6-fold for rAAV1ssGFP (23.0 ± 4.7 %) and of 7.3-fold 
for rAAV2ssGFP (16.8 ± 1.1 %) was measured after addition of MG132 (Figure 20 
A). Also, albeit less pronounced, an increase in transgene expression was 
observed for the vectors carrying self-complementary vector genomes, namely a 
2.8-fold enhancement with rAAV1 (46.5 ± 10.1 %) and a 4.4-fold with rAAV2 (18.4 
± 2.2 %) in presence of MG132. No significant enhancement of transgene 
expression was detected when combining rAAV3 to 5 transductions and the 
addition of proteasome inhibitors. 
 
 
Results 
 
53 
 
A 
 
B 
 
Figure 20: Transduction efficiency of rAAV1 to 5 (single-stranded and self-complementary vector 
genome conformation) in RAECs with and without MG132 treatment. RAECs were transduced with 
rAAV1 to 5 (GOI 5 x 104) encoding either for GFP as transgene in either a single-stranded (ss) (A) 
or a self-complementary (sc) (B) vector genome conformation, respectively. Transduction was 
performed in presence or absence of 40 µM MG132. After 4 h of incubation, cells were washed and 
analyzed by flow cytometry 3 d p.i. Shown are the results (means + SEM) of 3 (rAAV3, rAAV4, 
rAAV5) and 6 (rAAV1, rAAV2) independent experiments. (A) *=P<0.002 (B) *=P<0.02. 
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4.1.1.2.4 Neonatal rat cardiomyocytes show highest transgene 
expression after transduction with rAAV1 and rAAV4 
As described in the previous chapters, the rAAV-mediated transduction efficiency 
in RAECs is rather low. Also in vivo no transgene expression was detectable in 
transplanted hearts (4.1.1.1.3). Alternatively, intramyocardial injection as well as 
enhancement of the vascular permeability has been reported to result in 
measureable transgene expression. In these cases, cardiomyocytes have been 
the target cell population thus being maybe a more suitable target for our 
application. 
In order to evaluate the most efficient serotype for transduction of rat cardiac 
muscle cells and to compare that result with transduction of rat aortic endothelial 
cells, we investigated rAAV1 to rAAV5 on neonatal rat cardiomyocytes. Neonatal 
rat cardiomyocytes were kindly provided by B. Bölck (University Hospital of 
Cologne), but due to cell shortage only 2 experiments could be performed. On the 
first day, cells were cultured in medium containing 10 % horse serum and 5 % 
FCS. The following day, the cells were transduced with rAAV1 to 5 carrying the 
single-stranded GFP (ssGFP) genome. A GOI of 104 was chosen due to the high 
cell number per well (6 x 105, 6-well) and the limiting amount of applicable vector 
volume. Cells were analyzed for GFP expression 3 d p.i. by flow cytometry (Figure 
21 A) and fluorescence microscopy (Figure 21 B). Regarding the mean 
percentage for transgene-expressing cells, rAAV1 and rAAV4 showed the highest 
transduction efficiencies with 17.7 ± 3.0 % (mean ± SEM) and 14.0 ± 2.7 %, 
respectively. The widely used serotype 2 only reached 4.1 ± 0.2 % whereas the 
serotypes 3 and 5 were even less efficient (rAAV3 2.6 ± 0.2 % and rAAV5 2.9 ± 
0.5 %). Representative pictures of non-transduced and transduced (with rAAV1 or 
rAAV4) neonatal rat cardiomyocytes are shown in Figure 21 B. GFP-positive cells 
could only be detected in rAAV1 and rAAV4 transduced cells. 
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Figure 21: Transduction efficiency of rAAV1 to 5 in neonatal rat cardiomyocytes. Primary neonatal 
rat cardiomyocytes were transduced with 104 genomic particles per cell of rAAV2ssGFP. 
Transduction efficiency was evaluated 3 d p.i. by FACS analysis (A) and microscopy (B). In A, the 
results of 2 independent experiments are shown as mean + standard error of the mean (SEM). 
 
In Figure 22 transduction efficiencies of RAECs and primary rat cardiomyocytes 
were compared. Hence, mean values obtained for transduced cardiomyocytes 
were divided by the ones for RAECs as described in 4.1.1.2.3 and results are 
shown as fold change. Whereas rat cardiomyocytes have been transduced with 
rAAV1 to rAAV5ssGFP at a GOI of 104, RAECs received 5-fold higher vector 
amounts, but both flow cytometric analyses have been performed 3 d p.i.. As can 
be seen in Figure 22, more primary rat cardiomyocytes were successfully 
rAAV1 rAAV4 control 
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transduced compared to RAECs. Despite the 5 times lower vector amount applied 
on cardiomyocytes, 4.4-fold more cardiomyocytes than RAECs expressed GFP  
when rAAV1 was used and 1.8-fold more in the case of rAAV2. For the serotypes 
rAAV3 to rAAV5 an even higher fold change has been calculated as a 
consequence of the nearly background transgene expression in RAECs 
(maximum 0.4 % GFP expressing cells). Also in rat cardiomyocytes, transduction 
efficiencies using rAAV3 and rAAV5 were very low while rAAV4 resulted in 14 % 
transgene-expressing cells. 
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Figure 22: Comparison of transduction efficiencies between RAECs and primary rat 
cardiomyocytes. Shown are the fold changes of the mean transduction efficiencies of rat 
cardiomyocytes (GOI 104) divided by the amount of transgene expressing RAECs (GOI 5x104) 3d 
after transduction by the serotypes rAAV1 to rAAV5 encoding for ssGFP. The values are based on 
Figure 20 A and Figure 21 A.  
 
4.1.2 rAAV-mediated gene transfer into porcine heart 
4.1.2.1 Identification of the most suited serotype using PAECs as in vitro 
model 
Concerning the choice of the serotype, we did not rely on literature for the pig 
heterotopic heart transplantation experiments unlike for the rat model. Therefore, 
we first aimed to assess the most feasible serotype for this purpose as 
comparative studies in porcine cells have not been published. Porcine aortic 
endothelial cells (PAECs) were chosen as in vitro model to investigate rAAV-
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mediated transduction and potential intracellular barriers. PAECs were kindly 
provided by W. Kues (Institute of Farm Animal Genetics, Mariensee). 
Corresponding to chapter 4.1.1.2, we reconfirmed the endothelial character of the 
provided PAECs by the ability to take up the endothelial-specific marker Dil-
AcLDL. Therefore, PAECs were stained for 4 h with 1 µg/ml Dil-AcLDL in medium 
at 37 °C. After washing and fixing the cells for 15 min in 3 % paraformaldehyde, 
fluorescence and light microscope images were taken (200x magnification; Zeiss 
Axiovert S100). As can be seen in Figure 23, PAECs take up Dil-AcLDL efficiently 
thus confirming their endothelial character. 
 
Figure 23: Dil-AcLDL uptake of PAECs. PAECs were incubated in Dil-AcLDL for 4 h, washed and 
fixed in 3 % paraformaldehyde before fluorescence (A) and light microscope (B) images were taken 
(Zeiss Axiovert S100). 
 
4.1.2.1.1 PAECs are efficiently transduceable with rAAV2 
Endothelial cells are commonly described to be transduceable by AAV only at low 
efficiencies compared to HeLa cells and the human glioma cell line LN-229 
(Pajusola et al., 2002). In addition, comparative studies of different AAV serotypes 
in porcine endothelial cells are lacking. Therefore, we determined their 
permissiveness for the serotypes 1 to 5 and transduced PAECs with different 
amounts of the respective vectors (GOI 1 x 104, 5 x 104 or 1 x 105). Moreover, we 
investigated if second-strand synthesis of the natural single-stranded (ss) vector 
genome in PAECs impairs efficient transduction as published for other cell lines 
(McCarty et al., 2003). Thus, we compared transduction efficiencies of rAAV1 to 
rAAV5 vectors encoding for the transgene in the single-stranded or double-
stranded vector genome conformation, respectively. Transduction efficiency was 
A B 
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determind 3 d p.i. by flow cytometry and shown as mean + standard deviation in 
Figure 24. 
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Figure 24: Transduction of PAECs with rAAV1 to 5 carrying single-stranded (ss) or self-
complementary (sc) GFP genomes. For transduction 3 different vector-to-cell ratios (GOI of 104, 5 x 
104 or 105) were used shown as differently colored bars. PAECs were transduced by the serotypes 
1 to 5 coding either for ssGFP or scGFP. The number of GFP-expressing cells was determined 3 d 
p.i. by FACS analysis and shown as mean + standard deviation. 
 
As can be clearly seen, rAAV2 is the most efficient serotype for PAEC 
transduction. Comparing the means after administration of 104 genomic particles 
per cell (GOI) of rAAV2, scGFP (67.0 ± 0.02 %) vectors showed 2 times higher 
values than ssGFP-containing (34.5 ± 0.4 %) particles. Use of 5 times higher 
vector amounts per cell further increased the number of transgene-expressing 
cells to 83.4 ± 1.4 % for ssGFP- and 89.5 ± 0.3 % for scGFP-encoding rAAV2 
vectors. These values changed minimally by administration of even higher vector 
concentrations (105 GOI) (ssGFP 88.4 ± 3.2 % and scGFP 87.6 ± 0.03 %) 
indicating saturation. 
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The serotypes 1 and 3 to 5 coding for ssGFP showed very low transduction 
efficiencies even at highest vector concentrations (GOI 105) (rAAV4 4.5 ± 0.1 %; 
rAAV5 6.1 ± 4.2 %). Also for scGFP vectors of the serotypes 3 and 4 only a low 
number of transduced cells could be detected with efficiencies of maximal 4.8 ± 
2.2 % for rAAV3 and 4.5 ± 2.8 % for rAAV4 at a GOI of 105. The second efficient 
scGFP-containing vector at this GOI with a transduction efficiency of 41.1 ± 0.1 % 
was rAAV5 which showed initially 5.2 ± 0.3 % transgene-expressing cells at a GOI 
of 104 and 34.9 ± 0.5 % (GOI 5 x 104). Also for rAAV1scGFP the number of 
transgene-expressing cells could be enhanced by use of higher GOIs, namely 
from 2.1 ± 0.6 % (GOI 104) to 26.2 ± 6.0 % (GOI 105). 
 
  rAAV1 rAAV2 rAAV3 rAAV4 rAAV5 
GOI 104 1.4 1.9 1.1 0.6 2.7 
GOI 5x104 8.3 1.1 2.5 0.7 14.8 
GOI 105 9.8 1 2.5 1 6.7 
 
Table 2: Transgene expression using scGFP compared to ssGFP vectors. Shown are the fold 
changes of the means of transduction efficiencies of scGFP vectors divided by the means of the 
ssGFP vectors of the respective serotype and vector amount. 
 
In conclusion, application of rAAV1scGFP and rAAV5scGFP vectors resulted in 
higher transduction efficiencies compared to the corresponding ssGFP vectors as 
shown in Table 2. For rAAV3 an up to 2.5-fold higher amount of GFP-expressing 
cells was obtained using rAAV3scGFP. In contrast, the generally low transgene 
expression after rAAV4ssGFP transduction was not enhanced by application of 
rAAV4scGFP. For rAAV2, an effect of vector genome conformation was only 
observable at a GOI of 104 as higher vector amounts resulted in maximal 
transduction efficiencies of around 90 %. In summary, serotype 2 showed the 
highest expression in PAECs.  
4.1.2.1.2 Visualization of rAAV2 capsids in the cytoplasm of PAECs 
By confocal microscopy, we aimed to visualize the highly efficient transduction of 
PAECs by rAAV2 (4.1.2.1.1). We were especially interested to compare these 
results with confocal images of the RAEC transduction which showed only low 
transgene expression (4.1.1.2.1 and 4.1.1.2.1). Therefore, PAECs were prepared 
like RAECs. Cells were transduced by rAAV2ssGFP at a GOI of 5 x 104 and fixed 
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4 h p.i.. Intact AAV2 vector capsids were stained with A20 antibody and RRX-
conjugated secondary antibody (red), while the nuclear membrane was visualized 
by anti-Lamin B and Cy5-conjugated secondary antibody (blue) staining.  
 
 
Figure 25: Visualization of PAEC transduction by rAAV2.  PAECs were transduced by a GOI of 5 x 
104 rAAVssGFP and fixed 4 h p.i.. Intact capsids were stained with A20 antibody and RRX-
conjugated secondary antibody (red), whereas nuclear membrane was visualized by anti-Lamin B 
and Cy5-conjugated secondary antibody (blue). Shown are representative images of a 
superimposed (A) and a horizontal section (0.2 µm) (B) taken by confocal laser scanning 
microscopy (LSM 510 Meta, Zeiss). 
 
In the superimposed picture in Figure 25 A, large aggregates of vector signals 
were visible distributed all over the cell. A representative image of a vertical plane 
section is depicted in Figure 25 B and reveals that signals are located within the 
cytoplasm. This picture differs from the one obtained for RAECs and a perinuclear 
accumulation – as seen with other cell types – could not be detected. 
4.1.2.2 Heterogenic pig heart transplantation 
Despite the existence of small animal models, species-specific large animal 
models are needed for preclinical evaluation. Porcine hearts are physically and 
physiologically closely related to human hearts thus being ideal as xenografts. 
Moreover, pigs serve as preclinical models to develop gene therapy approaches 
for cardiovascular diseases or organ transplantations. Unfortunately, large animal 
models require huge vector amounts to achieve significant transduction. 
Heterotopic pig heart transplantations were performed by L. Burdorf and 
colleagues (Department of Heart Surgery, Ludwig-Maximillians-University Munich) 
B A 
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as described in 7.5.2. In order to prolong vector circulation in the heart after 
intracoronary vector application, an in situ Langendorff perfusion system was 
developed. Thus, the warmed and oxygenated blood containing the vector solution 
recirculated for about 40 min in the warm and beating heart enhancing the chance 
of vector entry as shown by our results obtained for the normothermic 
transplantation in the rat model. As immunosuppressive therapy the animals 
received 1.5 mg/kg body weight Tacrolimus per day. 
As rAAV2 was revealed as the most efficient serotype in in vitro experiments of 
PAECs, we used this serotype in vivo. Large vector amounts had to be produced 
by triple transfection of HEK293 cells. Cell lysates were purified by iodixanol 
gradient centrifugation followed by heparin affinity chromatography to further purify 
and additionally concentrate the vector preparation (7.3.6). Genomic titers have 
been determined by qPCR. 
In a first approach, we used 2 x 1012 genomic particles rAAV2ssLacZ, assessed 
the amount of vector genomes within the heart samples by qPCR and eventual 
transgene expression by X-Gal staining of cryosections. In a second experimental 
setting, we applied 2.3 x 1013 genomic particles of rAAV2scLuci. Also here, 
transgene DNA levels of the heart were analyzed by qPCR. Luciferase was 
evaluated by a luciferase detection assay. Both times histamine (100 µg in 10 ml 
volume over 4 min injected into the perfusion system) was administered to render 
vessels permeable thus allowing to overcome endothelial barrier and to transduce 
endothelial as well as cardiac muscle cells. This was in contrast to our rat 
transplantations where we focused on endothelial cells as target and observed 
that the transduction efficiency obtained for the endothelium is very limited in vivo 
as well as in vitro. However, the situation in the porcine model might be different 
as we observed a very efficient transduction (up to 90 %) of PAECs in vitro.  
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Figure 26: Dissection scheme for analysis of the transplanted porcine heart. As depicted, organ 
samples were taken form 4 different horizontal levels of the myocard (A). Mapping of the numbers 
are shown whereas left side of each level represents the ventral and right the dorsal part of the 
heart (B). The numbers 37 to 45 account for samples of the right ventricle (RV), whereas 25 to 36 
are taken from the septum region at the different planes. Samples of the left ventricle (LV) are 
divided into origin of outer (1 to 12) and inner (13 to 24) myocardial wall. 
 
The hearts were explanted after 21 d and dissected following the scheme depicted in  
Figure 26. Samples were taken from 4 different levels from the very superior part 
of the ventricle (level I) to the apex cordi (level IV). The right ventricular (RV) 
samples were numbered 37 to 45, the septum region 25 to 36 in respect to the 
level. Regarding the left ventricle (LV), samples were taken from the outer (1 to 
12) and inner (13 to 24) regions. For the first time, such a detailed and complete 
analysis of a vector perfused heart has been done as previous reports only 
analyzed the perfusion bed of the left anterior coronary (Kaspar et al., 2005; 
Raake et al., 2008). The main regions supplied by the coronaries correspond to 
the numbers 37, 39, 27 on level I, 40, 42 and 30 on level II and 43 and 45 on level 
III. Minor branches of the coronaries are located in the regions 7, 9, 11, 12 and 34 
of the levels III and IV.  
4.1.2.2.1 Successful vector delivery, but no transgene expression 
from single-stranded vector genomes in porcine heart 
The first animal had received 2 x 1012 rAAV2 encoding for β-galactosidase in a 
single-stranded vector genome conformation intracoronarily while connected for 
38 min to the in situ Langendorff perfusion system (7.5.2). Additionally, histamine 
(100 µg in 10 ml volume over 4 min) was infused to increase permeability of the 
vessel wall. 21 d after transplantation, native heart, kidney, spleen, lung and liver 
as well as the transplanted heart were explanted whereas the latter was dissected 
following the above described scheme (4.1.2.2). Total DNA was extracted (7.2.5) 
and 100 ng were analyzed by qPCR for the presence of vector genomes and 
porcine GAPDH which was used for normalization (7.2.8). In contrast to our results 
in the rat model where we could not quantify the amount of vector genomes, gene 
transfer efficiency could be quantified in the pig model. The PCR products were 
verified by melting curve analyses and agarose gel electrophoreses (data not 
shown). In Figure 27 the results of 2 independent qPCRs for both genes are 
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depicted as copy number per µl DNA solution ± standard deviation whereas 1 µl 
corresponds to 50 ng DNA.  
The highest background signal for samples of an untreated animal was 31 
copies/µl. In all samples obtained from the transplanted heart LacZ DNA was 
detectable exceeding our detection limit and varying from 146 ± 58 (sample 5) to 
26,147 ± 4,715 (sample 40) copies/µl. Of note, 66.7 % of the samples were in the 
range of 1,000 to 10,000 copies/µl.  
The outer parts of the left ventricle showed the lowest overall amount of vector 
DNA of all heart regions with an average copy number of 431 (146 ± 58 to 974 ± 
230) for levels I to III. Level IV showed higher values ranging from 1,988 ± 548 
(sample 11) to 14,484 ± 6871 (sample 12) copies/µl. Inner regions of the left 
ventricle tended to result in higher amounts of vector genomes, namely between 
739 ± 476 and 8,753 ± 1,857 copies/ µl.  
Within the septum area, all samples yielded between 1,000 and 10,000 copies/µl 
with a mean of 3,677 ± 2,085 copies/µl. Lowest amount of transgene DNA was 
measured in sample 32 (961 ± 131), while the highest value was detected in 
sample 31 (8,585 ± 2, 023). However, no preference for a certain dissection level 
could be determined. For each level, the first value (ventral part of the septum) 
was the highest, while means decreased more and more towards the dorsal parts 
(with exception of sample 32).  
The same tendencies could be seen in the right ventricle levels I and II. Thus, the 
vector DNA amounts detectable in the area neighbouring the septum in the ventral 
part was also in this case higher than the 2 other samples of the same plane. The 
highest values of all heart samples were measured in the right ventricle with 
26,147 ± 4,715 copies/µl for sample 40 and 19,503 ± 7,424 for number 44. 
Minimal transgene DNA amounts were detected in sample 39 with 989 ± 106 
copies/µl. The overall average copy number in the right ventricle was 8,324 ± 
8,766 copies/µl. 
Regarding extracardiac organs for determination of vector excess after 
transplantation, none of the analyzed organs exceeded the values for the negative 
control animal. Thus, no transduction could be measured in non-target tissues of 
the transplanted and rAAV-treated pig. 
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Figure 27: Distribution of vector genomes in the transplanted pig. The piglet received 2 x 1012 
genomic particles of rAAV2ssLacZ intracoronary and was explanted after 21 d. The control animal 
did not receive any vector. The amount of LacZ DNA in the respective heart regions (right ventricle; 
left ventricle; septum) and organs was determined by qPCR and normalized to GAPDH. Shown are 
the results of 2 independent PCR runs for each gene as transgene copy number per µl DNA (1 µl 
equals 50 ng DNA) (+ standard deviation). RV, right ventricle; LV, left ventricle. 
 
Additionally, tissue sections were performed by cryotom tissue dissection to 
investigate if transgene expression had occurred (M. Odenthal, Institute of 
Pathology, Cologne). The same protocol was used as described for rat heart 
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transplanted organs (4.1.1.1.3, 7.4.1). Briefly, sections were stained with X-Gal (2 
d), counterstained by 0.5 % eosin solution (8 min) and analyzed by light 
microscopy. Despite the detection of vector genomes, X-Gal activity could not be 
detected in any of the samples (data not shown).  
4.1.2.2.2 Successful vector delivery and transgene expression from  
self-complementary vector genomes in porcine heart 
Self-complementary (sc) vector genome conformation is known to enhance 
transgene expression in vitro and in vivo (McCarty et al., 2003). Also in PAECs, 
the efficiency of transgene expression by rAAV2scGFP was higher than for single-
stranded (ss) rAAV2 which was most obvious at lower vector-to-cell ratios 
(4.1.2.1.1). Therefore, we assayed if use of a sc vector would result in detectable 
transgene product levels in vivo. We chose luciferase (Luci) as transgene. Vector 
production, operation including use of Langendorff perfusion system (recirculation 
time 39 min), vector administration and histamine injection were performed as 
described in chapter 7.5.2. It was possible to produce rAAV2scLuci at high titers, 
thus 2.3 x 1013 genomic particles were administered. The organs were explanted 
21 d later and the heart was dissected following the scheme depicted in Figure 26. 
At first, DNA was extracted (7.2.5) and the level of transgene and housekeeping 
gene in 100 ng DNA by qPCR using the LightCycler Fast Start DNA Master SYBR 
Green I Kit (Roche) was evaluated as described in 7.2.8. PCRs were performed 2 
times independently. As the amount of luciferase was quantifiable, the level of 
luciferase DNA could be normalized to the porcine GAPDH gene as shown in 
Figure 28. The PCR products were verified by melting curve analysis and agarose 
gel electrophoresis (data not shown). Values are given as copy number/µl 
whereas 1 µl corresponds to 50 ng DNA. 
As can be seen in Figure 28, luciferase PCR did not result in transgene-specific 
background signals in organs of the control animal. 
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Figure 28: Distribution of vector genomes in the transplanted animal. The pig received 2.3 x 1013 
genomic particles of rAAV2 encoding luciferase in the self-complementary vector genome 
conformation intracoronary and was explanted after 21 d while the control animal was non-
transduced. The amount of transgene DNA in the septum, left and right ventricle and organs was 
determined by qPCR and normalized to the houskeeping gene GAPDH. Shown are the results of 2 
independent PCR runs for each gene as normalized transgene copies/µl DNA (1 µl corresponds to 
50 ng DNA) (+ standard deviation). RV, right ventricle; LV, left ventricle. 
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Evidently, luciferase DNA was detected in every sample albeit at different levels. 
The highest overall values were observed in the samples 12 and 24 of the left 
ventricle with 20,601 ± 335 copies/µl (mean ± standard deviation) and 28,985 ± 
197, respectively. Also the lowest transgene DNA amount was detected in this 
area with 136 ± 1 copies/µl in sample 4. No tendencies could be observed in the 
left ventricle regarding distribution of transgene DNA. In most cases (9 out of 12) 
the levels of luciferase DNA was higher in the inner regions compared to the outer 
counterparts. The highest values within the outer regions were measured in level 
IV (10,493 ± 9,215 copies/ µl; 852 ± 1211 for levels I to III). 
Within the septum region, in sample 33 the highest amount of luciferase DNA with 
15,281 ± 2,622 was detected, while sample 34 showed the lowest with 251 ± 14 
copies/µl. Within the level IV the average amount of transgene DNA was the 
lowest compared to the other levels. Nevertheless, mean luciferase DNA level in 
the septum (4,519) was higher than in the ventricular regions (left ventricle 3,262; 
right ventricle 1,343). 
As already stated, the lowest transgene DNA amount was detected in the right 
ventricle. The copy numbers ranged from 237 ± 149 (sample 41) to 2,935 ± 957 
(sample 43). 
Additionally to the ventricular and septum samples, 2 parts of the atrium were 
analyzed showing high transgene copy numbers with 15,541 ± 2,051 (atrium I) 
and 1,728 ± 742 copies/µl (atrium II). 
After confirming the existence of transgene DNA in the transplanted and 
transduced heart, we evaluated the presence of transgene product by luciferase 
detection assay (7.4.4). Therefore, the amount of protein per sample was 
determined by Bradford assay to allow normalization of the luciferase signal. 
Approximately 20 mg of tissue was homogenized in 400 µl lysis buffer (Renilla 
Luciferase Assay System, Promega) by ball mill, incubated for 1 h on ice and 
pelleted (30 min, 16,000 x g, 4 °C). 5 µl of the supernatant was measured by 
Bradford assay in an ELISA reader at a wavelenght of 595 nm 3 times 
independently (7.4.3). 
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Figure 29: Luciferase activity in transplanted porcine heart and other organs after intracoronary 
vector injection of rAAV2Luci or without vector treatment (control animal). The animal organs of the 
transduced and non-transduced pigs were explanted 21 d after transplantation and analyzed for 
luciferase activity. Protein amount was determined 3 times by Bradford assay for normalization of 
luciferase signal. Shown are the normalized results of 3 independent luciferase assays as relative 
change of relative light units (RLU) + standard deviation compared to the septum of the control 
animal. RV, right ventricle; LV, left ventricle. 
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For detection of luciferase activity 20 µl protein lysate was mixed with 100 µl assay 
buffer and 1 µl substrate (Renilla Luciferase Assay System, Promega) and 
measured by luminometer. Only a limited amount of samples was measured at 
once as chemiluminescence fades fast. The measurement was repeated 3 times 
independently. Normalization to total protein amount of 110 µg followed to allow 
comparison of relative light units (RLU). In Figure 29 the relative changes in RLU 
(mean ± standard deviation) in comparison to a sample obtained from the septum 
area of a transplanted, but non-treated pig are shown. 
Remarkably, all cardiac samples showed detectable luciferase activity. 
Interestingly, variances were immense reaching from 1.4-fold (± 0.1) (sample 41) 
to 215.0-fold (± 56.4) (sample 15). Sites of high expression were heterogeneously 
distributed. Whereby, the 3 samples showing the highest activity were located in 
the inner wall of the left ventricle (sample 15: 215.0 ± 56.4; sample 17: 53.1 ± 9.4; 
sample 24: 162.1 ± 17.4). The levels of the remaining samples of the inner 
ventricular region were similar to the outer regions. Regarding the outer part of the 
left ventricle, luciferase activity varied from 1.9 ± 0.3 fold to 29.5 ± 6.7 fold with a 
mean change of 13.1-fold.  
Also in the septum region, the luciferase activity ranged from 1.7 ± 0.1 fold 
(sample 31) to 34.8 ± 5.1 fold (sample 28) with an overall mean of 9.6-fold.  
In the right ventricle, only 2 out of 9 samples showed a more than 5-fold increase 
in luciferase activity, namely sample 39 with 15.7 ± 3.3 fold and sample 44 with 
26.8 ± 6.7 fold. 
Analyses of extracardiac organs revealed absence of detectable amounts of 
luciferase. The separately analyzed samples of the cardiac atrium showed an 
increase of 8.3 ± 1.3 fold for atrium I, but only a marginal change of 1.3 ± 0.8 fold 
for atrium II. 
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4.2 Establishment of rAAV-mediated gene transfer into CD34+ 
cells 
4.2.1 Second-strand synthesis is a limiting step in CD34+ cell 
transduction 
As already summarized in 3.2.3, publications on rAAV-mediated transduction of 
human CD34+ cells are hardly comparable due to differences in vector production, 
titration and applied vector amounts in addition to varying cell origin and isolation 
techniques. So far, only rAAV2 has been evaluated in human CD34+ cells, but with 
conflicting results regarding their transduction efficiencies. In this study we aimed 
to develop a protocol for efficient transduction of CD34+ cells by making use of the 
now available improvements in AAV vector technology. Thus, we compared rAAV2 
which is the most commonly used AAV serotype in ex vivo and in vivo gene 
transfer applications with rAAV3 known for its tropism for hematopoietic cells and 
rAAV5 which is the most divergent serotype for their applicability in CD34+ cell 
transduction (Bantel-Schaal et al., 1999; Chiorini et al., 1999; Handa et al., 2000; 
Lu, 2004). All three serotypes were produced as pseudotypes with single-stranded 
(ss) or self-complementary (sc) vector genomes by a helper virus-free packaging 
method to exclude any assistance of helper virus particles in transduction and to 
determine the role of vector genome conformation (McCarty, Monahan, and 
Samulski, 2001; Xiao, Li, and Samulski, 1998) (7.3.6.1, 7.3.6.2). As the various 
serotypes differ in their tropism, we did not use transducing titers for normalization 
of the vector preparations, but equal vector genomes per cell (GOI). The genomic 
titers of all rAAV vector preparations were determined by quantitative PCR and 
ranged between 6.6 x 1010 (rAAV5scGFP) and 1.1 x 1012 (rAAV2ssGFP) genomic 
particles/ml as shown in Table 3, thus revealing that all vectors could be produced 
with a reasonable efficiency (7.3.6.4) (Theiss et al., 2003). 
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rAAV3
1. preparation 2. preparation 1. preparation 1. preparation 2. preparation
ssGFP 4.9x1011 1.1x1012 8.6x1011 3.1x1011
scGFP 5.3x1011 2.0x1011 1.7x1011 6.7x1010 6.6x1010
rAAV2 rAAV5
 
Table 3: Genomic titers of rAAV vector preparations. The serotypes rAAV2, rAAV3 and rAAV5 
encoding either for single-stranded (ss) or self-complementary (sc) GFP have been produced as 
described in chapter 7.3.6.1 and 7.3.6.2. Genomic titers were determined by qPCR and are 
indicated as vector genomes per ml. 
 
CD34+ cells were isolated out of cord blood by separating peripheral mononuclear 
cells by Ficoll-density gradient centrifugation and subsequent magnetic cell sorting 
for CD34 (Direct CD34 Progenitor Cell Isolation Kit, Miltenyi Biotech) as described 
in 7.3.7.1. After pre-expansion of the cells for 2 to 4 days in serum-free culture 
medium (Stem Span, CellSystems) containing Flt3-ligand (100 ng/ml), SCF (100 
ng/ml), IL-3 (20 ng/ml) and IL-6 (20 ng/ml), cells were transduced with a GOI of 
105 of rAAV2, rAAV3 or rAAV5 coding for GFP in a single-stranded or self-
complementary vector genome conformation. Cells were washed 3 h p.i. cultured 
for 3 additional days and assayed for transgene expression by flow cytometry. 
Results are shown in Figure 30 as mean + standard error of the mean (SEM) of 3 
(rAAV3, rAAV5) and 8 (rAAV2) experiments of different donors. 
As depicted in Figure 30, neither transduction with rAAV3ssGFP nor 
rAAV5ssGFP, both encoding for GFP in a single-stranded vector genome 
conformation, resulted in a detectable amount of transgene expression, although 
vector genomes were detected in these CD34+ cells by qPCR experiments as 
shown in Figure 31. AAV2ssGFP transduction resulted in GFP expression, but 
only a marginal transduction efficiency of 8 ± 2.5 % (mean ± SEM) was achieved. 
In contrast, use of self-complementary instead of the naturally occurring single-
stranded vector genome conformation resulted in a significant increase in 
transduction efficiency for all three serotypes. Also in this case rAAV2 was the 
most efficient serotype reaching a transduction efficiency of 57.2 ± 2.6 %. Thus, 
second-strand synthesis is a limiting step in rAAV-mediated transduction of CD34+ 
cells.  
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single-stranded 
vector genomes 
self-complementary 
vector genomes 
rAAV2 8.0 ± 2.5 57.2 ± 5.2 
rAAV3    0 ± 0.1  4.8 ± 2.2 
rAAV5    0 ± 0.1  7.4 ± 2.2 
 
Figure 30: Transduction efficiencies of CD34+ cells by rAAV2, rAAV3 and rAAV5 coding for GFP in 
single-stranded (ss) or self-complementary (sc) vector genome conformation. Pre-expanded CD34+ 
cells were transduced with a GOI of 105. 3 h p.i. medium was exchanged and 3 d p.i. 2x104 cells 
were analyzed by flow cytometry. Bar graph shows the mean of 3 (rAAV3 and rAAV5) and 8 
(rAAV2) independent experiments with cells obtained from umbilical cord blood of different donors. 
The data in the enclosed table are given as mean percentage of positive cells ± standard error of 
the mean (SEM). 
 
In order to investigate if the differential transgene expression observed for the 3 
serotypes was due to potential limitations in cell entry, we determined the amount 
of transgene DNA isolated from rAAV-treated CD34+ cells. Therefore, cells were 
thawed, expanded and transduced as described above with a GOI of 104 of 
rAAV2, 3 or 5 encoding for ssGFP or scGFP. Cells were washed and extensively 
trypsinized to remove non-internalized vectors 3 h p.i.. The extracted DNA 
samples were analyzed by qPCR for GFP and normalized to human GAPDH 
gene. For all samples the crossing points for GAPDH showed a comparable value 
ranging from 23.4 to 24.4 cycles thus confirming that equal DNA amounts have 
been analyzed. Results of 2 independent experiments are shown in Figure 31 as 
normalized copy number + standard deviation. Melting curve analyses revealed 
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one specific PCR amplification product for all rAAV-treated cell samples, while 
non-transduced controls showed only unspecific products. Therefore, only values 
obtained for the rAAV-treated cell samples are shown in Figure 31. 
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Figure 31: Quantitative analysis of transgene DNA isolated from CD34+ cells 3 h p.i. with the 
indicated vectors. Thawed cells were pre-expanded for 3 d and transduced with a GOI of 104 of 
rAAV2, 3 or 5 encoding ssGFP or scGFP. 3 h p.i., cells were washed and extensively trypsinized 
and total DNA was extracted. Quantitative PCR analyses were performed for GFP and normalized 
to human GAPDH. Results are shown as copy number + standard deviation. 
 
As depicted in Figure 31, serotype 2 was most efficient in entering CD34+ cells. 
Entry was independent of the genome conformation (1.1 x 107 ± 6.8 x 106 copies 
for ssGFP and 7.1 x 106 ± 6.9 x 105 copies for scGFP), as expected. The value for 
rAAV2scGFP was only 0.6-fold lower than for the rAAV2ssGFP. Also for rAAV3 
which was the second efficient serotype in entry, the values obtained for scGFP 
(3.0 x 106 ± 1.5 x 106 copies) were only 1.2-fold higher than for ssGFP vectors (3.7 
x 106 ± 2.1 x 106 copies). Serotype 5 entered the cell with the lowest efficiency. In 
comparison with rAAV5ssGFP (7.7 x 105 ± 5.3 x 105 copies), 2.6-fold more vector 
genomes were detected after transduction with rAAV5scGFP (2 x 106 ± 1.3 x 106 
copies). These observations reveal that all serotypes are in principle able to enter 
CD34+ cells, however, they differ in their efficiency. For rAAV2ssGFP, e.g. 3.7 and 
14.4-fold higher amounts of vector genomes were intracellularly detected than for 
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rAAV3 and rAAV5, respectively. Thus, the higher transduction efficiency of rAAV2 
compared to rAAV3 and rAAV5 might be explained at least in part by variations in 
cell entry efficiency. 
4.2.2 Loss of transgene expression during prolonged cultivation times 
A transduction efficiency of almost 60 % was commonly reached in human CD34+ 
cells 3 d p.i. with rAAV2scGFP (GOI 105). At least for certain applications stable 
gene expression would be desirable, e.g. for expression of anti-thrombotic or 
cytoprotective factors for maintenance and survival of colonized vascular 
prosthetic grafts and cardiac valves. Thus, we determined if expression level 
persisted. Briefly, CD34+ cells were either freshly isolated or thawed 
(CellSystems), pre-expanded and transduced with rAAV2 coding either for ssGFP 
or scGFP. Cells were washed 3 h p.i., further cultivated and analyzed for GFP-
expression by FACS analyses 3 d p.i.. One week thereafter, flow cytometric 
analyses were repeated. Results are summarized in Figure 32 as mean 
percentages of GFP expressing cells + standard error of the mean of 5 
independent experiments. 
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Figure 32: Transgene expression in CD34+ cells 3 and 10 d p.i.. Pre-expanded fresh or thawed 
CD34+ cells were transduced with a GOI of 105 of rAAV2ssGFP or rAAV2scGFP and 2x104 cells 
were analyzed for GFP expression 3 and 10 d after transduction. Shown are the mean percentages 
of transgene expressing cells + standard error of the mean of 5 independent experiments. 
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Comparably to the values obtained in 4.2.1, transduction with rAAV2scGFP 
resulted in 58.5 ± 1.3 % with rAAV2ssGFP in 5.9 ± 0.5 % transgene-expressing 
cells 3 d p.i.. However, GFP expression declined strongly in the case of 
rAAV2scGFP treated cells (13.3 ± 5.3 %) when the cells were further cultivated. 
The already low level of transgene expression by rAAV2ssGFP after 3 d changed 
only marginally (4.1 ± 1.7 %) within 7 days of further cultivation. 
4.2.3 Heparin inhibits transduction with rAAV2 approving HSPG as 
primary receptor 
Heparan sulfate proteoglycan (HSPG) has been described as primary receptor for 
AAV2 (Summerford and Samulski, 1998). To investigate if HSPG is also involved 
in rAAV2-mediated CD34+ cell transduction, competition studies using heparin, a 
soluble analogue of HSPG, were performed (Figure 33). In addition, this 
experiment allows to distinguish between vector and pseudotransduction since 
addition of heparin is unable to impair GFP protein transduction. 
Therefore, CD34+ cells were freshly isolated from cord blood. Peripheral 
mononuclear cells were separated by Ficoll-density gradient centrifugation and 
sorted for CD34 by MACS (Direct CD34 Progenitor Cell Isolation Kit, Miltenyi 
Biotech) as described more detailed in 7.3.7.1. After pre-expansion for 2 to 4 d, 
cells were transduced with a GOI of 105 rAAV2scGFP in presence or absence of 
971 units of heparin. Cells were washed 3 h p.i.. Transduction efficiency was 
analyzed 3 d p.i. by flow cytometry (Figure 33 A) and fluorescence microscopy 
(Figure 33 B). Results of 3 independent experiments obtained with cells of 
different donors are shown as mean percentage of GFP-expressing cells + 
standard error of the mean (mean ± SEM).  
Comparable to results presented in 4.2.1, transduction efficiencies over 50 % 
(56.7 ± 5.3 %) were obtained with rAAV2scGFP (Figure 33 A). In contrast, 
transduction was almost completely abolished by adding heparin (1.2 ± 0.7 %; 
P<0.0003) (Figure 33 A). In line with these results, fluorescence microscopy 
revealed GFP-expressing cells when only rAAV2 was applied while no GFP 
expression was detected when rAAV2 transductions were performed in presence 
of heparin and in non-transduced controls (Figure 33 B). These results show 
clearly that HSPG acts as a primary receptor for rAAV2 transduction. Moreover, 
pseudotransduction in CD34+ cells can be excluded. 
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Figure 33: Inhibition of rAAV2scGFP-mediated transduction by heparin. 971 units of heparin 
(Sigma) were applied to 8 x 104 pre-expanded CD34+ cells, followed by 105 genomic particles of 
rAAV2scGFP per cell. In parallel, cells were transduced with the same amount of vector in the 
absence of heparin. Cells were incubated for 3 h at 37 °C and 5 % CO2, followed by a washing 
step. 3 d p.i. 2 x 104 cells were analyzed by flow cytometry (A) and fluorescence microscopy (B). 
Results presented in (A) are the mean of 3 independent experiments using CD34+ cells isolated 
from umbilical cord blood from 3 different donors. Data are shown as mean percentage of GFP-
expressing cells, error bars as standard error of the mean (SEM).  
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4.2.4 Transduction efficiency correlated with the availability of α5β1 
integrins 
Thus far, in addition to the primary receptor HSPG, 5 cellular receptors have been 
described for AAV2 (Akache et al., 2006; Asokan et al., 2006; Kashiwakura et al., 
2005; Qing et al., 1999; Summerford, Bartlett, and Samulski, 1999; Summerford 
and Samulski, 1998). Fibroblast growth factor receptor (FGFR) or hepatocyte 
growth factor receptor (HGFR, c-met) and possibly laminin receptor may enhance 
AAV2 binding to the cell surface. The subsequent interaction with the coreceptor 
αvβ5 integrin induces endocytosis and most likely a rearrangement of the 
cytoskeleton, thus enabling AAV to enter the cell and be trafficked towards the 
nuclear area (Sanlioglu et al., 2000). Recently, α5β1, a second integrin molecule, 
functioning as an alternative AAV coreceptor has been identified (Asokan et al., 
2006). Therefore, we determined the surface expression level of αvβ5 and α5β1 on 
CD34+ cells isolated from human cord blood (freshly isolated (CB1) or cells by 
CellSystems (CB2)) or human bone marrow (kindly provided by N. Fein and H. 
Abken, University Hospital of Cologne) by flow cytometry at the day of 
transduction (after 2 to 4 d of expansion)
 
to assess which of these two integrins is 
likely available to allow AAV2 entry into CD34+ cells. In addition, these cells were 
transduced with a GOI of 105 rAAV2scGFP, washed 3 h later and determined for 
transgene expression at 3 d p.i. by flow cytometry.  
As shown in Figure 34 A, independent of the source of CD34+ cells, transduction 
efficiencies above 50 % were obtained. Also irrespective of the source, high 
expression of α5β1 integrin was observed at the day of transduction, whereas the 
expression of αvβ5 was strongly depending on the donor and ranged between 0.5 
% and 59.5 %. Representative FACS plots are depicted in Figure 34 A, 
demonstrating the shift of CD34+ cells stained either with anti-α5β1 or anti-αvβ5 
antibody and secondary antibody (PE-labeled) compared to the isotype control. 
This result indicates that transduction efficiency most obviously correlated with the 
availability of α5β1 integrin. 
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A 
 
B 
source of 
CD34+ cells αvβ5 [%] α5β1 [%]
GFP expression 
[%]
CB1 59.5 n.d. 58.0
43.8 n.d. 66.5
39.5 n.d. 65.0
CB2 33.4 78.8 62.7
2.4 91.8 55.2
22.8 96.2 60.3
0.5 82.8 68.8
BM 3.5 84.4 52.0
 
Figure 34: Correlation between availability of αvβ5 and α5β1 integrins and transduction efficiency. 
(A) Representative FACS plots (cells stained with 1st and 2nd antibody (bold lines), isotype control 
(normal lines) (B) Percentages of αvβ5 and α5β1 integrin (primary antibodies MAB1961 and 
MAB1999 by Chemicon) expressing cells within CD34+ cell preparations from 3 different sources as 
assessed by flow cytometry. Subsequently, these cells were transduced with a GOI of 105 of 
rAAV2scGFP and transgene expression was determined by FACS analysis 3 d p.i. Three different 
sources were used: Freshly isolated cord blood CD34+ cells (CB1) from 3 different donors, 4 
different samples of cord blood CD34+ cells purchased from CellSystems (CB2), and one sample of 
CD34+ cells isolated from bone marrow (BM); n.d.= not determined. 
 
Moreover, we determined integrin levels on freshly thawed cells which have been 
reported to be not tranceduceable (Nathwani et al., 2000). According to Hart and 
colleagues, α5β1 integrin expression becomes upregulated in CD34+ cells by pre-
expansion of CD34+ cells in SCF-containing medium (Hart et al., 2004). In line with 
this, FACS analyses of freshly thawed CD34+ cells (prior to expansion) showed no 
R1
M1
M1
αvβ5 integrin α5β1 integrin 
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expression of αvβ5  and a maximum of 3.3 % α5β1 integrins, while more than 77 % 
α5β1 integrin and less than 2 % αvβ5 integrin-expressing cells were detectable at 3 
d after expansion (Table 4). 
 
αvβ5 [%] α5β1[%] αvβ5 [%] α5β1[%]
0 3.3 0.5 82.8
0 0 1.6 77.4
w/o pre-expansion pre-expanded
 
Table 4: Amount of CD34+ cells displaying integrins before and after pre-expansion. CD34+ cells 
were freshly thawed and directly stained for αvβ5 and α5β1 integrins (w/o pre-expansion). The 
amount of integrins was determined by FACS analyses. The procedure was repeated with pre-
expanded cells after 3 d. Shown are the results of 2 independent experiments with pooled donors. 
 
We further aimed to support the assumption that α5β1 integrin serves as 
coreceptor in CD34+ cell transduction. Wild type AAV2 contains a NGR motif 
associated with α5β1 integrin binding (Asokan et al., 2006). Therefore, we used an 
AAV2 mutant described to be deficient for α5β1 integrin binding due to an arginine 
to alanine substitution at the amino acid position 513 in the respective NGR motif 
(NGR R513A) (Asokan et al., 2006). Assuming that rAAV2 transduction relies on 
α5β1 integrins, CD34+ cell transduction by a non-α5β1 binding mutant should be 
significantly impaired. Thus, CD34+ cells were analyzed for the amount of both 
integrins at the time of vector administration by flow cytometry (Figure 35 B). αvβ5 
integrins were not detectable on the pre-expanded cells in this experiment. In 
contrast, more than 90 % of the cells displayed α5β1 integrins. Hence, only α5β1 
integrins were available to potentially assist vector entry and results on 
transduction studies can directly be correlated with this coreceptor. The pre-
expanded CD34+ cells (CellSystems) were transduced with a GOI of 104 of rAAV2 
or NGR R513A encoding scGFP. Washing and trypsinization of the cells 3 h p.i. 
should eliminate non-internalized vectors. Cells were cultivated for 3 further days 
before transgene expression was determined by FACS analyses. As depicted in 
Figure 35 A, the amount of GFP-expressing cells after transduction with NGR 
R513A (4.6 ± 0.4 %) was 5.6 times lower than with rAAV2 (25.9 ± 3.3 %). This 
result strongly supports our assumption that α5β1 and not αvβ5 integrins mediate 
cell entry of rAAV2 into CD34+ cells. 
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Figure 35: Transgene expression in CD34+ cells transduced with rAAV2 and NGR R513A. CD34+ 
cells (CellSystems) were thawed and pre-expanded for 3 d. The amount of integrins was 
determined by FACS analyses (B) at the day of transduction with a GOI of 104 of either rAAV2 or 
NGR R513A encoding scGFP. 3 h p.i., cells were washed, extensively trypsinized to remove non-
internalized vectors and further cultivated. Flow cytometric analyses for GFP expression were 
performed 3 d p.i. (A). Shown are the means + SEM of 3 independent experiments. 
 
4.2.5 Enhancement of transgene expression using retinoic acid and 
Trichostatin A 
Various attempts have been made to increase transgene expression after viral or 
non-viral gene transfer. A widely used promoter which also found application in our 
study is derived from the immediate-early region of cytomegalovirus (CMV) gene. 
The CMV promoter induces high transgene expression levels in various tissues 
and cells likely due to a number of cis-regulatory elements mediating to which 
binding of transcription factors like NF-κB, CREB, AP-1 and retinoic acid receptor 
(RARs, RXRs) can occur (Angulo et al., 1996; Boshart et al., 1985; Ghazal et al., 
1992; Guo et al., 1996; Loser et al., 1998; Rideg et al., 1994; Rotondaro, Mele, 
and Rovera, 1996; Wade, Klucher, and Spector, 1992). The latter is of special 
interest, since addition of retinoic acid was shown to enhance transcription from 
CMV promoters, e.g. in endothelial cells after adenoviral transgene delivery 
(Angulo et al., 1996; Gaetano et al., 2000). Despite the high transcriptional activity 
α5β1 [%] αvβ5 [%] 
92.00 0.54 
96.99 0.32 
98.36 0.84 
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that is normally achieved with CMV promoters at early times after transduction 
with viral vectors, promoter silencing after a longer period represents a major 
hurdle that impairs a long lasting transgene expression in vivo, in vitro and in stem 
cells (Xia et al., 2007). Recently, the histone-deacetylase inhibitors (HDACi) 
Trichostatin A (TSA) and FR901228 have been shown to enhance adenovirus-
mediated transgene expression in hematopoietic and endothelial cells (Gaetano et 
al., 2000; Kitazono et al., 2002). Thus, we intended to determine the effect of 
single or combined treatment with TSA and RA on AAV-mediated transgene 
expression in CD34+ cells. CD34+ cells (CellSystems) were thawed and pre-
expanded as described in 7.3.7.2.   
In a first series of experiments, we incubated pre-expanded CD34+ cells with 
rAAV2scGFP at a GOI of 105 in the presence of different RA (5-5000 nM) and/or 
TSA (3.125-500 ng/ml) concentrations to determine the most suited amount of 
these drugs for our experiments. Cells were washed 3 h p.i., cultured for 3 d in 
medium supplemented with the respective drug and then analyzed by flow 
cytometry (data not shown). These analyses revealed an optimal concentration of 
10 µM for RA and of 25 ng/ml for TSA.  
Next, we incubated pre-expanded CD34+ cells with rAAV2scGFP at a GOI of 105 
of either drugs, alone or in combination, and determined the percentage of GFP-
expressing cells as well as the mean fluorescence intensity (MFI) as a value for 
transduction efficiency and transcriptional activity, respectively, at 3 d p.i. by flow 
cytometry (Figure 36). On average, a 3.4-fold (mean ± 0.2 SEM; P=0.006) 
increase in the MFI was observed when RA was administered, while addition of 
TSA resulted in 1.3-fold increased MFI (mean ± 0.3 SEM; P<0.25). Further, when 
RA and TSA were added in combination, the highest increase in the MFI value 
(5.9-fold ± 1.1; P=0.002) was observed, thus revealing a synergistic effect of the 
two drugs. As a consequence of the increased transcriptional activity, more CD34+ 
cells reached a high transgene expression level. Thus, by adding these two 
transcriptionally active drugs, the amount of cells with a reasonable transgene 
expression could be increased from 61.4 ± 4 % to 85.6 ± 0.3 % (mean ± SEM; 
n=3; P<0.002) (Figure 36). 
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A 
 
B 
  
C 
  transgene expression mean fluorescence intensity 
  GFP-expressing cells ± SEM [%] MFI ± SEM 
w/o drugs 61.4 ± 4.0 48.8 ± 9.7 
TSA 69.5 ± 5.4   61.4 ± 13.8 
RA 82.7 ± 1.0 166.8 ± 25.3 
TSA+RA 85.6 ± 0.3 288.2 ± 39.1 
 
Figure 36: Enhancement of rAAV2scGFP-mediated transgene expression by Trichostatin A (TSA) 
and retinoic acid (RA). 8x104 pre-expanded CD34+ cells (CellSystems) were treated with either 25 
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ng/ml TSA (Sigma) and/or 10 µM RA (Sigma) at the time of transduction with rAAV2scGFP. In 
parallel, cells were transduced with the same amount of vector in the absence of the drugs (only 
solvent). 3 h p.i. cells were washed and fresh medium containing the drugs or solvent without drugs 
as control were added. 3 d p.i. transgene expression was measured of 2x104 cells by cell 
cytometry. (A) Bar graph indicates the mean fluorescence intensity as detected by FACS analysis; 
(B) Bar graph showing the increase in the percentage of GFP-expressing cells in the presence of 
the two drugs. (n=3; error bars= SEM; *= P≤0.006). (C) Indicated is the correlation between 
increase in the percentage of GFP expressing cells and the enhancement of MFI in the four tested 
conditions.  
 
4.2.6 CD34+ cells are able to take up Dil-AcLDL after endothelial 
differentiation assay 
CD34+ cells are also known as endothelial progenitor cells defined by their ability 
to differentiate into endothelial cells. Therefore, we evaluated the potential of 
CD34+ cells to take up acetylated low-density lipoproteins (Dil-AcLDL) as 
endothelial cell marker after pre-expansion, rAAV2 transduction and subsequent 
incubation in endothelial differentiation medium. Cells were seeded onto 
fibronectin-coated plates to enable attachment. For coating, the plates were 
incubated with 10 µg/ml fibronectin in PBS over night at 4 °C. Subsequently 
solution was taken off and plates were dried.  
CD34+ cells (CellSystems) were thawed, pre-expanded for 2 to 4 d and 
transduced with a GOI of 105 rAAV2 encoding either single-stranded or self-
complementary GFP vector genomes. Transduction efficiency was determined by 
FACS analysis 3 d p.i.. At the same time, these cells were seeded onto 
fibronectin-coated plates in endothelial basal medium (EBM-2 + supplements) 
including 20 % FCS and 50 ng/µl VEGF for induction of endothelial differentiation. 
Every 3 d, half of the medium was exchanged carefully. 10 d after inititation of 
differentiation, adherent cells showed a spindle-shaped morphology and were 
incubated with 1 µg/ml Dil-AcLDL diluted in medium for 4 h at 37 °C. Cells were 
fixed with 3 % paraformaldehyde and analyzed for Dil-AcLDL uptake by 
fluorescence microscopy (200x magnification; Zeiss Axiovert S100). 
Representative images of 3 independent experiments are shown in Figure 37. Red 
fluorescence could be detected in nearly all of the non-transduced and previously 
transduced cells indicating differentiation into endothelial cells. These results 
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indicate that the rAAV transduction process did not interfere with differentiation 
and endothelial cell-specific Dil-AcLDL uptake. 
 
 
Figure 37: Dil-AcLDL uptake of CD34+ cells after 10 d of incubation in endothelial differentiation 
medium. CD34+ cells were pre-expanded and transduced with a GOI of 105 of rAAV2 coding for 
single-stranded (ss) or self-complementary (sc) GFP. 3 d p.i., cells were seeded onto fibronectin-
coated plates and cultivated in endothelial differentiation medium for 10 d before incubation in 1 
µg/ml Dil-AcLDL containing medium for 4 h. Cells were fixed and analyzed by fluorescence 
microscopy (200x magnification; Zeiss Axiovert S100). Shown are representative images of 3 
independent experiments for endothelial differentiation. 
 
For later applications, differentiation of transduced endothelial progenitor cells into 
endothelial cells is required. Therefore, we investigated the potential correlation 
between transduced cells and cells which have taken up Dil-AcLDL. As GFP 
fluorescence was not detectable after 10 d we analyzed the adherent cells for 
presence of vector genomes. After intense washing, the adherent cells were 
trypsinized and DNA was extracted using the DNeasy Blood & Tissue Kit 
(Qiagen). 100 ng DNA of the samples were analyzed by qPCR for the transgene 
GFP and normalized to the housekeeping gene GAPDH. Mean values for GFP 
DNA of 3 independent experiments are depicted in Figure 38 and shown as copy 
number per 50 ng DNA + standard deviation. The background level for GFP DNA 
in the non-transduced control was 1.1 x 103 + 1.5 x 103 copies/50 ng DNA, but this 
value was based on amplification of unspecific and specific products as revealed 
by melting curve analyses. Therefore, the background level is supposed to be 
much lower and is depicted as striped bar in Figure 38. In contrast, DNA samples 
non-transduced rAAV2scGFP rAAV2ssGFP 
Dil-AcLDL 
light 
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from transduced cells showed only the GFP-specific PCR product in the respective 
melting curve analyses. 
Interestingly, the amount of transgene after transduction with rAAV2ssGFP (5.9 x 
105 + 5 x 105 copies/50 ng DNA) equalled the level of rAAV2scGFP transduction 
(6.1 x 105 + 4.2 x 105 copies/50 ng DNA) (GOI 105). Both values exceeded the 
background signal more than 500 fold which clearly indicates presence of vector 
genomes within the DNA of the adherent cells. As nearly all cells were positive for 
Dil-AcLDL uptake as shown in Figure 37, this result strongly suggests that 
transduced CD34+ cells maintained their ability to differentiate into endothelial 
cells. 
 
 
Figure 38: Level of transgene DNA in transduced and non-transduced cells after endothelial 
differentiation assay. CD34+ cells were pre-expanded and transduced with rAAV2 coding either for 
ssGFP or scGFP with a GOI of 105. 3 d after, cells were seeded onto fibronectin-coated plates in 
endothelial differentiation medium und cultivated for 10 d. After repeated washing, DNA was 
extracted from the adherent cells and 100 ng were analyzed in qPCR. Values were normalized to 
GAPDH and shown as GFP copy numbers per 50 ng DNA + standard deviation. In contrast to the 
transduced samples, melting curve analyses of the non-transduced samples revealed also other 
PCR products beside GFP and are therefore depicted as striped bar. Summarized are results from 
3 independent experiments.  
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4.3 Further applications of serotypes 
4.3.1 Serotype 2 is superior in transduction of primary melanoma cells 
As part of a publication on tumor cell directed gene transfer, primary melanoma 
cells from three different patients (MediGene, Martinsried) were transduced with 
the serotypes 1 to 5 to compare the transduction profiles of primary tumor cells 
and tumor cell lines (Hacker et al., 2005). Tumor cell lines have been grown in 
long-term culture and might therefore show differences. Primary melanoma cells 
were transduced with a GOI of 1 x 104 rAAV1 to rAAV5 encoding the transgene in 
the commonly used single-stranded vector genome conformation (ssGFP). Since 
rAAV2 was the most efficient serotype on the melanoma cell line MV3 primary 
cells were additionally transduced with a lower GOI of 1 x 103 for this serotype. 
Transgene expression was determined 48 h p.i. by FACS analysis.  
 
 
Figure 39: rAAV-mediated gene transfer in primary melanoma cells. Primary melanoma cells from 
3 different patients were transduced with rAAV1 to rAAV5 at a GOI of 1x104. Additionally, a 
transduction experiment was performed using rAAV2 at a GOI of 1x103. 48 h later, the amount of 
GFP-expressing cells was determined by FACS analysis. 
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Although patient-specific variations in transduction efficiencies were observed, 
rAAV2 was superior in all cases compared to rAAV1, rAAV3 and rAAV5 (Figure 
39). The level of transgene expression ranged from 6.4 % (patient 1) to 80.5 % 
(patient 2) at a GOI of 1 x 104. Even at tenfold lower vector amounts reasonable 
transduction efficiencies of 35.6 % (patient 2) and 24.6 % (patient 3) were 
obtained with rAAV2ssGFP. Interestingly, for the other serotypes no unique order 
of transduction efficiencies could be observed; it was rather depended on the 
patient. Whereas tumor cells derived from patient 1 and 3 were nearly resistant to 
rAAV5 transduction, 35.6 % of the cells from patient 2 were GFP-positive. A 
comparable picture was obtained for rAAV1 transduction. In contrast, rAAV4 was 
revealed as second best serotype for transduction of melanoma cells derived from 
patient 3. 
4.3.2 Serotype 2 is superior in transduction of primary porcine 
fibroblasts and HeLa cells  
Besides porcine endothelial cells, primary porcine fibroblasts have been evaluated 
for their permissiveness of rAAV transduction. These cells are of special interest 
for somatic cell nuclear transfer in pigs, a procedure which is carried out by our 
cooperation partners in the Institute of Farm Animal Genetics, Mariensee (B. 
Petersen, H. Niemann) (Betthauser et al., 2000; Onishi et al., 2000). Transgenes 
are introduced into porcine fibroblasts which are then screened for the occurrence 
of stable integration events. These cells are fused to enucleated oocytes and 
transferred surgically into the foster mother. This technology greatly improved the 
generation of transgenic animals, however, the efficiency (born piglet/transferred 
embryos) is still low. The ability of wild-type AAV2 to integrate site-specifically 
could be favorable for this application as it minimizes the risk of deleterious 
insertions. 
First, we assessed the efficiency of fibroblast transduction by the serotypes 1 to 5. 
Therefore, primary porcine fibroblasts were transduced by 3 different vector 
concentrations of rAAV1 to 5 encoding for the transgene GFP in a single-stranded 
(ss) or self-complementary (sc) vector genome conformation, respectively. The 
amount of GFP-expressing cells was determined by flow cytometry 2 d p.i.. rAAV2 
was the most efficient serotype in fibroblast transduction reaching 87.8 ± 5.3 % 
with ssGFP and 96.3 ± 1 % with scGFP at a GOI of 105. Also serotype 5 was 
highly efficient with 75.7 ± 1.2 % (ssGFP) and 84.1 ± 11.6 % (scGFP) at the 
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highest vector concentration. The serotypes 1 and 3 showed similar transduction 
efficiencies of about 5 % for the ssGFP and of 30 % for scGFP vectors. AAV4 
displayed the lowest transgene expression levels of 2.1 % (ssGFP) and 8 % 
(scGFP). At a GOI of 103 only rAAV2ssGFP (13.6 ± 4.9 %), rAAV2scGFP (64.9 ± 
8.7 %) and rAAV5scGFP (22.9 ± 1.4 %) resulted in transduction levels above 0.5 
%. Overall, transduction with scGFP vectors at GOI 104 and 105 resulted in higher 
transduction efficiencies compared to ssGFP vectors in all serotypes. 
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Figure 40: Transduction efficiencies of rAAV1 to rAAV5 on porcine fibroblasts. Primary porcine 
fibroblasts were transduced with 3 different GOIs (103, 104 or 105) of the serotypes 1 to 5 coding 
either for single-stranded or self-complementary GFP. The amount of GFP-expressing cells was 
determined 2 d p.i. by FACS analysis. Results are shown as mean + standard deviation of 3 
independent experiments. 
 
The same experiments have been performed in parallel with the highly permissive 
tumor cell line HeLa to correlate these transduction efficiencies to those of porcine 
fibroblasts and other cell types. HeLa cells were transduced with rAAV1 to rAAV5 
coding for ssGFP or scGFP at a GOI of 103 and 104. The amount of GFP-
expressing cells was determined 2 d p.i. by flow cytometry. Also in these cells, 
rAAV2 was the most efficient serotype whereas already 90 ± 1.8 % GFP-positive 
cells were detected at a GOI of 103 of the ssGFP vector. In the case of 
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rAAV2scGFP nearly every cell expressed GFP (about 99 %) (both GOIs). In 
contrast to porcine fibroblasts, rAAV3 was revealed as the second efficient 
serotype followed by rAAV1. At a GOI of 103 rAAV3ssGFP resulted in only 4.9 ± 
4.2 % GFP-expressing cells while 55.4 ± 2 % were measured at a GOI of 104. 
Regarding rAAV3scGFP these values were 48.3 ± 4.7 % and 93.9 ± 0.5 % for the 
respective vector amounts. Although transduction with rAAV1scGFP (GOI 104) 
resulted in comparable transgene expression levels (93.7 ± 1 %), 35.9 ± 3.5 % 
GFP-expressing cells were measured when tenfold less vectors were applied. As 
expected, transduction with rAAV1ssGFP showed a transduction efficiency of 
maximal 43.2 ± 5.1 %. In contrast to transduction of porcine fibroblasts, serotype 5 
showed much lower transgene expression levels in HeLa cells with 17.9 ± 4 % 
(ssGFP) and 68.5 ± 7.7 % (scGFP) at GOI 104. On the other hand, rAAV4 was the 
vector with the lowest efficiency among these 5 serotypes in transduction of both 
cell types. In HeLa cells, a GFP-expression of 11.9 ± 4.7 % (ssGFP) and 24.2 ± 
6.7 % (scGFP) was determined for rAAV4 at a GOI of 104.  
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Figure 41: Transduction efficiencies of rAAV1 to rAAV5 on HeLa cells. HeLa cells were transduced 
with rAAV1 to rAAV5 encoding for ssGFP or scGFP at GOI 103 and 104. Transgene expression 
levels were determined 2 d p.i. by flow cytometry. Results are shown as mean + standard deviation 
of 3 independent experiments. 
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4.4 Vector genomes are detected in spleen following 
intracerebral injection of rAAV2 
Results summarized in this chapter are part of a publication in which rAAV2 was 
used to express single-chain antibodies against prion receptor intracerebrally in a 
scrapie mouse model (Zuber, et al., in press). This work was performed in 
collaboration with C. Zuber and S. Weiss (Gene Center, Munich).  
As reported by our cooperation partners, the 37/67 kDa laminin receptor acts as a 
receptor for internalization of prions and is potentially involved in propagation and 
pathogenesis (Ludewigs et al., 2007; Vana et al., 2007; Zuber, Ludewigs, and 
Weiss, 2007). Its level has been shown to be increased in spleen and brain of 
scrapie infected hamsters amd mice - the organs where the abnormal form of the 
prion protein is mainly found (Rieger et al., 1997). Therefore, different approaches 
have been done to block laminin receptor in order to reduce binding and 
internalization of the abnormal prion protein (Gauczynski et al., 2006; Leucht et al., 
2003; Vana and Weiss, 2006). In this recent report, the efficiency of single-chain 
antibodies (scFv) (S18 and N3) against the laminin receptor has been 
investigated. S18 and N3 have been selected by phage display. An unrelated 
single-chain scFv (C9, a scFv directed against the HBV coat protein) served as 
control. These antibodies had prior been assayed for their protective effect in vivo 
by passive immunotransfer into scrapie infected mice (Zuber et al., 2008). AAV2 
has been chosen as vector system to provide the transgene. The rAAV2 vectors (5 
x 109 genomic particles) encoding S18, N3 or C9 were microinjected 
intracerebrally into the hippocampus followed by injection of scrapie homogenate 
into the same site 2 weeks after vector application. Expression of the scFv N3 in 
the brain was detected pointing to a successful transduction of neuronal cells. The 
second organ known to contain elevated amounts of prion protein is the spleen. 
Thus, spleens were analyzed for a potential therapeutic effect of single-chain 
antibodies with regard to proteinase K resistant prion protein level, which is 
associated with the infectious prion agent. Both groups having received 
therapeutic vectors (rAAV2-S18 and rAAV2-N3) showed lower prion protein levels 
than control animals after rAAV2-C9 injection (90 d p.i.). We analyzed 100 ng DNA 
of the spleen samples for the respective transgene (S18 and C9) and 
housekeeping gene (GAPDH) DNA by qPCR followed by agarose gel 
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electrophoresis of the PCR product (Figure 42). As depicted in Figure 42, we could 
demonstrate the presence of the therapeutic (S18, samples B and C) and control 
(C9, sample A) DNA in mouse spleens. An unrelated animal having received PBS 
was used as negative control (N). In the C9-PCR, the rAAV2-C9 injected animal 
(A) clearly showed a C9-specific band, whereas the unrelated control (N) was 
negative. Also in the S18-PCR, S18-specific DNA was detected in both rAAV2-
S18 treated mice (B and C). An unspecific signal was amplified in sample C and 
the control N as shown in Figure 42. GAPDH levels were comparable between the 
samples confirming that equal DNA amounts have been analyzed. 
These results point to a crossing of the blood-brain barrier of the vectors and 
subsequent transduction of the spleen. 
 
 
 
Figure 42: Detection of C9, S18 and GAPDH DNA within mouse spleens. 5x109 genomic particles 
of rAAV2-S18 or rAAV2-C9 were microinjected intracerebrally. 2 weeks after, scrapie homogenate 
was administered to the same site. 90 d p.i., spleen DNA was extracted and analyzed for GAPDH, 
S18 or C9 DNA, respectively. PCR products were analyzed by agarose gel electrophoresis. A, 
rAAV2-C9 injected mouse; B and C, rAAV2-S18 injected mice; N, unrelated mouse having received 
PBS; +, plasmid DNA containing the respective transgene as positive control; NTC, non-template 
control. 
GAPDH 
C9 
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 A      N      +     NTC 
B       C       N      +     NTC 
  A        B        C  N      NTC 
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5 Discussion 
5.1 Heterotopic heart transplantations 
5.1.1 Approaches for endothelial transduction in rat model 
We assessed the feasibility of rAAV2-mediated transduction of endothelium in a 
heterotopic rat heart transplantation model after intracoronary injection either in 
normothermic (n=3) or hypothermic (n=3) hearts (4.1.1.1). In addition, vector was 
applied into the tail vein without transplantation (n=2). PCR analyses revealed the 
presence of transgene DNA in transplanted hearts (HTX) independent of the 
operation technique. Only one animal (B2) did not show any transgene DNA which 
might be due to the 10-fold lower vector amount that has been injected. The 
existence of vector DNA in several liver samples (A1, A3 and B1) indicates that 
considerable amounts of vector did not enter cardiac cells, but were transported to 
other organs. This is in line with a comparable rat transplantation model of 
intracoronary vector injection where the transgene could also be detected in the 
liver (Kaspar et al., 2005). Interestingly, transgene DNA was measureable in the 
livers of both transplantation groups (A and B). In the hypothermia group, where 
the vector was injected into the cold and cardioplegic heart, rAAV is able to bind to 
its receptor, but cell entry is likely to be impaired due to the low temperature. After 
transplantation and flooding with blood, a loss of vectors might occur before the 
heart has reached physiologic temperature which is likely to vector entry. In 
contrast, administration into the normothermic heart allows immediate cell entry of 
the vector. Therefore, we expected that injection into the normothermic heart could 
be supportive of gene transfer into the heart. Our results indeed showed stronger 
signals corresponding to our vector DNA in transplanted heart samples of the 
normothermia than of the hypothermia group. Therefore, we suggest performing 
further gene transfer experiments in normothermic hearts. 
Vector DNA was detectable in all animals (besides B2) in the transplanted heart. 
Thus, rAAV2 can enter cardiac cells. However, neither transgene mRNA nor β-Gal 
activity were detected. Based on our detailed in vitro analyses, discussed in the 
next chapter, this impairment is most likely due to an inadequate intracellular 
processing of the vector. 
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Concordantly with our in vivo results, Byrne’s group observed that a transcoronary 
single-shot vector injection into cardioplegically arrested rat hearts followed by 
transplantation does not result in a detectable transgene expression (Asfour et al., 
2002). They solved this problem by introducing an atrial septal defect which 
allowed the ex vivo recirculation of the vector (rAAV2ssLacZ). This was performed 
for 20 min at 15 °C in oxygenated Krebs-Henseleit solution. Analyses of the 
transplanted heart revealed a successful transduction with a significant X-Gal 
staining. Thus, prolonging the contact time between viral vectors and target cells 
seems to affect transduction efficiencies positively and would be one of the options 
to improve transduction efficiencies in our model. 
Successful heart transduction by injection of 1.5 x 109 infectious units of 
AAV2CMV-LacZ intracoronary into the cardioplegic heart was reported for a 
mouse model (Svensson et al., 1999). Critical for the success of this approach 
performing a 15 min ex vivo perfusion was most likely the high volume to conquer 
the endothelial barrier due to the high pressure. Numerous attempts have been 
made to increase vascular permeability and thereby overcoming the endothelial 
barrier since endothelial cells seem to be inadequate cell types for achieving high 
levels of transgene expression. In line, intracoronary administration of histamine 
and vector (using amounts comparable to our experiments) resulted in 20 - 32 % 
transgene expression in cardiomyocytes as demonstrated by Kaspar and 
colleagues (Kaspar et al., 2005). These publications point out that increased 
vascular permeability (e.g. histamine, high pressure) could be another possibility 
which alone or in combination with a prolonged incubation time may improve in 
vivo transduction efficiencies of heart tissue. 
Iwanaga and colleagues reported that less than 1 % of cardiomyocytes were 
positively stained for X-Gal activity after injection of rAAV2ssLacZ into hypothermic 
rat hearts despite administration of the vasoactive substance P (as alternative to 
overcome the endothelial barrier) in a big volume (Iwanaga et al., 2004). The 
clamping of the vessels and the vector amount were similar to our approach with 
the exception that we additionally transplanted the heart. This emphasizes that in 
vivo gene transfer into heart tissue is still an experimental approach and many 
controversial results have been described. Previous studies in hamsters 
performed by the same group also revealed absence of β-galactosidase activity, 
but observed immune reactions which were also observed in their rat model 
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(Hoshijima et al., 2002). In both studies, absence of signs of inflammation, but 
transgene expression was detected when phospholamban was used as transgene 
instead of LacZ. The same technique of pulmonary and aortic artery occlusion and 
administration of substance P in addition to intra-aortic injection of rAAV2LacZ did 
not lead to inflammation, but resulted in high myocardial transduction after 4 
weeks in a mouse model (Iwatate et al., 2003).  
Predominantly myocardial not endothelial transgene expression was detected. 
Observations by Li and colleagues demonstrated high β-Gal activity in the 
myocardium and its complete absence in the vessels after intracoronary vector 
delivery in heterotopic heart transplantation in a hamster model (Li et al., 2003). 
On the other hand, transgene expression was detected in endothelial cells and the 
perivascular area in a comparable approach in a rat model after injection of 1 x 
1012 rAAV2GFP vector genomes, but storage of the graft in Histidine-Tryptophan-
Ketoglutarate (HTK) solution for 6 h prior to implantation (Tsui et al., 2003). 
However, in this case the amount of transduced endothelial cells was not 
quantified and leaves room for discussion. 
As an alternative, direct rat myocardial injections have been published to be 
successful (Dandapat et al., 2007; Liu et al., 2006; Palomeque et al., 2007). 
Especially, the administration of a vector construct identical to the here used 
rAAV2ssLacZ at comparable vector amounts (4 x 1011 particles) indicates the 
potential difference in efficiencies between intramyocardial and intracoronary 
vector injections (Liu et al., 2006).  
Injection into skeletal muscle resulted in successful cDNA detection and X-Gal 
staining in our experiments. Consistent with our results, Xiao and colleagues 
published long-term rAAV2-mediated gene expression in mouse skeletal muscle 
(Xiao, Li, and Samulski, 1996). 
In summary, reports on successful transgene expression emphasize vascular 
permeability and a prolonged exposition time of the vector as critical factors. 
Furthermore, cardiomyocytes seem to be the more suited target cells in contrast to 
our setting where we aimed to transduce endothelial cells which are the first target 
in graft rejection by intracoronary vector injection. Taking into account previous 
publications and our here reported results, the inefficient in vivo transgene 
expression is most likely due to endothelial cell-based intracellular restrictions (see 
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below) impairing efficient rAAV2-mediated transgene expression. In further 
experiments, the use of histamine or other vasoactive substances are 
recommended in order to transduce also cardiomyocytes. Ideally, vectors should 
be injected into the normothermic heart to improve cell entry as suggested from 
our results. 
5.1.2 In vitro studies of RAECs 
5.1.2.1 Superiority of rAAV1 in rat cardiac endothelial and cardiomyocyte 
transduction 
Since our in vivo application of AAV2-based vectors did not result in transgene 
expression, we aimed to identify a more suited AAV serotype for transduction of 
cardiac endothelium using primary rat aortic endothelial cells (RAECs) as in vitro 
model. However, all analyzed serotypes were inefficient. Nevertheless, rAAV1 
seems to be superior in comparison to rAAV2 to 5. Our results are in line with 
observations reported by Chen and colleagues comparing the same serotypes at 7 
d p.i. (Chen et al., 2005). In our hands, rAAV2 was the second efficient vector in 
contrast to Chen and colleagues who described a stronger effect for rAAV5 which 
even surpassed the efficiency of rAAV1 at 14 d p.i.. Thus, our results are 
consistent with these observations, although describing transduction efficiencies at 
an earlier time point.  
In order to estimate the efficiency of rAAV-mediated gene transfer into rat 
myocardium – the alternative target cell population in heart tissue – we compared 
transduction efficiencies for rAAV1 to 5 on primary neonatal cardiomyocytes. Best 
transgene expression levels were obtained by serotype 1 followed by rAAV4. 
Comparative in vitro analyses of neonatal cardiomyocyte transduction have not 
been published so far. Only rAAV2-mediated transductions have been reported in 
several publications (Kaspar et al., 2005; Maeda et al., 2000; Svensson et al., 
1999). Kaspar and colleagues for instance, transduced primary cells with 104 
DNase-resistant particles/cell which likely correspond to “our” 104 genomic 
particles/cell approach (Kaspar et al., 2005). In contrast to our observations (4.1 % 
after 3 d) they were able to reach transgene expression in 60 % of the cells 2 d 
p.i.. Also Maeda and colleagues reported similarly high transduction efficiencies 
(Maeda et al., 2000). The discrepancy to our results (4.1 % with rAAV2ssGFP at a 
GOI of 104) is not clear and due to variations in the experimental details not easily 
explainable. 
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The relevance of our in vitro studies in cardiomyocytes can be estimated from 
recent reports (Palomeque et al., 2007; Su et al., 2006). Intramyocardial injection 
of rAAV1 in rat resulted in higher transgene expression than rAAV2 corresponding 
to transduction efficiencies in primary cardiomyocytes (Palomeque et al., 2007). 
Also in a mouse model of myocardial injection rAAV1 was revealed as superior 
serotype in comparison to rAAV2 to 5 (Su et al., 2006). However, these 
efficiencies can be exceeded by other serotypes like rAAV6 or the recently 
identified rAAV8 (Palomeque et al., 2007). Of note, recent publications point 
towards a possibility to target the heart in vivo as rAAV9 seems to possess at least 
a preferential tropism for heart tissue (Inagaki et al., 2006; Pacak et al., 2006). 
These experiments have been performed in mice and nonhuman primates and 
showed superior effects for rAAV9 than for rAAV8 which was described before as 
the serotype of choice in mice (Wang et al., 2005).  
In conclusion, the application of rAAV1 compared to rAAV2 showed higher 
transduction efficiencies in endothelial cells in our as well as in published 
experiments. Also in vivo the superior effect of rAAV1 compared to rAAV2 after 
intramyocardial injection has been reported. Therefore, we recommend the use of 
alternative serotypes, e.g. rAAV1 or – based on the most recent reports – rAAV9 
instead of rAAV2. 
5.1.2.2 Barriers in endothelial cells impair rAAV-mediated transgene 
expression 
Obtained levels for rAAV-mediated transgene expression in endothelial cells are 
low in vivo and in vitro (Nicklin et al., 2001a; Pajusola et al., 2002). Therefore, we 
intended to investigate this problem in detail using rAAV2-mediated transduction of 
rat aortic endothelial cells (RAECs) as model system. Until establishment of a 
successful transduction, vectors have to overcome multiple barriers such as cell 
membrane, endosomal compartment, cellular protein degradation machinery and 
nuclear membrane. Of these numerous steps, we investigated the question of 
entry and perinuclear accumulation. Moreover, the effects of a proteasome 
inhibitor and second-strand synthesis were studied. 
Laser scanning microscope studies in transduced RAECs revealed AAV-specific 
perinuclear accumulation of incoming particles (4.1.1.2.1). This results points to 
occurrence of vector entry and intracellular trafficking towards the nucleus in 
RAECs. Also Sipo and colleagues reported vector entry into human microvascular 
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endothelial cells albeit they observed that 50 % of the vectors stayed on the cell 
surface as they could be removed by trypsinization (Sipo et al., 2007). It can be 
assumed that the vectors are sequestered at the cell surface since endothelial 
cells express high levels of extracellular matrix including HSPG, which serves as 
primary receptor for AAV2 (Pajusola et al., 2002). Although we cannot comment 
on the efficiency of entry and perinuclear accumulation processes we conclude 
that vector entry is maybe to some extent, but not primarily, the reason for the low 
transduction efficiency in RAECs. Other steps like endosomal processing or 
nuclear translocation of vector genomes might contribute as well. 
We observed a significant enhancement (7.3-fold for rAAV2ssGFP; P<0.002; 4.4-
fold for rAAV2scGFP; P<0.02) in transgene-expressing RAECs transduced with a 
GOI of 5 x 104 in presence of 40 µM of the proteasome inhibitor MG132 3 d p.i. 
(4.1.1.2.1). In line with this result, we could also demonstrate an enhancement in 
transduction efficiency in the colon carcinoma cell line HT29 after application of 
the tripeptidyl aldehyde proteasome inhibitor MG132 which reversibly blocks the 
catalytic centre of the 26 S proteasome (Hacker et al., 2005; Oka et al., 2004). 
Interestingly, MG132 was published to enhance transduction efficiency 
significantly in human endothelial cells at 104 transducing particles/cell of 
rAAV2ssGFP (Nicklin et al., 2001a). In contrast to our results in RAECs, Pajusola 
and colleagues reported only a minor increase of GFP-expressing cells in human 
umbilical vascular endothelial cells (HUVEC; 1.3-fold) and human saphenous vein 
endothelial cells (SVEC; 3.2-fold) in vitro and in rabbit carotid artery assay in vivo 
(Pajusola et al., 2002). The mechansim by which proteasome inhibitors enhance 
rAAV-mediated transduction remains to be elucidated. Thus, proteasome inhibitors 
seem not to act simply by preventing the degradation of internalized virions or 
vector DNA (Douar et al., 2001; Duan et al., 2000; Yan et al., 2002). Interestingly, 
treatment with proteasome inhibitors increased the amount of ubiquitin detected 
on rAAV2 and rAAV5 capsids allowing to hypothesize that ubiquitin might serve as 
signal for uncoating or it possibly assists nuclear translocation of rAAV or vector 
genomes (Yan et al., 2002). Indeed, it is known that ubiquitin also gains 
proteasome-independent functions in regulation of cellular processes such as cell 
division, differentiation, signal transduction and protein trafficking (Mukhopadhyay 
and Riezman, 2007). 
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Once the vector genomes are located in the nucleus, natural single-stranded 
vector genomes first have to undergo second-strand synthesis. This step has been 
determined as rate-limiting process for efficient transduction by rAAV in certain cell 
types (Ferrari et al., 1996; Fisher et al., 1996). However, use of rAAV2scGFP only 
marginally enhanced the transduction efficiency in RAECs (1.8-fold increase 
compared to rAAV2ssGFP). Thus, we assume that this conversion is maybe not 
as efficiently performed as in certain cell types like HeLa, but has not to be 
considered as the main reason for impaired transgene expression as it was 
observed in the case of CD34+ cells (see chapter 4.2.1).  
An enhancement of the amount of transgene-expressing cells by using self-
complementary vector genomes and addition of MG132 demonstrated that RAECs 
are in principle able to induce transgene expression. Thus, it can be assumed that 
the CMV promoter as reason for impaired transduction efficiency can be excluded 
at least in short term assays in vitro. Other groups also support this assumption as 
strong activities in human endothelial cells could be observed (Pajusola et al., 
2002). However, CMV promoter silencing processes in vivo cannot be excluded. 
Therefore, the choice of endothelial cell-specific promoters, e.g. the FLT-1 
promoter which also would guarantee selective expression, would be a reasonable 
variation in our future experiments (Nicklin et al., 2001b). Nonetheless, in our in 
vitro model, we rather tend to exclude a contributory effect of the CMV promoter 
on the low level of transgene expression. 
In summary, the intracellular detection of vector particles and the significantly 
enhanced transgene expression achieved by co-application of MG132 reveal that 
rAAV vectors are able to enter rat endothelial cells. Furthermore, intracellular 
transport of viral vectors towards the nucleus is not impaired albeit we cannot 
comment on its efficiency. Conversion of single-stranded vector genomes into a 
transcriptionally active vector genome conformation occurs maybe less efficiently 
than in other cells, but is also not the main limiting step. By the addition of 
proteasome inhibitors, however, a yet unknown limiting step could be overcome. 
Since no details about the mechanism by which proteasome inhibitors enhance 
AAV transduction are clear, it is currently impossible to speculate which 
intracellular events/steps are hampered. As outlined above, use of alternative 
serotypes or of targeting vectors seems to be currently the best way to cope with 
the observed limitation.   
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5.1.3 Porcine endothelial cells are highly permissive for AAV 
As preparation for our in vivo gene transfer into porcine hearts, primary porcine 
aortic endothelial cells (PAECs) were used as in vitro model to estimate the 
efficiency of rAAV-mediated gene transfer into endothelial cells of this species in 
order to determine the best suited serotype among rAAV1 to rAAV5. This study, 
which is indeed the first report on a comparative analysis of different serotypes on 
PAECs revealed that AAV vectors are suitable for transduction of this cell type. 
Actually, results obtained with PAECs exceeded the efficiencies for rodent and 
human endothelial cells (Nicklin et al., 2001a; Pajusola et al., 2002). Serotype 2 
was superior in transduction efficiency in comparison with rAAV1 and rAAV3 to 
rAAV5 and yielded about 90 % transgene-expressing cells using rAAV2 encoding 
GFP in the single-stranded as well as in the self-complementary vector genome 
conformation at a GOI of 105 (4.1.2.1.1). As expected, at lower vector-to-cell ratios 
rAAV2 containing the self-complementary vector genomes achieved higher 
transduction efficiencies. Concerning the other serotypes, rAAV5 was revealed as 
the second and rAAV1 as third efficient serotype for PAEC transduction. According 
to rAAV2, higher transduction efficiencies were measured for vectors containing 
the self-complementary vector genome conformation. 
Our results reveal rAAV2 as the ideal serotype among rAAV1 to rAAV5 for porcine 
endothelial transduction. These high transduction efficiencies in PAECs are 
astonishing as endothelial cell transduction has commonly been reported to be low 
(Pajusola et al., 2002).  
Further analyses of transduction by confocal laser scanning microscopy revealed 
large aggregates of intact capsids in PAECs in contrast to RAECs transduced at 
equal GOIs. This observation suggests a more efficient entry of rAAV2 into PAECs 
than into RAECs. In both cell types intact capsids were detected exclusively within 
the cytoplasm indicating occurrence of vector uncoating before or during nuclear 
entry in line with Lux and colleagues (Lux et al., 2005). 
5.1.4 AAV vector mediated transgene expression in porcine hearts 
Although gene transfer into the heart has been assessed in rodents, large animal 
models are indispensable for preclinical evaluation. Only a limited number of 
reports on rAAV-mediated gene transfer in porcine heart has been published so 
far (Kaplitt et al., 1996; Kaspar et al., 2005; Raake et al., 2008). Here, we 
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determined the efficiencies of heart transduction by intracoronarily injected rAAV2 
vectors, which had turned out to be the most efficient serotype on PAECs. To 
increase vascular permeability, histamine was applied simultaneously. The two 
transplanted animals received different amounts of particles. Moreover, the 
vectors differed in the encoded transgene and in the vector genome conformation 
(2 x 1012 rAAV2ssLacZ and 2.3 x 1013 rAAV2scLuci) (4.1.2.2). Although this 
precludes a direct comparison, we decided to change the transgene since 
packaging efficiency and thereby the amount of applicable vector amount could be 
greatly enhanced by the use of luciferase instead of β-galactosidase. In both 
experiments, vector genomes were detected in all cardiac sections 21 d after 
transplantation as determined by qPCR. However, transgene expression could 
only be detected in the second animal that received a higher vector dose and a 
vector encoding luciferase in a self-complementary genome conformation. 
Based on our own results and on published reports it is likely that a substantial 
contribution to the successful rAAV-mediated transgene expression is attributable 
to the self-complementary vector genome conformation used in this approach 
(Andino et al., 2007; McCarty et al., 2003). Moreover, the applied vector amount 
was ten times higher in the second animal. The assumption that vector amounts 
are crucial even in local applications like intracoronary vector injections is 
supported by results described by Kaspar and colleagues (Kaspar et al., 2005). 
They reported a successful gene expression in 3 of 4 pigs when a ten times higher 
vector amount was applied than we used in our first animal. Furthermore, 
considerably higher transduction efficiency was detected using 5.28 x 1013 vectors 
which correspond to about the same vector amount per kilogram body weight that 
we used. 
Since both transgenes were controlled by the same promoter (CMV) this option 
can be excluded. However, low expression of β-Gal might have remained 
undetected due to the less sensitive quantification methods (X-Gal staining of 
tissue sections followed by microscopical analyses) while even tiny amounts of 
luciferase activity were measureable. Nevertheless, as already stated a direct 
comparison of both approaches is not possible and further experiments have to be 
performed to elucidate which of the discussed points solely or in combination are 
responsible for the successful gene transfer that was achieved in the second pig. 
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5.1.5 Distribution of transgene DNA and product in the two animals 
In contrast to previous studies we performed the cardiac gene transfer in a heart 
transplantation setting as large animal model for xenotransplantation. Thereby, the 
vector-modified heart was transplanted into the abdomen of the recipient pig 
resulting in altered blood flow namely through the coronaries into the right atrium 
and ventricle and through the pulmonary arteries into the donor circulation 
excluding the left ventricle from the blood flow. To evaluate transduction 
efficiencies we dissected the heart into 4 levels and numerous samples of the left 
and right ventricle as well as of the septum region as depicted in Figure 26.  
Comparing vector distribution in the left ventricle, both animals showed 
tendentially higher levels in the inner wall than in the outer part (4.1.2.2.1, 
4.1.2.2.2). Moreover, highest values were obtained in the apex cordi (level IV) of 
both pigs. The region of highest mean copy numbers was the septum whereby the 
two ventral samples in level I and II (25, 26, 28, 29) revealed higher transgene 
DNA amounts than the third sample (27, 30). The only difference between both 
animals in the left ventricle was observed in level IV where the ranking of vector 
amount in the samples was inverted. Concerning level III, the DNA distribution was 
again similar, whereas lowest DNA amount was detected in the middle sample. 
Furthermore, the two animals showed no correlation regarding vector genome 
distribution in the heart tissue. While in the rAAV2ssLacZ injected pig in all regions 
of level I and II the copy number decreased from the ventral to the dorsal part, this 
was only the case in level III of the rAAV2scLuci transduced animal. 
Yet unexplained is the fact that regions of highest amounts in transgene DNA did 
not correspond to areas located at the assumptive course of the left anterior 
coronary which should be represented by the regions 27, 30, 37, 39, 40, 42, 43 
and 44 as well as smaller branches supplying the regions 7, 9, 11, 12 and 34. 
However, an individual variation in course of the vessels may serve as an 
explantation (the course of vessels in our two animals has not been recorded by 
our cooperation partners).  
We were interested to which extent transgene DNA levels correspond to the 
transgene expression level. Due to the lack of expression in the first animal, this 
question could only be addressed to the second animal that had received 
rAAV2scLuci. Luciferase levels varied from 1.4-fold (sample 41) to 215-fold 
Discussion 
 
106 
 
(sample 15) when normalized to a non-treated porcine sample. With some 
exceptions the variation in vector DNA amount did not mirror the luciferase levels 
of the respective samples. Solely for all levels of the inner wall of the left ventricle, 
levels I to III in the septum region and level I of the right ventricle, the highest DNA 
sample correlated with the corresponding highest luciferase activity. Since similar 
studies have not been performed yet, we cannot compare our results with 
published reports.  
In contrast to the published observations in non-transplanted animals, thus in 
hearts with a nature course of blood circulation, we detected transgene expression 
in the entire heart not only in the region of the left anterior coronary (Kaplitt et al., 
1996; Kaspar et al., 2005; Raake et al., 2008). In relevant publications only the 
territory of the left anterior descending (LAD) coronary was analyzed (Kaspar et 
al., 2005; Raake et al., 2008). Kaplitt and colleagues also analyzed other regions 
of the heart, but observed transgene expression exclusively within the LAD 
territory (Kaplitt et al., 1996). Also the vector application methods differed from our 
approach of indirect (into the aorta) antegrade (with natural blood flow) 
intracoronary vector application while connected to a newly developed in situ 
Langendorff reperfusion system for prolonged exposure of the vector to the heart. 
Closest to our setting were experiments by Kaspar and colleagues who applied 
heparin affinity purified rAAV2 vectors encoding for CMV promoter-controlled GFP 
at comparable vector amounts (2.6 - 5.3 x 1013 DNase resistant particles 
rAAV2ssGFP) (Kaspar et al., 2005). However, we have to take into account that 
their pigs were double in weight compared to our animals. Also in their approach, 
histamine was administered to increase vascular permeability followed by 
catheter-based vector injection directly into the left circumflex coronary. In contrast 
to our experiments, pigs were analyzed after 8 weeks and the central core of the 
perfusion bed showed gene-expression in 12 % of the cells. Since we detected 
luciferase activity by luminometer a direct comparison between the 12 % GFP-
expressing cells and our relative light units (RLU) is impossible. However, the high 
luciferase activity detected in some of our samples may point to a higher level of 
gene transfer efficiency.  
Recently, Raake and colleagues published a comparative analysis for transgene 
expression using rAAV6 and a heparin binding mutant of rAAV2 after pressure-
regulated retrograde (into the anterior cardiac vein) intracoronary vector injection 
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(Raake et al., 2008). Serotype 6 was determined as superior to the rAAV2 mutant, 
but it was not compared to rAAV2. Moreover, another recent publication revealed 
rAAV1 as more efficient than rAAV2 at least in intramyocardial injection into the 
porcine heart (Su et al., 2008). 
Regarding extracardiac organs, no transgene DNA or expression was detected in 
any of the pigs. Therefore, we conclude that the major part of the vector entered 
cardiac cells efficiently without measureable systemic distribution. Especially the 
novelty of the in situ Langendorff reperfusion system for recirculation of 
oxygenated blood at normothemic conditions after vector injection over a longer 
time might have enhanced the transduction of cardiac cells and therefore limited 
gene transfer into extra-cardiac organs. This is in line with Kaspar and colleagues 
who used a direct catheter-based vector delivery in presence of histamine and 
analyzed the organs 8 weeks p.i. and observed no signs of transgene expression 
in non-cardiac pig organs (Kaspar et al., 2005). However, a biodistribution analysis 
for transgene DNA was not performed (Kaspar et al., 2005).  
Altogether, transgene DNA distribution coincides only partially between the two 
pigs. Also the amount of transgene DNA did not correlate with the level of 
transgene expression. Moreover, the transgene-containing regions were not 
consistent with the course of the left anterior coronary as reported by other groups. 
Instead, we detected transgene expression in the entire heart albeit at different 
levels. 
5.1.6 Potential of rAAV2 for animal cloning 
As already described in 4.3.2, porcine fibroblasts are used by our cooperation 
partners of the Institute of Farm Animal Genetics (Mariensee) for somatic cell 
nuclear transfer. We evaluated the feasibility of rAAV vectors for mediating gene 
transfer into these cells. The high efficiency of rAAV2 transduction qualifies this 
vector for further analyses. In order to achieve site-specific integration, the 
transfection of a Rep-coding plasmid or addition of Rep protein could be an option. 
So far, transgenes have been transfected into fibroblasts and analyzed for 
integration events. Interestingly, porcine fibroblasts and the highly permissive 
human tumor cell line HeLa showed the same transduction profile concerning the 
serotypes rAAV1 to rAAV5. 
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Insertion of transgene into the oocyte is another approach, which was used here 
for the generation of genetically manipulated cattle. Our partners observed that 
addition of rAAV2 to the medium is sufficient for transduction. Thus, the vector is 
able to overcome the zona pellucida of the oocyte. Moreover, they injected a 
plasmid coding for Rep into the oocyte. Intense GFP expression of the blastocysts 
has been observed. Although transfer of the embryos into cows and maintenance 
of pregnancies are difficult and expensive, one calf treated with rAAVscGFP was 
born. Unfortunately, it did not show any transgene DNA which might be due to lack 
of vector integration. 
Although not completed, these preliminary experiments suggest rAAV2 as 
potential vector for production of transgenic animals. 
5.2 Investigations on CD34+ cells 
5.2.1 Most efficient serotype rAAV2 is limited by second-strand 
synthesis 
CD34+ cells gained increasing attention for the treatment of hematopoietic 
diseases as well as for induction of neovascularization in ischemic regions or sites 
of endothelial injury. Beneficial effects of combined cell and gene therapeutical 
approaches are now being evaluated (Melo et al., 2004). So far, only the serotype 
2 coding for single-stranded (ss) vector genomes has been studied in human 
CD34+ cell transduction, but with controversial results. Comparative analyses of 
several serotypes as well as the influence of second-strand synthesis using self-
complementary (sc) vectors have exclusively been performed in murine CD34+ 
cells (Zhong et al., 2006). Therefore, we assessed the most efficient serotype 
among rAAV2, rAAV3 and rAAV5 (4.2.1). AAV2 was clearly revealed as the most 
suitable serotype. While single-stranded genomes containing vectors only resulted 
in a minor transduction efficiency for rAAV2 (8 %), rAAV3 and rAAV5 did not show 
any transgene expression 3 d after transduction with a GOI of 105. The use of 
scGFP vectors could enhance GFP-expression for those serotypes only slightly 
(4.8 % for rAAV3 and 7.4 % for rAAV5). In contrast, almost 60 % transduction 
efficiency was obtained by rAAV2scGFP. This immense difference in the amount 
of transgene-expressing cells after administration of either scGFP or ssGFP vector 
genomes can be explained by limitations in second-strand synthesis as previously 
described for other cell types (Hacker et al., 2005; McCarty, Monahan, and 
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Samulski, 2001). The only comparative analysis of both vector conformations in 
transduction of hematopoietic progenitor cells – even though of murine origin – 
also approved this step as limitation of transduction pathway (Zhong et al., 2006). 
In transduction of murine hematopoietic progenitor cells rAAV1 has been 
described as most efficient serotype.  
In order to determine if the differential expression levels of the serotypes 2, 3 and 
5 are based on unequal entry, we determined the amount of vector genomes in 
the total DNA of CD34+ cells 3 h p.i. with ssGFP and scGFP vectors at a GOI of 
104 (4.2.1). Serotype 2 clearly entered the cell most efficiently, followed by rAAV3 
and then rAAV5. Thus, a less efficient entry is at least one reason for the lower 
level of transgene expression obtained by rAAV3 and 5. Moreover, similar 
transgene levels of scGFP and ssGFP vectors of the respective serotype 
confirmed that the difference in their transgene expression is only accounted by 
the different vector conformations. 
The high transgene expression level observed 3 d p.i. with rAAV2scGFP declined 
by 4.4-fold within one further week of cultivation. This is in line with observations of 
transient gene expression over a period of 10 to 14 d p.i. as reported by Nathwani 
and colleagues (Nathwani et al., 2000). One explanation could be a 
downregulation of promoter activity as previously described for CMV promoter in 
hematopoietic and mesenchymal progenitor cells in comparative promoter 
analyses (Byun et al., 2005). For that reason, use of vectors containing promoters 
distinct from CMV promoter should be considered. Moreover, loss of non-
integrated vector genomes during cell divisions might also contribute to the 
decreasing amount of GFP-expressing cells. 
As discussed in the introduction, publications on rAAV2-mediated transduction of 
CD34+ cells present conflicting results. Early experiments have been performed 
with low purified crude vector lysates which have been generated by use of 
adenovirus as helper virus (Fisher-Adams et al., 1996; Goodman et al., 1994; 
Hargrove et al., 1997; Zhou et al., 1994). Thus, helper virus contaminations could 
have assisted second-strand synthesis thereby enabling transgene expression 
(Alexander, Russell, and Miller, 1997). As we produced our vectors in a helper-
free method with subsequent iodixanol gradient centrifugation as described in 
3.1.4 we could exclude this effect. Besides vector production, also titration, 
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isolation and cultivation of CD34+ cells varied in the different reports. Our 
conditions were most comparable to experimental settings as described by 
Nathwani and colleagues (Nathwani et al., 2000). They reported an efficient gene 
transfer into human cord blood-derived CD34+ and CD34+CD38- cells using highly 
purified helper virus-free rAAV2 preparations. Isolation of the cells was performed 
corresponding to our protocol and also the choice of cytokines (albeit not the 
concentrations and medium) for cultivation and the use of pre-expanded (2 d) cells 
for transduction was equal to our approach. In contrast, they used a multiplicity of 
infection of 106 which corresponds to a GOI of approximately 107 representing 
about 100 times higher vector amounts of rAAV2ssGFP than in our experimental 
setting. Nonetheless, they only observed low transduction efficiencies of 10 to 23 
% after vector incubation over night and further cultivation for 24 to 48 h using high 
or low dose cytokine concentrations. Our results showed 8 % GFP-positive cells 3 
d p.i. with rAAV2ssGFP at a GOI of 105. Cells were only incubated with vector for 
3 h and the used cytokine concentrations lied in between the reported ones. This 
emphasizes a more efficient transduction in our hands. Even though they showed 
that transduction efficiencies could be enhanced from 10 to 51 % by using higher 
cytokine concentrations and addition of TNFα (MOI of 106) this value did not reach 
efficiencies obtained for rAAV2scGFP transduction (57 %) at lower GOI in our 
experiments. Moreover, we could demonstrate a significant enhancement in 
transgene-expressing cells (85.6 %) by coadministration of rAAV2scGFP, 
Trichostatin A and retinoic acid as described in 4.2.5 and discussed more detailed 
in 5.2.4 which was not reported before. In conclusion, we reported highly efficient 
transduction of cord blood-derived CD34+ cells.  
5.2.2 Transduction procedure does not interfere with endothelial 
differentiation 
The ability to differentiate into endothelial cells is a prerequisite for successful 
neovascularization and engraftment of CD34+ cells. In order to investigate if this 
ability is affected by AAV transduction, we evaluated the differentiation potential of 
transduced and non-transduced CD34+ cells 3 d p.i.. After 10 d of cultivation in 
differentiation medium on fibronectin-coated plates, the cells showed a spindle-
shaped morphology and took up Dil-AcLDL efficiently independent of the vector 
application. This experiment verified that our CD34+ cells could differentiate into 
endothelial cells. However, it was – most likely due to promoter silencing events – 
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not possible to visualize GFP expression to correlate definitely differentiated and 
transduced cells. Therefore, we analyzed the DNA from differentiated cells for 
presence of transgene DNA by qPCR. Equal amounts of GFP DNA in samples of 
cells transduced with rAAV2ssGFP and rAAV2scGFP vectors (about 6 x 105 
copies after normalization to GAPDH) confirmed the presence of vector DNA 
within cells after 10 d of differentiation assay. As can be seen in the microscope 
images, nearly all cells showed Dil-AcLDL uptake. Thus, it seems likely that also 
transduced cells maintained their ability for differentiation. 
5.2.3 Receptor and coreceptor studies 
Heparan sulfate proteoglycan (HSPG) has been described as primary receptor for 
rAAV2 transduction (Summerford and Samulski, 1998). However, Handa and 
colleagues reported that certain cell types like mutants of the CHO-K1 cell line 
deficient for glycosaminoglycan can be transduced by AAV2 (Handa et al., 2000). 
Therefore, we were interested to evaluate if HSPG is involved in rAAV2-mediated 
CD34+ cell transduction by competitive inhibition with the soluble analogue of 
HSPG, heparin (4.2.3). Studies on hematopoietic progenitor cell lines suggested 
the presence of HSPG on the cell surface (Drzeniek et al., 1999; Stocker et al., 
1996). Whereas rAAV2scGFP-transduced cells showed again almost 60 % 
transduction efficiency, presence of heparin reduced the number of GFP-
expressing cells to background level. This confirms the involvement of HSPG in 
CD34+ cell transduction and thereby also the presence of that receptor on the cell. 
The abundance of receptors and coreceptors on the cell is a factor which 
determines susceptibility of the respective cell type to rAAV transduction. 
Ponnazhagan and colleagues observed large differences in transgene expression 
of rAAV2-transduced bone marrow-derived human CD34+ cells of 12 donors 
(Ponnazhagan et al., 1997). Half of the donor cells were refractory to rAAV2 
transduction at a MOI of 100, while the others showed efficiencies ranging from 15 
to 80 %. This difference was attributed to the differential susceptibility of the cells 
as assessed by virus-binding assays with radiolabeled virus. In contrast, we 
observed transduceability of CD34+ cells of all donors whereas much lower 
variations in transgene expression were detected (lowest 24.1 % and highest 69.4 
% values; SEM 5.2 %; n=8) as depicted in Figure 30. Absence of a significant 
variation in transduction efficiency in individual cell samples was also reported by 
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Nathwani and colleagues (Nathwani et al., 2000). Since Ponnazhagan’s 
publication, HSPG was described as primary receptor for rAAV2 as well as 5 more 
coreceptors. FGFR, HGFR and eventually laminin receptor were proposed to 
enhance AAV2 binding to the cell (Akache et al., 2006; Kashiwakura et al., 2005; 
Qing et al., 1999). Subsequently, AAV2 interacts with αvβ5 integrin thus inducing 
endocytosis and probably cytoskeletal rearrangements necessary for efficient 
trafficking (Sanlioglu et al., 2000). Recently, α5β1 integrin has been identified as an 
alternative AAV coreceptor (Asokan et al., 2006). In order to investigate which of 
the integrins most likely assists vector entry, we evaluated the abundance of the 
two integrin coreceptors on CD34+ cells in relation to the transduction efficiency. 
Therefore, we measured the level of integrins at the day of transduction (after 2 to 
4 d of pre-expansion) by FACS analysis and determined GFP-fluorescence of 
transduced cells 3 d p.i. (4.2.4). These experiments were performed with bone 
marrow-derived and freshly isolated or bought (pooled from different donors) cord 
blood-derived CD34+ cells. The amount of αvβ5 integrin varied largely from 0.5 % 
to 59.5 % whereas the level of α5β1 integrin was generally higher (78.8 – 96.2 %) 
and more evenly distributed. Analyses of transduction efficiencies 3 d later 
revealed a minimum of 52 % GFP-expressing cells. Comparing the amount of the 
two integrins with the transgene expression point to a correlation of α5β1 integrin 
and transgene expression. Especially, the examples of extremely low αvβ5 integrin 
levels of 0.5 and 2.5 % together with high α5β1 integrin amounts and more than 55 
% GFP expression emphasizes this assumption. These observations would 
support α5β1 integrin as coreceptor.  
To further confirm the role of this integrin for transduction, we compared 
transduction efficiencies of rAAV2 and a mutant, NGR R513A, deficient for α5β1 
integrin binding (Asokan et al., 2006). As the amount of αvβ5 integrin displayed on 
the cells was below 1 % and above 90 % for α5β1 integrin at the time of 
transduction, the obtained result could be correlated solely with the activity of α5β1 
integrin. The NGR R513A mutant was 5.6 times less efficient than rAAV2 which 
allows the conclusion that α5β1 integrin serves as coreceptor in CD34+ cell 
transduction. For CD34+ cells, a physiological role of α5β1 integrins has been 
assigned as attachment receptor to fibronectin which is part of the extracellular 
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matrix of the bone marrow stroma (Dao et al., 1998; Hurley, McCarthy, and 
Verfaillie, 1995). 
Interestingly, surface expression of at least α5β1 integrins seemed to be induced 
by culturing in cytokine-containing medium as both αvβ5 and α5β1 integrins were 
nearly undetectable on freshly thawed cells as determined in 2 independent 
experiments. After 3 d of pre-expansion in medium supplemented with SCF, IL-3, 
IL-6 and Flt3L, less than 2 % of the cells displayed αvβ5 integrins while on more 
than 77 % α5β1 integrins were detectable. This is in line with Hart and colleagues 
who reported an upregulation of α5β1 integrins upon cultivation in SCF-containing 
medium (Hart et al., 2004). The absence of α5β1 integrins on freshly isolated 
CD34+ cells might explain the untransduceability by rAAV2 vectors as previously 
reported (Nathwani et al., 2000). Therefore, pre-expansion of CD34+ prior to 
transduction might be favourable not only in terms of the growing cell number. 
5.2.4 Effects of the transcriptionally active drugs TSA and RA 
Although we already obtained a high transgene expression of about 60 % in 
CD34+ cells after transduction with rAAV2scGFP, we assessed the potential of 
further increasing this value by transcriptionally active drugs. Therefore, we 
followed the report of Gaetano and colleagues who observed an enhancement of 
transgene expression in adenovirus-transduced endothelial cells by the histone 
deacetylase inhibitor (HDACi) Trichostatin A (TSA) and retinoic acid (RA) 
(Gaetano et al., 2000; Kitazono et al., 2002). FACS analyses 3 d p.i. revealed an 
increase in transgene-expressing cells by the use of TSA and RA. The use of TSA 
alone only showed a minor increase from 61.4 % to 69.5 % GFP-positive cells. In 
contrast, RA induced a stronger enhancement up to 82.7 % transgene-expressing 
cells and 3.4-fold higher values in mean fluorescence intensity (MFI). However, 
the combination of both drugs resulted in highest transgene expression (85.6 %) 
and 5.9-fold increased in MFI. These results are in line with observations in 
adenoviral-mediated transgene expression by Gaetano and colleagues (Gaetano 
et al., 2000). Thus, we recommend the treatment of CD34+ cells with TSA and RA 
in gene transfer experiments with rAAV vectors containing a CMV-promoter for 
enhancement of transgene expression. 
The effect of these drugs is in part based on the influence on the strong viral CMV 
promoter containing numerous cis-regulatory elements mediating binding of 
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transcription factors such as retinoic acid receptors (RARs, RXRs) (Angulo et al., 
1996; Ghazal et al., 1992). Retinoic receptors bind to retinoic acid response 
elements (RARE) on promoters of RA-target genes and recruit protein complexes 
including HDACs (Chambon, 1996). The induced remodelling processes result in 
transcriptional repression. Binding of RA causes release of the HDAC activities 
and HATs are subsequently recruited to the RAREs leading to reactivation of 
transcription due to increased DNA accessibility to the transcriptional machinery. 
Thereby, the enhancement in transgene expression by rAAV containing a CMV-
promoter controlled transgene upon RA coadministration can be explained (Fazi et 
al., 2005).  
On the other hand, HDACi act in multiple ways (Dokmanovic and Marks, 2005). 
Most obviously, they inhibit the deacetylation of histones thus inducing enhanced 
accessibility of the DNA to transcriptional processes. As AAV DNA has been 
proposed to be complexed with histone-like structures, it is imaginable that HDACi 
might influence these structures as well (Marcus-Sekura and Carter, 1983). CMV 
promoter silencing has been shown to occur frequently in vitro and in vivo, thus 
impairing efficient transgene expression for longer periods (Xia et al., 2007). 
Interestingly, Chen and colleagues reported reactivation of silenced CMV promoter 
in rAAV- and retrovirus-transduced cells by use of TSA (Chen et al., 1997). 
Additionally, HDACs and HATs also regulate non-histone proteins which are 
involved in the control of cell-cycle progression, differentiation and apoptosis 
(Dokmanovic and Marks, 2005). Therefore, HDACi might be implicated in the 
regulation of these targets. Especially the participation of HDACi and RA in the 
control of RA-target genes might explain their synergistic effect in our experiments 
(Minucci et al., 1997). These drugs are also evaluated for tumor therapy whereas 
several groups reported enhanced effects of combined TSA and RA treatment in 
vitro and in vivo (De los Santos et al., 2007; Touma et al., 2005). 
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5.2.5 Outlook 
This work aimed to contribute to gene- and cell-based strategies for the treatment 
of heart diseases. Modification of heart tissue by rAAV gene transfer prior to 
transplantation was the focus of the first part of this thesis. The ultimate goal of 
this approach in our rat model was its use as screening platform for factors 
impairing transplant rejection. As outlined above, none of the investigated 
serotypes resulted in reasonable transduction efficiencies on RAECs although 
rAAV1 was more efficient than rAAV2. If rAAV1 is also more efficient in vivo as it 
has recently been published, remains to be determined (Palomeque et al., 2007; 
Su et al., 2006). Based on recent reports, rAAV9 could even be better suited 
(Inagaki et al., 2006; Pacak et al., 2006). An alternative to the change in serotype 
are targeting strategies. AAV peptide libraries containing rAAV capsid mutants that 
differ from each other only by 7mer peptides with random sequences displayed in 
cell surface-exposed regions have been developed (Perabo et al., 2003; Muller et 
al., 2003). These libraries are used to select for capsid mutants that enter the cell 
specifically via the inserted peptide and are processed efficiently with the 
respective target cells. Our group has already developed in close collaboration 
with A. Baker (University of Glasgow, UK) rAAV targeting vectors for human and 
mouse endothelial cells using the phage display technology (Nicklin et al., 2001). 
Furthermore, in two different approaches we could prove in vivo targeting ability 
and transgene expression as well (Work et al., 2006; White et al. 2004). Thus, the 
targeting technology holds promise to design vectors overcoming the intracellular 
barriers hampering rAAV-mediated gene expression in endothelial cells. 
Crucial for the in vivo transduction efficiency is maybe the use of self-
complementary vector genome conformation of rAAV vectors. This can be 
assumed from our results in pig studies, but remains to be demonstrated. Overall, 
the results on gene transfer into porcine heart were quite promising. However, the 
number of analyzed pigs is very low and additional transplantation experiments 
have to be performed before proceeding to the evaluation of therapeutically 
relevant genes, e.g. immunomodulatory genes for their ability to prolong graft 
survival. The requirement of large vector amounts, however, will remain the major 
hurdle in transduction of porcine heart. Therefore, the search for potentially more 
efficient serotypes or the selection for vector targeting is reasonable. 
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The second part focused on the rAAV-mediated transduction of CD34+ cells for 
which an efficient protocol was established. Vector safety is a principal concern for 
clinical applications. Especially the tumor development in two patients during a 
retrovirus-based clinical SCID trial caused by insertional tumorigenesis has 
revealed this risk (Hacein-Bey-Abina et al., 2003). Even though AAV2 is rarely 
integrating, it has to be determined if vector genomes possess an integrating 
ability in CD34+ cells (Kotin, Linden, and Berns, 1992). These ongoing 
experiments are performed by ligation-mediated PCR (LM-PCR) in close 
collaboration with B. Fehse (Johann Wolfgang Goethe-University Frankfurt) 
(Kustikova et al., 2007). Actually, especially if long-term expression is needed, it 
would be favorable to induce vector genome integration. The AAV system offers 
the possibility to direct vector integration to a specific region in the human 
genome, e.g. by addition of Rep protein or Rep-encoding sequences, an approach 
which is clearly in the focus of the future work in this project (Kotin et al., 1990). 
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6 Materials 
6.1 Chemicals and Solutions  
Product Company 
5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-Gal) 
Roth, Karlsruhe 
Agar-Agar Roth, Karlsruhe 
Agarose Invitrogen, Karlsruhe 
all trans-Retinoic Acid (RA) Sigma, Deisenhofen 
Aqua bidest. (Ampuwa) Fresenius Kabi, Homburg 
Biotin Conjugate Streptavidin Dianova, Hamburg 
Boric Acid Merck, Darmstadt 
Bovine Serum Albumine AppliChem, Darmstadt 
Bovine Serum Albumine (BSA) Standard Set BioRad, München 
Calcium Chloride Sigma, Deisenhofen 
Chloroform Merck, Darmstadt 
Dil-AcLDL CellSystems, St. Katharinen 
Dimethylsufoxide (DMSO) Riedel-de Haën, Seelze 
DPX Mountant for Histology Fluka, Neu-Ulm 
EDTA Roth, Karlsruhe 
Eosin G-Solution 0.5 % aqueous Merck, Darmstadt 
Ethanol Roth, Karlsruhe 
Ethidium Bromide Roth, Karlsruhe 
Fibronectin from Human Plasma Sigma, Deisenhofen 
Gelatine Sigma, Deisenhofen 
Glycerol Roth, Karlsruhe 
Heparin B. Braun Melsungen AG 
Heparin (used for CD34+ cells) Sigma, Deisenhofen 
HEPES Roth, Karlsruhe 
Hydrochloric acid Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Lipofectamin 2000 Invitrogen, Karlsruhe 
Lymphoprep (Ficoll) Sentinel, Milan, Italy 
Magnesium Chloride Roth, Karlsruhe 
Mangan Chloride Merck, Darmstadt 
MassRuler DNA Ladder Mix MBI Fermentas GmbH, St. 
Leon-Rot 
MG132 Sigma, Deisenhofen 
MOPS Sigma, Deisenhofen 
OptiMEM Invitrogen, Karlsruhe 
Optiprep Density Gradient Medium (Iodixanol) Sigma, Deisenhofen 
Paraformaldehyde Sigma, Deisenhofen 
PBS 10x Biochrom, Berlin 
Peptone/Tryptone Roth, Karlsruhe 
Potassium Acetate Merck, Darmstadt 
Potassium hexacyanoferrat II trihydrat  Fluka, Neu-Ulm 
Potassium hexacyanoferrat III  Sigma, Deisenhofen 
Quick Start Bradford Dye Reagent BioRad, München 
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Sodium Chloride Roth, Karlsruhe 
Sodium Hydroxide Roth, Karlsruhe 
Sodium Phosphate Roth, Karlsruhe 
Trichostatin A (TSA) Sigma, Deisenhofen 
Tris Merck, Darmstadt 
Triton X-100 Sigma, Deisenhofen 
Trizol Reagent  Invitrogen, Karlsruhe 
Vectashield Vector Laboratories, 
Burlingame 
X-Tra Solv Medite Histotechnic, Burgdorf 
Yeast Extract Roth, Karlsruhe 
6.2 Enzymes and Kits 
Product Company 
DNA restriction enzymes MBI Fermentas, St. Leon-Rot 
Benzonase Merck, Darmstadt 
Direct CD34 Progenitor Cell Isolation Kit Miltenyi Biotec, Bergisch-
Gladbach 
Renilla Luciferase Assay System Promega, 
DNeasy Blood & Tissue Kit  Qiagen, Hilden 
EndoFree Plasmid Kits Qiagen, Hilden 
PCR Purification Kit Qiagen, Hilden 
Gel Extraction Kit Qiagen, Hilden 
Quantitect SYBR Green PCR Kit Qiagen, Hilden 
RNase A (100 mg) Roche, Mannheim 
Transcriptor First Strand cDNA Synthesis Kit Roche, Mannheim 
DNase I Roche, Mannheim 
LightCycler Uracil-DNA Glycosylase (UNG) Roche, Mannheim 
 
6.3 Plasmids 
pXX6:  
Adenoviral helper plasmid encoding for VA, E2A and E4 and ampicillin resistance; 
pXX6 was kindly provided by J. Samulski (University of North Carolina, Chapel 
Hill, USA). 
pXR1, pXR2, pXR3, pXR4 and pXR5: 
The plasmids encoded for the capsids of the respective serotypes and the Rep 
proteins of AAV2 (Rabinowitz et al., 2002). For the serotypes 3 to 5 a portion of 
the serotype-specific Rep gene was substituted for that of AAV2. The Rep proteins 
are able to package transgenes flanked by the ITRs of AAV2 into the capsids. 
These plasmids were kindly provided by J. Samulski (University of North Carolina, 
Chapel Hill, USA). 
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pGFP single-stranded:  
The GFP plasmid consists of AAV ITR sequences flanking the hygromycin 
selectable marker gene controlled by the thymidine kinase promoter and the 
Aequorea victoria enhanced Green Fluorescent Protein (GFP) gene regulated by 
the Cytomegalovirus (CMV) promoter (Hacker et al., 2001). 
pGFP self-complementary:  
The enhanced GFP gene is controlled by the human CMV promoter. A deletion in 
one of the terminal resolution sites interferes with strand displacement resulting in 
a self-complementary genome, which is packaged into the viral capsid (Hacker et 
al., 2005). 
pLuci: 
The transgene cassette encoding for the CMV promoter controlled Luciferase 
gene is flanked by one intact ITR and one containing a mutated terminal resolution 
site. As in the pGFP self-complementary plasmid also this plasmid is packaged as 
pseudo double-stranded genome. The plasmid was constructed and kindly 
provided by my colleague Sibille Quadt-Humme. 
pZNL: 
This plasmid carries a CMV and an EM-7 promoter followed by a Zeocin-
resistance gene. After a fusion sequence the LacZ gene containing a nuclear 
localization sequence (NLS) and SV40pA follows. The transgene cassette is 
flanked by ITRs (Girod et al., 1999). 
pMV10-FLT-1: 
This construct contains a FLT-1 promoter, a LacZ gene and a CMVpA. The 
plasmid was kindly provided by A. Baker (University of Glasgow, Glasgow, UK). 
pNGR R513A: 
The plasmid based on pRC99 encoding for the Rep and Cap proteins of AAV2, 
contains a mutation within the cap sequence leading to a substitution at the amino 
acid position 513 (R→A). The construct was generated according to Asokan and 
colleagues and kindly provided by my colleague Anke Huber (Asokan et al., 2006). 
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6.4 Primers 
Primers were synthesized by Sigma-Genosys. 
 
GAPDH (Glycerinaldehyde-3-Phosphate Dehydrogenase) 
Human GAPDH forward:  5’-GAG TCC ACT GGC GTC TTCA 
Human GAPDH reverse:  5’-TTC AGC TCA GGG ATG ACC TT 
Porcine GAPDH forward:   5’-ACA TGG CCT CCA AGG AGT AAGA 
Porcine GAPDH reverse:  5’-GAT CGA GTT GGG GCT GTG ACT  
(Duvigneau et al., 2005) 
Rat GAPDH forward:   5’-ATC CCA GAG CTG AAC G 
Rat GAPDH reverse:   5’-GAA GTC GCA GGA GAC A 
  
eGFP (enhanced green fluorescent protein) 
eGFP 1 forward:   5’-GCT ACC CCG ACC ACA TGA AG 
eGFP 1 reverse:   5’-GTC CAT GCC GAG AGT GAT CC 
 
LacZ (Beta-Galactosidase) 
LacZ forward:    5’-ATC CTC TGC ATG GTC AGG TC 
LacZ reverse:    5’-CTG GGC CTG ATT CAT TCC 
 
Luciferase 
Luci forward:    5’-CGT GCT GGA CTC CTT CAT CA 
Luci reverse:    5’-TTG CGG ACA ATC TGG ACG AC 
 
C9 
C9 forward:    5’-GAA GCA CGC GTA TCC TAT GA 
C9 reverse:    5’-ATT ATT AGT CGG CCT CAT CC 
 
S18 
S18 forward:    5’-AGG GAG ACA GCC TCA GAA ACT TTT 
S18 reverse:    5’-CGC CGA ATA GCA CAT TTA CAT GAT 
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6.5 Antibodies 
Primary antibodies 
 Anti-αvβ5 (MAB1961):  monoclonal; mouse α-human; Chemicon 
 Anti-α5β1 (MAB1999):  monoclonal; mouse α-human; Chemicon 
 Anti-Lamin B (M-20; sc6217): polyclonal; α-mouse; SantaCruz Biotechnology 
 Anti-AAV intact capsid (A20): monoclonal; mouse IgG1 hybridoma 
supernatant; DKFZ Heidelberg, J. Kleinschmidt 
Secondary antibodies 
 PE-conjugated goat α-mouse IgG (ab7002-500); monoclonal; abcam 
 Cy5-conjugated AffiniPure donkey α-goat IgG (H+L); Jackson 
ImmunoResearch 
 Rhodamine Red-X- (RRX-) conjugated AffiniPure goat α-mouse IgG (H+L); 
Jackson ImmunoResearch 
6.6 Bacteria Strains 
E.coliDH5α:  
F-, lac1-, recA1, endA1, hsdR17, ∆(lacZYA-argF), U169,F80dlacZ∆M15, supE44, 
thi-1, gyrA96, relA1; (Hanahan, 1983) 
6.7 Eukaryotic Cells 
For culturing and media conditions please refer to the chapters 6.8 and 7.3 
6.7.1 Immortalized Cell Lines 
HEK293 
Human embryonic kidney cells, transformed with Ad5 DNA and containing the 
adenoviral genes E1a and E1b; American Type Culture Collection (ATCC); 
(Graham et al., 1977) 
HeLa 
Human epithelial cervix adenocarcinoma cells; ATCC; (Scherer, Syverton, and 
Gey, 1953) 
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6.7.2 Primary cells 
Rat aortic endothelial cells (RAEC) 
These cells were isolated by a non-enzymatic outgrowth method of thoracic aortic 
rings as described by Nicosia and colleagues (Nicosia, Villaschi, and Smith, 1994). 
Adult Lewis rats were used as donors. After isolation the cells were characterized 
by their ability to take up Dil-AcLDL and to stain for von Willebrand Factor (vWF) 
as well as endothelial markers like CD31 by FACS analysis. Morphologically the 
endothelial cells can be identified by their cobblestone formation. The cells were 
kindly provided by M. Seifert (Charité Berlin). 
Rat neonatal cardiomyocytes 
Neonatal cardiomyocytes were isolated from 1 to 3 d old Wistar rats by E. Saygili 
as described before (Saygili et al., 2007; Zobel et al., 2007) and provided by B. 
Bölck (University Hospital Cologne). Hearts were digested with collagenase and 
trypsin. Afterwards, the myocytes were purified by passage through a Percoll 
gradient. Cells were grown in DMEM/Ham’s F-12 supplemented with 10 % horse 
serum and 5 % fetal bovine serum. After 1 or 2 d depending on the cells, the 
medium was removed and the cells were washed and maintained in serum-free 
DMEM/Ham’s F-12. Then, the neonatal cardiomyocytes were transduced directly. 
Porcine aortic endothelial cells (PAEC) 
Porcine aortic endothelial cells were provided by W. Kues (Institute of Farm 
Animal Genetics, Mariensee). First, the piece of porcine aorta was rinsed with PBS 
and antibiotics to remove erythrocytes. For isolation of endothelial cells, 
prewarmed Collagenase type II solution (1 mg/ml in PBS) was injected into the 
aorta. After 15 min incubation at 37 °C the solution was aspirated and centrifuged 
in the same volume of DMEM (5 min, 1000 rpm). The pelleted cells were grown in 
DMEM, 10 % FCS and ECGF and seeded into gelatin-coated flasks. Endothelial 
cells can then be recognized by their cobblestone morphology. 
Porcine fibroblasts 
Fetale porcine fibroblasts were isolated by outgrowth of fibroblasts of explant 
culture and kindly provided by B. Petersen (Institute of Farm Animal Genetics, 
Mariensee). 
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Human CD34+ cells 
CD34+ cells were either freshly isolated as described in chapter 7.3.7 or 
purchased as frozen cells from CellSystems (7.3.7.2). 
Melanoma cells 
Primary melanoma cells from 3 different patients were kindly provided by 
MediGene AG (Martinsried). 
 
6.8 Culture Media and Supplements 
Product Company 
Ampicillin Sigma, Deisenhofen 
Ascorbic acid Sigma, Deisenhofen 
Bovine apo-transferrin Sigma, Deisenhofen 
Bovine insuline Sigma, Deisenhofen 
DMEM/Ham's F-12 PAA, Pasching 
Dulbecco's MEM + Glutamax-I (DMEM) Invitrogen, Karlsruhe 
Endothel Basal Medium PAA, Pasching 
Endothelial Cell Basal Medium-2 + supplements 
(EBM-2) 
Lonza 
Fetal Calf Serum (FCS) Invitrogen, Karlsruhe 
Hygromycin B Roche, Mannheim 
Lithium chloride Sigma, Deisenhofen 
Penicillin/Streptomycin (P/S) Invitrogen, Karlsruhe 
Phosphate-buffered saline (PBS) Invitrogen, Karlsruhe 
recombinant human Fms-related tyrosine kinase 3 
ligand (Flt3L) 
Dunnlab, Asbach 
recombinant human Interleukin 3 (IL3) Dunnlab, Asbach 
recombinant human Interleukin 6 (IL6) Endogen 
recombinant human Stem Cell Factor (SCF) Endogen 
recombinant human VEGF 165 R&D Systems 
Sodium selinate Sigma, Deisenhofen 
StemSpan serum-free expansion medium CellSystems, St. Katharinen 
Trypsin-EDTA Invitrogen, Karlsruhe 
 
Media compositions for cell types are listed below: 
HeLa, HEK293, melanoma cells and porcine aortic endothelial cells (PAEC): 
 Dulbecco’s-MEM and Glutamax-I 
 10 % FCS 
 100 U/ml penicillin and 100 mg/ml streptomycin 
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Porcine fibroblasts: 
 Dulbecco’s-MEM and Glutamax-I 
 20 % FCS 
 100 U/ml penicillin and 100 mg/ml streptomycin 
Rat aortic endothelial cells (RAEC): 
 Endothel Basal Medium (PAA) 
 10 % FCS 
 5 µg/ml gentamycin 
Neonatal rat cardiomyocytes: 
 DMEM/Ham’s F-12 
 10 mg/ml ampicillin 
 1 µg/ml bovine insuline 
 5 µg/ml bovine apo-transferrin 
 1 nM sodium selinate 
 1 nM lithium chloride 
 25 µg/ml ascorbic acid 
 (10 % horse serum and 5 % FCS only during the first 1 to 2 d 
after isolation) 
CD34+ cells (expansion medium): 
 Stem Span serum-free expansion medium 
 IL-3 20 ng/ml 
 IL-6 20 ng/ml 
 SCF 100 ng/ml 
 Flt3-ligand 100 ng/ml 
CD34+ cells (endothelial differentiation medium): 
 Endothelial Cell Basal Medium-2 + supplements as provided 
 20 % FCS 
 50 ng/ml VEGF 165 
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6.9 Laboratory Equipment and Disposables 
Product Company 
µQuant Microplate Spectrophotometer BioTek Instruments, Bad Friedrichshall 
Axiovert 25 CFL Carl Zeiss, Göttingen 
Axiovert S100 Carl Zeiss, Göttingen 
Balance Adventure Pro Ohaus, NJ, USA 
Blood collecting bag MacoPharma 
Cell Culture Plastic Ware Beyer, Düsseldorf 
Centrifuge 5415D Eppendorf, Hamburg 
Centrifuge 5-6B Beckman, München 
Centrifuge 5810R Eppendorf, Hamburg 
FACScalibur Becton Dickinson, Heidelberg 
Filter (0.22 µm, 0.45 µm) Schleicher & Schuell Micro Science, 
Dassel 
General laboratory ware VWR, Darmstadt 
Heater/Magnetic Shaker Heidolph MR 
3001 
Heidolph Instruments, Schwabach 
Hera -80 ºC freezer Heraeus 
Heraeus Lamina Heraeus 
HiTrap Heparin Affinity Columns (1 ml) Amersham Pharmacia Biotech, Freiburg 
Incubator Hera Cell 150 Heraeus 
Incubator Shaker Innova 4430 New Brunswick Scientific, NJ 
LightCycler 1 Roche, Mannheim 
LightCycler Capillaries Roche, Mannheim 
LightCycler carousel centrifuge Roche, Mannheim 
LSM 510 Meta Carl Zeiss, Göttingen 
Microplate Luminometer LB 96 V EG&G Berthold, Bad Wildbad 
Mini Sub GT Gel Electrophoresis Unit BioRad, München 
MiniMACS system Miltenyi Biotech 
Mixer Mill MM300 Retsch, Haan 
Olympus Vanox-S AH-2 Olympus, Hamburg 
pH Meter Seven Easy Mettler-Toledo, Schwerzenbach 
Pipettes and Filtertips Sarstedt 
Power Supply Renner, Dannstadt 
Pump P-1 Amersham Pharmacia Biotech, Freiburg 
Reaction tubes (1.5 ml, 2 ml) Eppendorf, Hamburg 
Sorvall T-865 rotor Thermo Scientific 
Sorvall Ultracentrifuge OTD Combi Thermo Scientific 
Spectrophotometer BioRad SmartSpec 
3000 
BioRad, München 
Syringes and Needles B. Braun Melsungen, Melsungen 
Thermomixer Comfort Eppendorf, Hamburg 
Vortex Genie 2 Scientific Industries, NY, USA 
Waterbath Medingen W6 Medingen, Freital 
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6.10  Data Treating Software 
Microsoft Office Excel 2003; Micrografx Picture Publisher 8; Clone Manager 3; 
Adobe Photoshop CS2; specific software for the respective instruments 
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7 Methods 
7.1 Bacteria Culture 
7.1.1 Cultivation of Bacteria 
Bacteria were grown in LB medium at 37 °C under vigorous shaking over night. 
For generating single clones, bacteria were plated on plates containing LB and 
agar. 
LB medium:      10 g   tryptone 
        5 g   yeast 
        5 g   NaCl 
  15 g   agar 
                     ad 1 l distilled H2O 
7.1.2 Preparation of Competent Bacteria 
One bacterial colony of the strain DH5α was picked from an LB-agar plate and 
grown over night in LB at 37 °C. The following day the bacteria suspension was 
diluted 1:100 and grown till an optical density (OD) between 0.7 and 0.8 was 
reached. 50 ml of the suspension was cooled down for 10 min in an ice-cold water 
bath before pelleting the bacteria 10 min, 3200 rpm at 4 °C. The pellet was 
resuspended in 15 ml TFB I buffer and incubated 10 min at 4 °C. After centrifuging 
the bacteria (10 min, 800 x g, 4 °C), they were resuspended in 2 ml TFB II buffer. 
200 µl aliquots of the chemo-competent bacteria were shock-frosted in liquid 
nitrogen and stored at -80 °C. 
 
TFB I buffer (200 ml):  30 mM   potassium acetate 
                        100 mM  CaCl2 
                                               15 %   glycerol 
                                                 ad 190 ml H2O 
                Autoclavation, than addition of sterile filtered: 
     50 mM   MnCl2 
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TFB II buffer (50 ml):           10 mM   MOPS 
     75 mM   CaCl2 
     10 mM   KCl 
        15 %   glycerol 
     ad 50 ml H2O      
7.1.3 Transformation of Bacteria 
Chemo-competent bacteria were thawed on ice. 100 to 500 ng DNA were added 
to 50 µl bacterial suspension and agitated carefully. The mixture was incubated 30 
min on ice before heat shock treatment for 30 s at 37 °C. Immediately, bacteria 
were put back on ice. 5 min later 450 µl LB medium was added and mixed gently. 
250 µl of the suspension could then be distributed on LB agar plates containing 
ampicillin (50 µg/ml). Bacteria grew over night at 37 °C. Single colonies were 
picked and analyzed the next day. 
7.2  Working with nucleic acids 
7.2.1 Plasmid amplification and extraction 
For plasmid amplification and extraction the “Qiagen EndoFree Plasmid Mega Kit” 
was used according to the manufacturer’s instructions.  
Starter bacteria cultures were inoculated from either glycerol stocks or picked as 
single clones from selective plates and grown in selective LB medium. This culture 
should then be diluted 1:500 in an absolute volume of 2.5 l and grown shaking 
over night at 37 °C. Harvesting followed at 6000 x g for 30 min at 4 °C. For 
efficient alkaline lysis, the pellet was resuspended in 50 ml P1 buffer then inverted 
several times after adding 50 ml of buffer P2 and incubated 5 min at room 
temperature. Lysis was stopped and precipitation of genomic DNA, proteins and 
cell debris was enhanced by adding 50 ml of chilled buffer P3 and shaking 
vigorously until a white fluffy material has formed. The lysate was poured into the 
QIAfilter Cartridge which has been screwed onto a glass bottle and incubated for 
10 min. A vacuum source pulled the liquid through the filter. 50 ml of FWB2 buffer 
should then be added to the Cartridge, stirred and filtered again. Endotoxins could 
be removed from the filtrate by 12.5 ml ER buffer, inverting the bottle and 
incubation on ice for 30 min. The QIAGEN-tip 2500 was equilibrated by 35 ml QBT 
buffer before the lysate was applied to the column. 200 ml of washing buffer QC 
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were used to rinse the column before DNA was finally eluted in 35 ml buffer QN. 
DNA precipitation followed by adding 24.5 ml isopropanol, mixing and pelleting at 
3200 x g at 4 °C for a minimum of 30 min. Supernatant was removed and the 
pellet was washed with 7 ml 70 % ethanol and another centrifugation step for 10 
min. Again, the supernatant was taken off and the pellet was allowed to dry for 
some minutes before a suitable volume of endotoxin-free buffer TE was added. To 
minimize the risk of shearing events, the suspension was left over night in the 
fridge to let solve the DNA before quantification and analysis. 
7.2.2 DNA and RNA Quantification 
DNA and RNA samples were diluted in H2O before they were measured in a 
BioRad SmartSpec 3000 spectrophotometer. The measured wavelength is 260 
nm, concentrations are calculated by the conversion factors 50 µg/ml for double-
stranded DNA and 40 µg/ml for RNA. The purity of the DNA preparation is given 
by the ratio Abs 260 nm / Abs 280 nm. While 1.8 is ideal, lower values point to 
contaminations with proteins and aromatic substances whereas higher ratios 
indicate possible contaminations with RNA.  
7.2.3 Restriction Enzyme Digest  
Digestion with restriction enzymes was performed according to the manufacturer’s 
instructions in a 20 µl solution containing 1 µg of DNA, 1-10 units of restriction 
enzyme per 1 µg DNA and 1 x buffer. 
7.2.4 Agarose Gel Electrophoresis  
Restriction enzyme digests as well as PCR products were analyzed by agarose 
gel electrophoresis to verify the size of the fragments or products.  
Therefore, 1 x TBE buffer was boiled with the desired amount of agarose, mixed 
with the intercalating substance ethidium bromide (0.25 µg/ml) and poured into the 
gel chamber. The comb was directly inserted and taken out when solidification 
occurred before the chamber was put into the electrophoresis chamber containing 
1 x TBE. For large fragments 0.8 % agarose, for smaller ones 2 % was used. 300 
to 500 ng of restriction digested DNA or 10 µl of the PCR products were mixed 
with loading dye filled up with H20 to a final volume of 10 µl and loaded onto the 
gel. Depending on the size of the gel between 80 and 140 V and 200 mA was 
chosen for electrophoresis. 
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TBE Buffer (10 x):  540 g   Tris base 
275 g   boric acid 
         200 ml   0.5 M EDTA pH 8.0 
                                                 ad 5 l H2O 
7.2.5 Tissue DNA extraction 
Frozen animal tissue samples of about 50 mg were cut into small pieces and DNA 
was extracted using the DNeasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer’s instructions with small modifications. 
360 µl of the buffer ATL was added to the tissue samples as well as 40 µl of the 
Proteinase K (double amount of what is recommended). Tissue lysis was induced 
at 56 °C in a thermomixer for some hours up to over night incubation. After 15 s of 
vortexing, first 400 µl of buffer AL was added, vortexed, then 400 µl ethanol. Only 
fluid and very small precipitates were applied to the DNeasy Mini spin column in 
order to prevent blocking. DNA sticked to the column and the rest of the lysate 
was removed by centrifugation at 10,000 x g for 1 min. Salts and proteins were 
eliminated by two washing steps: The first time using buffer AW1 (centrifugation 
for 1 min at 16,000 x g) the second with buffer AW2 and 3 min of centrifugation for 
drying the membrane completely. DNA was eluted in 50 µl Tris (10 mM, pH 8.0) 
after 1 min of incubation on the membrane and 1 min of centrifugation at 10,000 x 
g. DNA concentration was measured as described in 7.2.2 and diluted to a final 
concentration of 100 ng/µl prior to quantitative PCR analysis. DNA was stored at   
-20 °C. 
7.2.6 Tissue RNA extraction 
RNA was exctracted using the Trizol / Chloroform method. Briefly, 1 ml of Trizol 
was pipetted into a 2 ml safe-lock tube containing one small metal ball. Tubes 
were put on ice after adding around 50 mg of organ. Homogenization was 
performed using a ball mill (Mixer Mill MM300, Retsch) at 30 Hertz for 3 min. The 
lysate was then incubated for 5 min at room temperature before 200 µl of 
chloroform were pipetted and vortexed. After 3 min of incubation at room 
temperature the mixture was centrifuged 15 min at 16,000 x g at 4 °C. After 
centrifugation 2 phases are visible, the lower Trizol phase and the upper aqueous 
phase containing the RNA. Carefully, the supernatant was pipetted into a fresh 1.5 
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ml tube without touching the protein interphase. For pelleting the RNA 500 µl of 
isopropanol was added, vortexed and incubated for 10 min at room temperature 
then centrifuged 15 min at 16,000 x g at 4 °C. Further washing of the pellet was 
done with 1 ml of 75 % ethanol and centrifugation (7,500 x g, 5 min, 4 °C). After 
removing the supernatant the pellet should be air-dried and resuspended in 30 
(heart) to 150 µl (liver) RNase-free water depending on the size of the pellet. RNA 
concentration was measured as described in 7.2.2 and stored at -80 °C. 
7.2.7 DNase I digest and cDNA synthesis 
To prevent unspecific signals in the cDNA PCR reaction due to remaining DNA in 
the RNA preparation, DNase I digest was done before Reverse Transcriptase (RT) 
reaction. 
RNA was thawed on ice and 10 µg were taken out. The RNA was mixed with the 
same volume of PBS, 1 U/µg RNA DNase I and 0.1 mg/ml BSA and 2.5 mM MgCl2 
as end concentration. Incubation for 30 min at 37 °C was stopped by adding 2.5 
mM EDTA end concentration and heating for 10 min at 65 °C. Samples were then 
put on ice. 
Transcriptor First Strand cDNA Synthesis Kit (Roche) was used to transcribe 
mRNA into cDNA according to the manufacturer’s instructions. Therefore, 1 µl 
Oligo dT-primer (50 µM) were added to around 3 µg of DNase I-digested RNA and 
filled up with RNase-free water up to 13 µl. Incubation at 65 °C for 10 minutes 
denatured the secondary structure. For starting the RT reaction the following 
reagents supplied with the kit were pipetted into the RNA-primer-mix to a final 
volume of 20 µl: 
   4 µl  RT buffer (5x) 
0.5 µl  RNase Inhibitor (40 U/µl) 
0.5 µl  RT (20 U/µl) 
   2 µl  dNTPs (each of 10 mM) 
 
The mix was incubated 1 h at 42 °C followed by a heating step (85 °C, 5 min). 
Afterwards, samples were put on ice or if not used immediately stored at -20 °C. 
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7.2.8 Quantitative Polymerase-Chain-Reaction 
For analyzing the DNA amount by quantitative polymerase-chain reaction (PCR) in 
a LightCycler 1 system (Roche) either a kit by Roche (LightCycler Fast Start DNA 
Master SYBR Green I) or by Qiagen (Quantitect SYBR Green PCR Kit) was used 
depending on the ability to accomplish the particular amplification in the most 
sensitive and specific way. The kit purchased from Roche was used to quantify 
GFP, Luciferase and porcine GAPDH genes whereas the Qiagen kit was applied 
for rat GAPDH and LacZ coding sequences. 
100 to 200 ng of DNA and cDNA were analyzed per capillary. For determination of 
genomic titer of AAV vector preparation 2 µl of the extracted DNA (7.3.6.4) was 
analyzed. 
 
Pipetting scheme using LightCycler Fast Start DNA Master SYBR Green I: 
2 µl   DNA or cDNA 
2 µl   Mix 1 
 2 µl   MgCl2 (25 mM) 
 0.1 µl   Primer forward (0.1 mM) 
 0.1 µl   Primer reverse (0.1 mM) 
 13.8 µl  H2O 
20 µl   
 
If Qiagen’s kit was applied, the following scheme was pipetted: 
2  µl  DNA or cDNA 
10  µl  Quantitect SYBR Green PCR Master Mix 
0.1  µl  Primer forward (0.1 mM) 
0.1  µl  Primer reverse (0.1 mM) 
7.8  µl  H2O 
20  µl   
 
For eliminating potential contaminations with PCR products of previous 
amplifications, LightCycler Uracil-DNA (UNG) Glycosylase was added. Its effect is 
based on cutting of Uracil-containing DNA. This nucleotide is only inserted during 
PCR where it is supplied in the mix. The enzyme works for 10 min at 40 °C and is 
inactivated during the denaturation step for 5 min at 95 °C. We used UNG 
Methods 
 
133 
 
glycosylase in very sensitive PCRs – here LacZ for analyzing material out of 
animals. 
2 µl  DNA or cDNA 
10 µl  Quantitect SYBR Green PCR Master Mix 
0.1 µl  Primer forward (0.1 mM) 
0.1 µl  Primer reverse (0.1 mM) 
0.25 µl  UNG (2 U/µl) 
7.55 µl  H2O 
20 ul   
 
Usually a supermix for all samples was prepared. First, the mix was pipetted into 
the glass capillaries followed by the DNA. Then the capillaries were closed. The 
following protocols were established: 
 
GFP-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 900 20 none 
       
Amplification 40 Quantification 95 10 " " 
   
63 3 " " 
 
  72 20 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
66 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
 
Luciferase-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 900 20 none 
       
Amplification 40 Quantification 95 10 " " 
   
69 5 " " 
 
  72 12 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
66 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
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Porcine GAPDH-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 900 20 none 
       
Amplification 40 Quantification 95 10 " " 
   
68 10 " " 
 
  72 15 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
66 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
 
LacZ and rat GAPDH-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 900 20 none 
       
Amplification 40 Quantification 95 10 " " 
   
68 10 " " 
 
  72 15 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
66 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
 
S18-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 600 20 none 
       
Amplification 45 Quantification 95 10 " " 
   
62 5 " " 
 
  72 10 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
60 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
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C9-PCR protocol: 
Program Cycles Analysis mode Temp (°C) Time (s) slope (°C/s) Acquisition 
mode 
Denaturation 1 None 95 600 20 none 
       
Amplification 38 Quantification 95 10 " " 
   
61 10 " " 
 
  72 10 " single 
 
      
Melting curve 1 Melting curves 95 0 " " 
   
60 10 " " 
   95 0 0.1 continuous 
       
Cooling 1 None 40 30 20 none 
 
To verify the amplified products, melting curves of the LightCycler runs were 
analyzed. Moreover, they could be analyzed in Agarose Gel electrophoresis. 
7.3 Eukaryotic cell culture 
7.3.1 Cultivation of Cells 
Cells were cultured at 37 °C in humid atmosphere containing 5 % CO2. For culture 
media please refer to chapter 6.8. 
7.3.2 Trypsinization 
To detach cells from the culture dishes, medium was taken off and cells were 
washed with PBS to remove rests of the medium. Then they were incubated in a 
small volume of trypsin in the incubator until detachment was visible. The reaction 
was stopped by addition of medium containing 10 % FCS. 
7.3.3 Counting  
After trypsinizing the cells, 10 µl of the suspension was transferred into a 
“Neubauer” chamber. Four squares were counted and an average was calculated. 
The number of cells (n) in one square equals n x 104 per ml.  
7.3.4 Seeding / Passaging 
Cells were transferred into a new culture dish in a suitable dilution of prewarmed, 
fresh medium. Agitation of the culture plates and flasks should guarantee 
homogenous distribution of the cells. 
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7.3.5 Freezing and Thawing Cells 
Cells were trypsinized and pelleted before resuspending them in 1 ml freezing 
solution containing 90 % FCS and 10 % DMSO. Immediately, the suspension was 
put on ice and then stored in liquid nitrogen. 
For thawing cells, the freezing vial was taken out of the liquid nitrogen tank and 
transported on ice. Carefully, the suspension was thawed in a water bath at 37 °C 
until only some rests of ice were left. Then, the cells were transferred into a 15 ml 
plastic tube containing prewarmed medium before pelleting the cells at 400 x g for 
5 min at room temperature in order to remove toxic DMSO. After resuspension in 
fresh medium, the cells were plated in culture dishes. For CD34+ cells another 
thawing protocol was followed (7.3.7.2). 
7.3.6 Vector production and purification  
7.3.6.1 AAV-Vector Packaging 
AAV particles were produced in HEK293 cells by the adenovirus-free production 
method using pXX6 to supplement the adenoviral helper functions (Xiao, Li, and 
Samulski, 1998). Briefly, 7.5 x 106 HEK293 cells were seeded in 15 cm2 cell 
culture plates. 24 h later (at an approximate confluence of 80 %) medium was 
exchanged and 2 h afterwards cotransfection was performed with the three 
packaging plasmids by the calcium phosphate method with a total of 37.5 µg 
plasmid DNA per 15 cm2 cell culture plate:  
7.5 µg   pXR1 (or pXR2/ pXR3/ pXR4/ pXR5 coding for the respective capsid) 
7.5 µg   transgene-encoding plasmid (contains ITRs) 
22.5 µg pXX6 (encodes for E2A, E4 and VA of Ad5) 
For each plate a solution of 1 ml CaCl2 (250 mM) was mixed with the plasmid DNA 
then 1 ml of the HBS buffer (50mM HEPES, 280mM NaCl, 1.5 mM NaP) was 
dropped onto the solution incubated for 2 min and pipetted onto the plate while 
cautious mixing with the medium. After 24 h incubation at 37 °C/ 5 % CO2 medium 
was exchanged with DMEM containing only 2 % FCS to reduce further cell 
divisions. The transfected cells were harvested and pelleted by low-speed 
centrifugation on the following day (48 h post transfection). The pellet was 
resuspended in lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.5)) and the 
cellular and nuclear membranes were destroyed by repeated freeze and thaw 
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cycles. To abolish genomic and plasmid DNA or RNA contaminants in the vector 
preparation, the suspension was treated with 50 U/ml Benzonase for 30 minutes at 
37 °C. Then, the suspension was centrifuged 30 min at 4 °C and 3,220 x g. The 
supernatant was taken off carefully and centrifuged again.  
7.3.6.2  Iodixanol Gradient Purification 
Discontinuous iodixanol gradient centrifugation was used to remove cellular 
debris. Full capsids are concentrated in the 40 % phase of the iodixanol gradient.  
Vector suspension was inserted into an ultracentrifugation tube. The different 
phases of the iodixanol gradient - beginning with 15 % - were sub layered by using 
a syringe connected to an Amersham Biosciences Pump P-1. 8, 6, 5 and 6 ml of 
the respective solutions were applied. The tube was filled up with PBS/MgCl2(1 
mM)/KCl(2.5 mM), closed and centrifuged at 63,000 rpm at 4 °C for 2 h (Sorvall 
Ultracentrifuge OTD Combi). Subsequently, the 40 % iodixanol phase was 
harvested. 
 15% 25% 40% 60% 
10x PBS 5 ml 5 ml 5 ml / 
1 M MgCl2 50 µl 50 µl 50 µl 50 µl 
2.5 M KCl 50 µl 50 µl 50 µl 50 µl 
5 M NaCl 10 ml / / / 
Optiprep 12.5 ml 20 ml 33.3 ml 50 ml 
0.5% Phenolred 75 µl 75 µl / 25 µl 
H20 ad 50 ml ad 50 ml ad 50 ml ad 50 ml 
 
7.3.6.3 Heparin Affinity Chromatography 
For purification of vectors which are able to bind to heparin, e.g. rAAV2 and 
rAAV3, affinity chromatography using heparin columns (1ml) from Amersham 
Pharmacia Biotec might be performed instead or additional to iodixanol gradient 
centrifugation. Therefore the Amersham Biosciences Pump P-1 was used. First, 
the column was equilibrated with PBS/MgCl2(1 mM)/KCl(2.5 mM), while the vector 
solution was diluted 1:10 in the same buffer and applied to the column. After a 
washing step with 20 ml PBS/Mg/K, vector was eluted with PBS/Mg/K plus 1 M 
NaCl in 500 µl steps.  
Methods 
 
138 
 
7.3.6.4 Vector titration 
For extraction of the vector genome from the viral particles the Qiagen DNeasy 
Blood & Tissue Kit was used according to the protocol for Isolation of Total DNA 
from Cultured Animal Cells. For alkaline lysis, 10 µl of the vector solution was 
mixed with 190 µl PBS, 200 µl buffer ATL and 20 µl Proteinase K and incubated 
for 10 min at 56 °C. Subsequently, the samples were vortexed and 200 µl of buffer 
AL and ethanol (96-100 %) were added. The solution was applied to a DNeasy 
Mini Spin column, centrifuged and washed in AW1 and AW2 buffer before the 
DNA was eluted in 200 µl Tris 10 mM pH 8.0. 
The genomic titer was then determined by quantitative PCR as decribed in 7.2.8. 
To quantify the amount of vector genomes within the extracted DNA, defined 
dilutions (1x108 to 1x105 genomic particles/µl) from the respective transgene-
encoding plasmid were prepared and used as standards in the quantitative PCR. 
7.3.7 Working with CD34+ cells 
7.3.7.1 Isolation and culturing of CD34+ cells 
Only the cord blood of mothers who gave their written agreement was recovered in 
heparin-containing bags directly after birth. The purification steps consist of an 
isolation of mononuclear blood cells (MBC) by Ficoll-density gradient followed by 
magnetic cell sorting of CD34+ cells. This work has been accomplished by Michele 
Cadau (Centro Cardiologico, Monzino, Italy). 
First, the blood was diluted in two volumes phosphate-buffered saline (PBS 
without Ca++ and Mg++). Two volumes of diluted blood were layered carefully over 
one volume of Ficoll. After 30 min of centrifugation at 400 x g in a swinging rotor 
without brake at room temperature, the MBC-containing ring between plasma and 
Ficoll was collected. Afterwards, the cells were washed twice in PBS/2 mM 
EDTA/5 % FCS by centrifugation (10 min, 400 x g, 4 °C) and resuspended in the 
precedent buffer solution. 
For the following positive selection with immunomagnetic beads the Direct CD34 
Progenitor Cell Isolation Kit (Miltenyi Biotech) was used according to the 
manufacturer’s instructions. MBCs were shaken for 30 min on ice with 100 µl Fc 
receptor blocking reagent per 108 cells before adding monoclonal mouse anti-
human CD34 antibody-coupled magnetic beads (IgG1 isotype). After an additional 
washing step like above, cells were resuspended in 500 µl PBS/ 2 mM EDTA/ 5 % 
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FCS and sorted on an activated column placed in the magnetic field of a MACS 
separator (miniMACS system, Miltenyi Biotech). The labelled cells are bound to 
the column and therefore separated from other cell populations. After rinsing the 
column with 1 ml PBS/ 2 mM EDTA/ 5 % FCS and removal of the column from the 
magnetic field, the magnetically retained cells can be eluted as positively selected 
cell fraction. The purity of the obtained cell fraction used to be more than 80 % as 
assessed by FACS analysis for CD34 expression. 
Cells were expanded prior to use for a 2 to 4 days in 300 µl medium in 96-well 
plates at 37 °C and 5 % CO2. Serum-free culture medium (Stem Span, 
CellSystems) was supplemented with Flt3-ligand (100 ng/ml), SCF (100 ng/ml), IL-
3 (20 ng/ml), IL-6 (20 ng/ml) and sterile filtrated. Medium was exchanged every 2 
to 3 d. 
7.3.7.2 Thawing of CD34+ cells 
Purchased cells from CellSystems were thawed according to the manufacturer’s 
instructions. Cells were almost completely thawed by putting them into a water 
bath (37 °C). 1 ml of pre-warmed StemSpan medium without cytokines was 
applied to the cells and then transferred into a 50 ml tube containing 50 µl DNase I 
(10,000 U/ml) for prevention of cell clumping. Fresh medium was dropped slowly 
to an end volume of 15 ml while turning the tube. Cells were pelleted (200 x g, 22 
°C, 15 min), the supernatant was taken off carefully and the procedure was 
repeated. Cells were counted and seeded in StemSpan medium containing 
cytokines into 96-well plates (for culture media see 7.3.7.1). 
7.3.7.3 Transduction of CD34+ cells with AAV 
After expanding the cells for 2 to 4 days, 8x104 cells per well were seeded in a 96-
well plate. Later, cells were incubated in medium with half-cytokine concentration 
containing the vector solution or iodixanol over a period of 3 h. Then a washing 
step with PBS was performed to remove the iodixanol. Cells were centrifuged at 
400 x g for 10 min at 4 °C und resuspended in fresh medium with normal cytokine 
concentration. 
7.3.7.4 Analysis of transduced CD34+ cells by FACS  
Cells were harvested, centrifuged at 400 x g for 10 min at 4 °C and resuspended 
in 250 µl PBS. The cells were directly used if GFP fluorescence should be 
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measured. For the analysis of αvβ5 integrins, cells were harvested and washed as 
above, but resuspended in 50 µl PBS and 1 µl of primary antibody (mouse anti-
human monoclonal antibody, 1 mg/ml, Chemicon). After 15 min incubation on ice 
and a following washing step, 1 µl of secondary antibody (goat anti-mouse IgG-PE 
labelled polyclonal antibody, abcam) was added to 50 µl cell suspension in PBS. 
FACS analysis started after 15 min incubation on ice and an additional washing 
step. Unstained cells and cells that were only treated with secondary antibody 
were used as controls. 
7.3.8 Dil-AcLDL uptake 
Endothelial cells can be characterized by their ability to take up acetylated low-
density lipoproteins (AcLDL). Acetylation of lysine rests inhibits binding to the LDL-
receptor. Instead the fluorescence (Dil-) labeled substance can be bound and 
taken up efficiently by scavenger receptors of endothelial cells and macrophages. 
Endothelial cells were incubated 4 to 5 h in 1 µg/ml Dil-AcLDL (CellSystems) 
diluted in medium at 37 °C. Then the supernatant was taken off and cells were 
rinsed twice with PBS prior to fixation in 3 % paraformaldehyde at room 
temperature for 15 min. After two more rinsing steps the plates were stored at 4 °C 
and analyzed by fluorescence microscopy (Zeiss Axiovert S100). 
7.4 Determination of protein 
7.4.1 Detection of beta-Galactosidase activity in tissue sections 
Cryosections were done in the Institute of Pathology (M. Odenthal, University 
Hospital of Cologne). Sections were dried over night and kept at -80 °C. For 
staining, they were put directly in 1.5 % glutaraldehyde/ PBS for 5 min and washed 
3 times for 30 s in distilled water. Then the object slides were incubated 2 min in 
PBS before changing to LacZ staining solution which consists of: 
 
    2 ml   X-Gal in DMSO (20 mg/ml) 
 100 µl   1M MgCl2 
  20 ml   50 mM Potassium hexacyanoferrat II trihydrat (50 mM) 
  20 ml   50 mM Potassium hexacyanoferrat III (50 mM) 
160 ml   PBS 
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The cryosections were incubated for 2 d at 37 °C in the dark. The following day the 
object slides were washed 2 times for 30 s in distilled water. If no counterstaining 
with eosin was performed, water was removed by an ascending ethanol series of 
70, 80 and 2 times 100 % for 2 min each. X-tra solv (Medite) was used as xylol 
substitute 2 times for 2 min before covering the object slides with DPX mounting 
medium for histology (Fluka). For counterstaining cryosections were incubated for 
8 min in 0.5 % eosin solution followed by 2 washing steps in 100 % ethanol for 2 
min. As above incubation with X-tra solv and covering were the last steps. Pictures 
were taken with an Olympus Vanox-S AH-2 microscope. 
7.4.2 Staining for beta-Galactosidase activity in cells 
The following values are calculated for a 1 cm2 well. Medium was taken off and 
cells were washed with PBS. Cells were fixed 5 min in 300 µ l 1.5 % glutaraldehyde 
diluted in PBS and washed again for 5 min in PBS. Then 500 µ l of LacZ staining 
solution were added to the cells and incubated at 37 °C for 3 to 7 h depending on 
the developing blue color intensity. 
LacZ staining solution for 10 ml: 
500 µl   X-Gal in DMSO (20 mg/ml) 
6.5 ml   PBS 
 1 ml   MgCl2 (20 mM) 
   1 ml   Potassium hexacyanoferrat II trihydrat (50 mM) 
   1 ml   Potassium hexacyanoferrat III (50 mM) 
Then LacZ solution was exchanged against 3 % DMSO/ PBS in order to stabilize 
staining and cells for some days. 
7.4.3 Bradford Assay 
To determine protein amount of tissue samples around 20 mg tissue were added 
to 400 µl lysis buffer (Renilla Luciferase Assay System, Promega) and one small 
metal ball to homogenize the tissue sample in a ball mill (Mixer Mill MM300, 
Retsch) at 30 Hertz for 3 min. After an incubation step of 1 h on ice the lysates 
were centrifuged for 30 min at 4 °C at 16,000 x g and the supernatant was 
transferred into a new Eppendorf tube. In double, 5 µl of the lysates (or adequate 
dilutions) and the BSA standards were pipetted into a 96-well plate. Then 250 µl 
room-temperature Bradford Dye 1 x were added and incubated 5 to 60 min. The 
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plate was be measured at a wavelength of 595 nm in an ELISA reader and 
analyzed by Microsoft Excel. 
7.4.4 Luciferase Assay 
20 µl of protein lysates (see 7.4.3) were put into a 96-well plate (Nunc) before a 
mixture of 100 µl assay buffer and 1 µl of the substrate (Renilla Luciferase Assay 
System, Promega) per well were added to the sample. Because the 
chemoluminescence is fading relatively fast, a maximum of 24 samples were 
measured at once. To compare relative light units these results were normalized to 
the total protein amount determined by Bradford assay. 
7.5 Heterotopic heart transplantation 
7.5.1 Rat heart transplantation 
Transplantations were performed by Lars Burdorf (B. Reichart, M. Schmöckel, 
Department of Cardiac Surgery, Ludwig-Maximilians University Munich). 
Described is the operation method using cardioplegic solution, the so-called cold 
heart transplantation, in contrast to transplantation of a warm and beating heart. 
The technique is the same, but without the use of cardioplegic solution. 
Male Sprague-Dawley rats were first narcotized by ether and then by peritoneal 
injection of Pentobarbital (60 mg/kg body weight). Organ recipients and donors 
were prepared in the same way, but only the recipients were layered onto a 
heating pad. After reaching chirurgical tolerance the animals were shaved and 
disinfected. Organ donors were prepared by abdominal incision. The intestines 
were put extraabdominal so that preparation of the infrarenal parts of the Vena 
cava inferior (V. cava inf.) and the Aorta abdominalis could proceed. The intestines 
and the opened abdomen had to be covered with moist tissues.  
For explantation of the heart, the anticoagulans hirudin (30 mg/kg body weight) 
was applied into the V. cava inf. two minutes prior to opening of the sternum and 
application of 10 ml ice-cold cardioplegic solution (Custodiol/HTK Bretschneider) in 
the V. cava inf., respectively. Aorta abdominalis and V. cava inf. were cut through. 
When reaching asystoly, Truncus pulmonalis was disconnected and cut through. 
For cardioprotection another 2 ml of cardioplegic solution was injected into the 
Aorta ascendens and then the vector solution was applied very slowly. Finally, the 
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Venae cavae were ligated and cut through together with the Aorta. The explanted 
heart is kept in ice-cold physiological saline solution until implantation. 
For implantation of the donor heart, the aorto-caval vessels are branched off 
infrarenally. Basically, incisions are made in these two vessels and then the donor 
Aorta ascendens was ligated to the Aorta abdominalis and the donor Truncus 
pulmonalis was anastomosed to the recipient V. cava inf.. Thus, blood flow was 
only circulating through the right part of the donor heart by entering through the 
aorta, flowing through the coronaries, the right atrium and ventricle to pass the 
pulmonary artery and then return into the circulation of the recipient. 
To prevent hypovolemia, 2 ml of warm physiological saline solution was given into 
the abdominal cavity, intestines are layered back and the abdomen was closed. 
As immunosuppressive therapy the animals received 0.3 mg/kg body weight 
Tacrolimus each day.  
 
A B
 
 
Figure 43: Anastomoses of the donor heart vessels with the aorta-caval vessels in the recipient 
abdomen. First showed schematic (A) and as picture taken during operation (B). The donor aorta 
ascendens is ligated to the recipient Aorta abdominalis and the donor pulmonary artery (Truncus 
pulmonalis) is ligated to the recipient Vena cava inferior. (Figures were kindly provided by L. 
Burdorf) 
 
7.5.2 Pig heart transplantation 
Transplantations were done by Lars Burdorf and colleagues (B.Reichart, 
Department of Cardiac Surgery, Ludwig-Maximilians-University Munich).  
Only piglets of the same litter and blood group found application. Narcosis of 
recipient and donor was performed in the same way. Midazolam (0.75 – 1.5 mg/kg 
Methods 
 
144 
 
body weight), Azaperon (25 mg/kg body weight), Ketamin (25 mg/kg body weight) 
and 0.5 mg Atropin were injected intramuscularly. Further drugs were applied by 
the ear vein like the anesthetic Propofol/Disoprivan (60-120 mg/h). Additionally, 
Enfluran (0.6 %) was given by inhalation.  
The pigs were fixed on the operation table. They were intubated and artificial 
respiration was induced (Servo 900). Vital parameters were observed by a central-
nervous catheter (V. jugularis) as well as electrocardiogram, analysis of saturation 
with oxygen and blood gas.  
In contrast to rat cardiac transplantation, where the vector was injected either in 
the warm and beating heart or in the cardioplegic heart followed directly by 
transplantation, our colleagues in Munich applied here a new system. This 
method, called in situ Langendorff perfusion system, allows recirculation of the 
vector solution in warmed and oxygenated blood through the beating heart in situ 
over a longer period (Figure 44). It might be of advantage that vectors are passing 
more than once the heart and having the opportunity for transduction, before 
circulating through other organs and binding there.   
 
 
Figure 44: Scheme of an in situ Langendorff perfusion system. All vessels are clamped (marked in 
yellow) while the blood circulates through the truncus pulmonalis in a reservoir to warm the blood. A 
roller pump supports blood flow whereas an oxygenator provides oxygen for gas substitution. The 
blood enters the heart via the aorta and passes the coronaries. Vector is injected shortly before the 
entry into the heart. (Figure was modified and kindly provided by L. Burdorf) 
 
Porcine heart in situ 
Venöse Kanüle 
warming reservoir 
roller pump 
oxygenator 
vector injection 
truncus  
pulmonalis  
aorta 
 V. cava 
superior 
V. cava 
inferior 
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In brief, the thorax of the donor pig was opened and the vessels and heart were 
made accessible. Hirudin (0.4 mg/kg body weight) was injected as anticoagulant. 
To connect the heart to the Langendorff perfusion system, needles were set into 
the aorta and the truncus pulmonalis. After clamping these vessels and the Venae 
cavae and after opening the needles connected to the Langendorff perfusion 
system, the blood circulates exclusively through the system. First, the blood is 
brought into a reservoir where it is warmed to 38 °C (physiological temperature). A 
roller pump supports blood flow and prevents stasis. As third element an artificial 
lung (oxygenator) enriches the blood with oxygen which goes back into the aorta. 
As this system pumps the blood retro gradually, it flows into the coronaries, from 
there into the right heart, takes the truncus pulmonalis and passes the perfusion 
system. Histamine (100 µg in 10 ml volume) was applied over a period of 4 min 
into the system in order to increase vascular permeability. Vector was injected 
shortly before the blood entered the heart via the aorta. Blood was circulating 
about 40 min before the heart was infused with cardioplegic solution (30 ml/kg 
body weight) to stop circulation.  
The following explantation and implantation of the donor heart was performed in a 
comparable way as described for the rat heart transplantation (7.5.1). The 
recipient V. cava inferior was ligated to the donor A. pulmonalis and the recipient 
Aorta abdominals to the donor Aorta ascendens, respectively. The blood flow is as 
follows: from the donor Aorta abdominalis through the Aorta ascendens into the 
sinus coronaries. Then, it flows into the right atrium and ventricle to leave then the 
graft by the A. pulmonalis. The myocard is supplied by the coronaries. 
For immunosuppression, Tacrolimus (0.3 mg/kg body weight) was already given 
during narcosis. From the second postoperative day on, 1.5 mg/kg body weight 
Tacrolimus was administered. Regularly, immunosuppression levels and other 
blood parameters were monitored. Functionality of the transplant was controlled by 
palpation and by electrocardiogram. 
21 d after operation, the organ recipient was anesthetized like before, intubated 
and catheterized. Color, contractions and morphology of the donor heart were 
assessed before explantation.  
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8 Abbreviations 
Amino acids  
A alanine 
C cysteine 
D aspartate 
E glutamate 
F phenylalanine 
G glycine 
H histidine 
I isoleucine 
K lysine 
L leucine 
M methionine 
N asparagine 
P proline 
Q glutamine 
R arginine 
S serine 
T threonine 
V valine 
W tryptophan 
Y tyrosine 
  
Bases  
A adenine 
C cytosine 
G guanine 
T thymine 
  
AAV adeno-associated virus 
Dil-AcLDL acetylated low density lipoprotein  
Ad adenovirus 
APC antigen-presenting cell 
bp base pair 
Bcl-2 B-cell lymphoma 2 
LacZ β-galactosidase 
BM bone marrow 
ch chromosome 
CD cluster of differentiation 
CB cord blood 
CTLA4 cytotoxic T-lymphocyte antigen 4  
d day 
EPC endothelial progenitor cell 
ELISA enzyme-linked immunosorbent assay 
Flk-1 fetal liver kinase 
FGF fibroblast growth factor 
FACS fluorescence-activated cell sorting 
Flt3-ligand Fms-related tyrosine kinase 3 ligand 
e.g. for example 
GAPDH glycerinaldehyde-3-phosphate dehydrogenase 
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GM-CSF granulocyte macrophage colony stimulating factor 
GFP green fluorescent protein 
HSC hematopoietic stem cell 
HO-1  heme oxygenase 1 
HSPG heparan-sulfate proteoglycan 
HGF hepatocyte growth factor 
HSV herpes simplex virus 
h hour 
HCMV human cytomegalie virus 
HPV human papilloma virus 
IL  Interleukin 
ITR inverted terminal repeat 
kDa kilo Dalton 
MMP matrix metalloproteinase 
min minute 
MOI multiplicity of infection 
MAPC multipotent adult progenitor cells 
NPC nuclear pore complex 
nt nucleotide 
ORF open reading frame 
PNRE perinuclear recycling endosome 
RBS Rep binding site 
RA retinoic acid 
RRX Rhodamine Red-X 
rpm rounds per minute 
s second 
SC stem cell 
Sca-1 stem cell antigen 1 
c-Kit stem cell factor receptor 
SDF-1 stromal cell-derived factor 1  
TRS terminal resolution site 
TLR toll-like receptor 
TGFβ transforming growth factor β 
CFTR transmembrane conductance regulator 
TSA Trichostatin A 
VE-caherin vascular endothelial cadherin 
VEGF vascular endothelial growth factor 
vIL-10 viral Interleukin 10 
VP viral protein 
vWF von Willebrand factor 
w/o without 
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